



# DECCAN HEALTH CARE

ANNUAL REPORT 2021- 2022











# ***CORPORATE INFORMATION***

## **BOARD OF DIRECTORS & KEY MANAGERIAL PERSONNEL**

Dr Minto Purshotam Gupta, Managing Director  
Meenakshi Gupta, Director  
Hitesh Mohanlal Patel, Director  
Ruchi Khattar, Independent Director  
Samhitha K, Independent Director  
Mohak Gupta, Chief Financial Officer  
Sheena Jain, Company Secretary

## **LISTED ON STOCK EXCHANGES**

Bombay Stock Exchange Limited (BSE)

## **REGISTERED OFFICE**

H.No. 6-3-348/4, Dwarakapuri  
Colony Punjagutta, Hyderabad,  
T.G - 500 082, India

## **REGISTRAR & SHARE TRANSFER AGENTS**

Bigshare Services Pvt. Ltd  
306, Right Wing, 3rd Floor, Amrutha  
Ville, Opp. Yashoda Hospital,  
Somajiguda, Rajbhavan Road,  
Hyderabad - 500082

## **STATUTORY AUDITOR**

Keyur Shah & Co.,  
Chartered Accountants

# *Inside*

---

## COMPANY OVERVIEW

- DHC Purpose
- Message from MD's Desk
- DHC Focused on the root cause
- What we do
- How we do it
- Our Quality
- Supply Chain Control
- Our Belief





# *Inside*

---

## COMPANY OVERVIEW

- Our Future Plans and goals
- Value Creation
- Our Products
- Awards & Recognition
- Statutory Reports





**DHC PURPOSE IS YOU.**

*Help you enjoy life,  
be happy!*

**SERVING NUTRACEUTICAL FOOD  
PRODUCTS SINCE 1996.**

**HELPING YOU HAVE A BETTER -  
QUALITY LIFE, GRACEFUL AGEING,  
DISEASE FREE BODY.**

**OUR GOAL IS:**

- REDUCE DEPENDENCE ON PHARMACEUTICAL, AYUSH MEDICINES.
- HELP PREVENT, CURE, REVERSE DISEASE.
- HELP REDUCE RISK OF SUFFERING FROM LIFESTYLE DISEASES.
- HELP IMPROVE RELATIONSHIPS
- IMPROVE PERFORMANCE, IMPROVE SAFE INDULGENCE.



## Message from MD's Desk

### NEW AMBITIONS FOR CONSUMERS, SHAREHOLDERS AND OUR PEOPLE

#### 2021-22 Performance

DHC has been delivering a programme of fundamental strategic emergence designed to pace up the company's growth, including shareholder returns. The Board is pleased that in 2021 it saw further progress against the clear priorities set to enable this: improving the pipeline and R&D productivity, sharpening commercial execution and expenses discipline and tackling the Company's structure, underpinned by a shift in culture. Building on the significant progress made over this period, I believe we are now firmly on track focused on Nutraceutical Food Products.

As a nutraceutical food science-led company, we have always harnessed the power of nutrition science to help consumers achieve their wellness goals. At DHC, we believe that it is not just what you achieve that counts, but how you achieve it. We define winning as delivering consistent and sustainable balanced growth and value creation. We're making gradual but real progress in our efforts to achieve this goal, but we still have work to do.

Targets for sustained performance - As well as performance in-year, the Board maintains a clear focus and oversight of the company's strategy and plans to expand into retail, new geographies which are proposed, subject to approvals, to happen in 2022.

**Dr M P Gupta**  
**Managing Director**



# **Nutraceutical Food Products (NFP)**



**From DHC**  
**STAY W.O.W**  
**BE YOUNG**





**DHC FOCUSED  
ON THE  
ROOT CAUSE**

# **Delivering DHC Nutraceutical Food Products (NFP) For your Nutraceutical Lifestyle**

For You, our focus is to allow the body to heal and shield itself from within by focusing on the root cause of the disease and health challenges. We go beyond the existing solutions to find non-invasive, simple, natural solutions to health challenges using natural nutrients as solutions. Nutrients indeed are safe, free of side effects and in efficacious quantities work as medicine for self-healing.

WHAT WE DO?

# DHC Discovers Nutraceutical Food Products (NFP) specific to your Lifestyle needs

For you, we Discover, Innovate, develop, and deliver in-house NFP with ingredients that are traditionally acclaimed and established, nature derived, and proved by modern Science to be safe and effective.





# IN THE MARKET



AGRI EVENT - INTERNATIONAL YEAR OF MILLETS, SHILPARAMAM

HOW WE DO IT?



# DHC Formulates NFP that is just right for you, and works for you

For you, we learned your body has 226 types of cells and they need specific nutrients to live and perform their function. We delicately blend and curate NFP with ingredients backed by scientific studies, including the latest research on prevention, reducing risk and incidence of life lifestyle diseases. Specific, target, pure, potent ingredients in efficacious quantities work synergistically to provide nutrients to cells to get the desired physiological health benefit.



# DHC Assures Quality Ingredients for use in your NFPs

For you, we process our own ingredients and ensure quality assurance for purity and potency from farm to finished product. We believe the goodness of the final product is derived from the way an ingredient is grown, cleaned, processed, potentiated and concentrated. The ingredients used to comply with the highest standards and are in compliance with FSSAI [India], GRAS [USA] and globally accepted ICA. We believe our clients deserve products of the highest quality and purity. We use natural, non-toxic, and write down to organic and vegan ingredients.



# IN THE MARKET



QMART PREMIUM STORE, GACHIBOWLI - HYDERABAD



IT & MEDIA COMPANY, MADHAPUR - HYDERABAD





# DHC makes NFP at its own GMP Factory

For you, we manufacture NFP at our own ISO, GMP Certified, and FSSAI [India]; US [DSHEA] compliant plant. We are not dependent on others to make our products. Brand makers, marketers use our resources and facility to convert their idea into an NFP

# **DHC delivers direct from the factory, fresh produced NFPs**


For you, we deliver NFP direct from the factory, fresh produce. You can pick from a select nearby community grocery, health, and wellness product store or preferably from your own factory online store ([www.beyoungstore.com](http://www.beyoungstore.com)).

NFPs are sensitive to the supply chain environment and temperature conditions that can affect potency and efficacy, as they are made from perishable natural food ingredients.





# SUPPLY CHAIN CONTROL





## **Attractively Priced Nutraceutical Food Product (NFP)**



# **DHC delivers value for every penny invested in NFPs**

For you, we keep prices as affordable as we can. We do not subscribe to the view that only high-priced NFPs have quality and efficacy. We give the best quality in efficacious quantities that work. We neither compromise on quality nor underdose, to make products affordable. We curtail big marketing celebrity spends to recover from you the same, via price. We spend on the core and keep packing looks minimalistic and clean, ensure hygiene, shelf-life and protection of the final product you consume.



# DHC delivers experience and expertise in NFPs

For you, in service since 1996. Founded by innovator, bio-scientist, who knows how the body works, love name Dr. Minto, Phd.

Dr. Minto has to his credit over **1600 nutraceutical recipes for you**, curated over 40 years of dedicated efforts on discoveries 'how to prevent disease and extend longevity with nutrients'.

He with a team of Phds in nutraceutical science, has **served over 100 Crore consumer doses of NFPs** and benefited millions of users. An unparalleled industry testimony. The Chief NFP Chef, Minto, as he like to be known, welcomes you to 'refurbish your home where you live, your body.'

# DHC Rekindles the importance of nutrients, NFPs for a healthy life

For you, transforming health and fitness with God provided natural solutions and not man-made chemicals. The Father of modern medicine, Hippocrates believed and advocated "Let Food Be Thy Medicine and Medicine Be Thy Food". DHC rekindles Hippocrates' belief and advocated nutrients to prevent diseases. Before the advent of modern medicines, some 150 years ago natural nutrients kept our ancestors healthy, fit and even cured diseases. Believe it, our ancestors lived healthier, fitter and longer life, happier life and suffered less as they gracefully aged.







**OUR FUTURE  
PLAN AND  
GOALS**

# **DHC is future-ready, with NFPs for tomorrow**

For you, predicting the emerging lifestyles and discovering nutraceutical solutions to keep you safe.

Developing antidotes for the silent killer, the bulging 'nutrient gap' that is the cause of discomfort, disorder, disease, and disability.

We are ready for your tomorrow today.

# DHC shares value from NFPs

Your business creates value. At DHC we share the value. As an SME DHC converted itself into a public company and is successfully listed on the Bombay Stock Exchange (BSE). 1000 plus value creators share the ownership of DHC. Regular additions testify to the growing trust. We salute the value supporters.

Trust underpins everything we do. We have maintained our acknowledged emergence in environmental, social and governance, demonstrated by our sector-steady position in the exchange. We remain deeply committed to addressing the issues that matter for our company, including pricing and access, global nutraceuticals, the environment, and inclusion and diversity, working with integrity and care.





# DHC's Proprietary Nutraceutical Food Products (NFPs) serve the following Wellbeing needs

Nutraceuticals Blended with Nutraceutical food ingredients to target Specific health Risks, improves fitness and wellbeing.

- ➔ Immunity Enhancing Nutrients
- ➔ Eye Fitness Nutrients
- ➔ Oxygen enhancing Nutrients
- ➔ Nutrients to enhance physical energy
- ➔ Nutrients to enhance mental energy
- ➔ Nutrients to enhance Sexual energy
- ➔ Heart Health Nutrients
- ➔ Bone Health Nutrients
- ➔ Joint Health Nutrients
- ➔ Prostrate Health Nutrients
- ➔ Liver Health Nutrients

# OUR PRODUCTS

---

- ➔ Gut Health and Cleansing Nutrients
- ➔ Insulin Activation Nutrients
- ➔ Body Detox Nutrients
- ➔ Hair Health and beauty Nutrients
- ➔ Skin Health and beauty Nutrients
- ➔ Cell Growth Nutrients
- ➔ Tissue Repair and Building Nutrients
- ➔ Get well Soon Nutrients
- ➔ Better Sleep Nutrients
- ➔ Focus and Clarity enhancing Nutrients
- ➔ Nutrients to Sustain Stress reduce Organ Damage
- ➔ Rest and Rejuvenate Nutrients
- ➔ Mood Elevating Nutrients
- ➔ Digestive Support Nutrients
- ➔ Anti-aging Antioxidant Nutrients



# OUR PRODUCTS

- ➔ Performance Enhancing Nutrients
- ➔ Pre-Pregnancy Fitness Nutrients
- ➔ Menses Fitness Nutrients
- ➔ Pregnancy Trimester Care Nutrients
- ➔ Post-natal Nutrients
- ➔ Puberty Growth Nutrients
- ➔ Weight management Nutrients
- ➔ Fertility enhancing nutrients
- ➔ Menopause Delaying Nutrients
- ➔ Andropause Delaying Nutrients
- ➔ Nutrients to reduce risk of Brain fog; Tech Neck, Tech eye syndrome



# IN THE NEWS

<https://www.adgully.com/after-floods-and-pandemic-washout-brands-betting-big-on-onam-this-year-122018.html>

**ADGULLY** ADVERTISING - MARKETING - MEDIA - PR - EXCLUSIVES - EVENTS - UPCOMING EVENTS - INTERNATIONAL

## After floods and pandemic washout, brands betting big on Onam this year

**MARKETING**

5 MINUTES TO READ  
AUG 31, 2022

**BY FRODO**  
@adgully  
News in the domain of Advertising, Marketing, Media and Business of Entertainment



Onam festivities this year have begun with much more positive sentiments amid a resurgent market. The festivities have remained subdued in the last couple of years due to the global pandemic, while the devastating floods in 2018 robbed all the joy of festival. Thus, there is great expectation from the Onam festival in 2022 by brands and advertisers for a bumper season.

The biggest festival in Kerala, Onam sees a spurt in purchases across categories, especially apparel, jewellery, consumer durables, household electronics and more. The buying frenzy and the plethora of offers by brands have transformed Onam into a mega shopping carnival from being a mere harvest festival.

**RELATED ITEMS** **SHARE**



"Celebrations in India are incomplete without the splurging involved, be it on food, clothes, decor or outings – and this now includes a spend on self-care nutrition and wellness," notes **Dr. Minto Purshotam Gupta**, Chairman and Managing Director, Deccan Healthcare Ltd.

<https://nuffoodsspectrum.in/2022/08/25/nutrient-deficiencies-are-silent-killers.html>

## Nutrient deficiencies are silent killers

August 25, 2022 **COLUMN** 3 minute read




The popular rephrased proverb 'An apple a day keeps the disease away' is more relevant today. Immunity and wellness products are the modern day 'apple'. They provide food nutrients every day, in required adequate quantities, to the body cells and make them function optimally. Because fit body cells, healthy body cells, mean fit and healthy body.

## 5 paisa

<https://www.5paisa.com/news/interview-with-deccan-healthcare-ltd>

Products ▾ Stocks ▾ Mutual Funds ▾ IPO ▾ Resources ▾

### Interview with Deccan Healthcare Ltd



Deccan Healthcare Ltd  
**Dr. Minto Purshotam Gupta**  
Chairman and Managing Director  
Deccan Healthcare Ltd

By Nipuna Research Team | Last Updated: 2022-08-12 11:13:58-43-05:20:07

▶ 0:00 / 3:32

We have improved demand by innovative wellness products that help people avoid sickness, asserts Dr. Minto Purshotam Gupta, Chairman and Managing Director, Deccan Health Care Ltd.



## Dalal Street Investment Journal

<https://www.dsij.in/dsijarticledetail/in-an-interaction-with-dr-minto-purshotam-gupta-chairman-and-managing-director-deccan-healthcare-ltd-25974-1>



Products - Insight - Markets -

### In an interaction with Dr Minto Purshotam Gupta, Chairman and Managing Director, Deccan Healthcare Ltd

Armaan Madhani / 12-Aug, 2022 / Categories: Trending, Interviews

[Facebook](#) [Twitter](#) [LinkedIn](#) [WhatsApp](#) [Email](#) [Telegram](#)



## Biz News Desk

<https://biznewsdesk.com/business/deccan-healthcare-plans-to-expand-in-india-and-overseas/>

**BUSINESS**

### Deccan Healthcare plans to expand in India and overseas

NEWS DESK 12 AUG 2022

Share

Read Time: 2 Minute, 16 Second



Hyderabad, August 2022: Deccan Healthcare Ltd, a leading nutraceutical products company with an aim to help consumers age gracefully, reduce risk of disease, prevent disease, and live a better quality of life, is expanding its product portfolio to include consumer health problems arising out of long digital screen time viewing and a diverse distribution network, both in India and overseas.

Commenting on the strategy, Mr. Minto Purshotam Gupta, Chairman and Managing Director said, "We would continue to increase our footprint in offline stores and expand into domestic and international markets in UAE and USA. We are currently exploring placing our products in 600 retail stores in the USA, which is the largest market in our segment."

"We plan to expand our global footprint with specific segmented products for the mass market in US, UK and Europe. We are looking at expanding focus in these markets over the next 5 years. We also look to do local manufacturing here. From 600 retail stores in the US, we would like to scale it up to 9000 in the next 5 years and be part of all the major retail chains in US."


## Business News Week

<https://businessnewsweek.in/business/deccan-healthcare-plans-to-expand-in-india-and-overseas/>

**BUSINESS**

### Deccan Healthcare plans to expand in India and overseas

Aug 27, 2022



## APN News

<https://www.apnnews.com/deccan-healthcare-plans-to-expand-in-india-and-overseas/>

## Deccan Healthcare plans to expand in India and overseas

Published on August 26, 2022

**Hyderabad** : Deccan Healthcare Ltd., a leading nutraceutical products company, with an aim to help consumers age gracefully, reduce risk of disease, prevent disease, and live a better quality of life, is expanding its product portfolio to include consumer health problems arising out of long digital screen time viewing and a diverse distribution network both in India and overseas.

Commenting on the strategy, **Mr. Minto Purshotam Gupta, Chairman and Managing Director** said, "We would continue to increase our footprint in offline stores and expand into domestic and international markets in UAE and USA. We are currently exploring placing our products in 600 retail stores in the USA which is the largest market in our segment.

We plan to expand our global footprint with specific segmented products for the main market in US, UK and Europe. We are looking at expanding focus in these markets over the next 5 years. We also look to do local manufacturing here. From 600 retail stores in the US, we would like to scale it up to 6000 in the next 5 years and be part of all the major retail chains in US."



## Bullet Daily News

<http://bulletedailynews.blogspot.com/2022/08/deccan-healthcare-plans.html>





## The Indian Practitioner

<https://theindianpractitioner.com/deccan-healthcare-plans-to-expand-in-india-and-overseas/>



The screenshot shows the website for 'The Indian Practitioner'. At the top, there is a red navigation bar with links for Home, Journal, Articles, Medi News, Features, Interviews, Opinions, and Events. Below this, the article title 'Deccan Healthcare plans to expand in India and overseas' is displayed, along with the date 'August 27, 2022'. A small photo of a man in a suit is visible. To the right, there is a 'Current Issue' section featuring the cover of 'The Indian Practitioner' magazine for July 2022. The cover lists various articles and topics.

## Smart Business News

<https://smartbusinessnews.com/health/deccan-healthcare-plans-to-expand-in-india-and-overseas/>

## Deccan Healthcare plans to expand in India and overseas

August 27, 2022



# IN THE NEWS

**B2B Chief**

<https://b2bchief.com/deccan-healthcare-plans-to-expand-in-india-and-overseas/>

Healthcare - News

Deccan Healthcare plans to expand in India and overseas

3 days ago



**Business News This Week**

<http://businessnewsthisweek.com/health/deccan-healthcare-plans-to-expand-in-india-and-overseas/>

**Deccan Healthcare plans to expand in India and overseas**

© August 27, 2022   Rekha Nair   Health   0





## Media Bulletins

<http://mediabulletins.com/business-world/deccan-healthcare-plans-to-expand-in-india-and-overseas/>

Business World Health

### Deccan Healthcare plans to expand in India and overseas

August 27, 2022



## Shreyas Wedmedia Solutions

<http://pr.shreyaswebmediasolutions.com/business/deccan-healthcare-plans-to-expand-in-india-and-overseas/>

Business

### Deccan Healthcare plans to expand in India and overseas

By Prabeen  
AUG 27, 2022



## Free Press Journal

<https://epaper.freepressjournal.in/3570730/Free-Press-Mumbai-Epaper-Edition/27-Aug-2022#page/8/3>

### Deccan Healthcare plans to expand in India and overseas

Deccan Healthcare Ltd. with an aim to help consumers age gracefully, reduce risk of disease, prevent disease, and live a better quality of life, is expanding its product portfolio to include consumer health problems arising out of long digital screen time viewing and a diverse distribution network both in India and overseas. Commenting on the strategy, Minto Purshotam Gupta, Chairman and Managing Director said, "We would continue to increase our footprint in offline stores and expand into domestic and international markets in UAE and USA."



# AWARDS & RECOGNITION

## AWARDS AND ACCOLADES



Top-100 SMES in India, SKOCH Order-Of- Merit awarded by Sameer Kochar, Chairman, SKOCH Group

Best Fastest Growing Online Nutrition Store, Associate Chambers of Commerce & Industry of India Certificate of Excellence

Fastest Growing SME of the year- Large Size, SME Business Excellence Awards Certificate of Excellence

Amongst Best 50 SME Companies to Invest in 2019, Dalal Street Investment Journal

International Gold Star Awards For Talented Personalities, Global Achievers Foundation

Honoured as Speaker in the Scientific Session, 70th Indian Pharmaceutical Congress, organised by IPCA

Deccan HealthCare among top brands, Hans News Service



Sharing similar views, Gaurav Aggarwal, a successful nutraceutical health entrepreneur and CEO of OneLife and Director of Latsons, India opined "Doctors largely are not familiar with nutraceuticals. Their focus has traditionally been on pharmaceutical drugs. There are a few doctors who are open to understanding nutraceuticals and functional foods and suggesting the same to their patients but that is a very small number."

However, in order to impart correct knowledge to doctors, nutraceuticals are needed to be supported with strong clinical trial results. The obtained supporting data can help ease off marketing approval from the regulatory authorities as well.

When further asked about what steps can be taken to make doctors aware about nutraceuticals and functional foods, Gaurav said, "A lot of work with doctors is needed in this space. Doctors have always focused on traditional pharma drugs. Consumers are shifting from synthetic drugs to more organic/ natural alternatives. The doctors also



"Nutraceuticals are value-added pills. They provide vitamins, minerals, amino acids, phytonutrients, etc. helping the consumer meet RDA. When RDA of these nutraceutical ingredients are not met by regular food they result in the deficiency of micronutrients. Increase in the deficiency of micronutrients with time causes medical conditions. At this stage, the consumer visits the doctor who prescribes medicines to overcome nutrient deficiencies and treat the patient. Pharmaceutical vitamins/mineral category is one of the biggest markets."

- Minto Gupta, CMD, Deccan Health Care Limited


realize this shift and have started looking into the nutraceutical space and the various products offered in this category. Companies need to educate and explain various benefits of the products to the doctors and convince them of the use and benefits work closely with doctors before a doctor would prescribe the products to their patients. Studies along with sampling are a key to gain the doctor's confidence."

"In the present scenario, I believe that except for registered dietitians and nutritionists, doctors do not receive a sufficient degree of training with regard to nutrition. Training doctors both at the entry level and throughout their course in nutritional sciences/dietetics and some physiology and plant chemistry will help expand their understanding of these products in a better way", said Nihal Mariwala, Founder of Setu, a homegrown natural nutritional supplements brand while sharing his thoughts on the steps needed to be taken in order to create awareness amongst doctors.

Dr. Sakharam suggested "A structured approach towards the KOL education on nutraceuticals is the key. Partnership between industry and academia, proactive and liberal initiatives by nutraceutical industry leaders towards KOL education and targeting of endorsement of

product quality done through KOL that effective promotion and of physicians and nutraceuticals is

With an increase in the food prescribed time is ripe and recommended by doctors closely with doctors they are





# AWARDS & RECOGNITION

## AWARDS AND ACCOLADES



India's 50 Transformational Brands, Winning category - Wellness Products &  
Top 50 transformational business leaders 2019 at House of Lords British Parliament and the Westminster conference centre, London

Certificate of Appreciation for Supporting Gender Diversity in India, Asian Women Leadership Summit

Sustainability Solution Provider of the Year 2019, India Sustainability Summit & Awards

Leader with a Purpose Award, Transformance India Leadership Summit & Awards

The Marketing Mastermind 2019, India's 50 Transformational Brands

Most Promising Business Leaders of Asia 19-20, The Economic Times

Women Entrepreneur of the year 2019, Business Connect Magazine



**MOHITA GUPTA,**  
Chief Business Officer, Deccan Healthcare

"With the ever-increasing digital penetration, Asia is placed uniquely to provide a platform to democratize consumer healthcare in form of increased penetration with smart pricing as the base, while efficiently redefining client-centered markets across the globe. This is in line with UN's Third Sustainable Development Goal (SDG) - "Ensure healthy lives and promote well-being for all at all ages". The current pace of digital innovations in consumer healthcare in Asia, powered through data-driven insight into social impact, given the large population base, can help develop a unique business model for improvement with technological interventions in this ever-promising sector."

# AWARDS & RECOGNITION

### MOHITA GUPTA

THE YOUNG ENTREPRENEUR WORKING TOWARDS THE NUTRITIONAL WELLNESS OF PEOPLE THROUGH BE YOUNG STORE



**BE YOUNG**  
Redefining Quality of Life

**MOHITA GUPTA**  
Chief Marketing Officer, Deccan HealthCare & CPG

There are all to connect with nature, and provide the right nutrients and energy to achieve superior Quality of Life. Entrepreneurial innovation and manufacturing ethos of each one ensured, BE YOUNG, works the best in nature through science, helping all consumers to connect with nature through science. This helps the formulation family reduce the Recommended Dietary Allowance (RDA) towards nutritional solutions for optimal nutrition, thereby improving Quality of Life.

BE YOUNG, began with the growing number of people who are over-weight and obese, leading to a rise in chronic diseases and health challenges through digital platforms. BE YOUNG, in alignment with the Global Nutrition and Health Goals (United Development Goals, having committed Quality of Life and Nutrition, together, and in their striving pathway to better livelihoods. They are building a community where every person is healthy or engaged or change maker to improve Quality of Life.

“Gupta says, “Our team is working together towards better Quality of Life through ensuring health, wealth and happiness as

**MISSION AND VISION STATEMENT IN SUPPORT OF THE GOALS**  
 Their core mission is to improve Quality of Life, that focus on the Safety of Food & Nutrition. BE YOUNG, when they started the process of growing the reach, which made BE YOUNG, approach more to nature. BE YOUNG, employee teams in areas of food & health, specifically through nature like and their inspiration then, they there to the best and most sustainable. Employee products are innovated and designed by Dr. NP Gupta, her father who has spent decades working on nutrition and healthcare along with his team of doctors, PhD students, and functional nutritionists. Most agree with environmental responsibility and sustainable biological science approaches, practices. BE YOUNG's focus is functional food products, ingredients, and nutritional value to their natural origin.

**LABOR STRUCTURE IN AN E-COMMERCE ENVIRONMENT**  
 Labor structure in an e-commerce environment is very complex. They are working according to unique programs, investments and having an excellent health. Gupta company culture, “Our team is growing, and the perspective on employees’ growth. “There are no special days for men and women. All 3 takes in the role of a leader. “But it takes more than willpower to care in an e-commerce environment.”

**BE YOUNG'S CONTRIBUTIONS**  
 • Focused on the large market opportunity of USA & India.  
 • Training and development of young talent, better ways engaging in training and sales of BE YOUNG products.  
 • Value & Cost driven.  
 • A technology and data driven to create digital journey experiences.

**BE YOUNG'S CONTRIBUTIONS**  
 • Rapid digitization and an increase in social media usage have increased awareness regarding nutrition and improved nutritional information.  
 • Changing of lifestyle is increasing the incidence of several diseases, such as diabetes, blood pressure, obesity and cardio-vascular problems among people, in urban areas. Higher income groups are the main consumers of preventive healthcare, and this will pose a considerable rise. Moreover, mental health consciousness, the rapid growth of the e-commerce market and online purchase, increase and driving the growth of their business model.

**BE YOUNG'S CONTRIBUTIONS**  
 • Employee teams in areas of food & health, specifically through nature like and their inspiration then, they there to the best and most sustainable. Employee products are innovated and designed by Dr. NP Gupta, her father who has spent decades working on nutrition and healthcare along with his team of doctors, PhD students, and functional nutritionists. Most agree with environmental responsibility and sustainable biological science approaches, practices. BE YOUNG's focus is functional food products, ingredients, and nutritional value to their natural origin.

**BE YOUNG'S CONTRIBUTIONS**  
 • Focused on the large market opportunity of USA & India.  
 • Training and development of young talent, better ways engaging in training and sales of BE YOUNG products.  
 • Value & Cost driven.  
 • A technology and data driven to create digital journey experiences.

**BE YOUNG'S CONTRIBUTIONS**  
 • Focused on the large market opportunity of USA & India.  
 • Training and development of young talent, better ways engaging in training and sales of BE YOUNG products.  
 • Value & Cost driven.  
 • A technology and data driven to create digital journey experiences.

## Certificate of Excellence

**CIMS**  
Medica

### HEALTHCARE EXCELLENCE AWARDS 2020

**VIRTUAL CEREMONY**  
Sunday, 5<sup>th</sup> July 2020

**INNOVATIVE ONLINE WELLNESS STORE**  
**BEYOUNG STORE**  
(DECCAN HEALTHCARE)

Authorised Signatory  
 Dr. Monica Spod Bhatia  
 Managing Director - CIMS Medica  
 Month of: 07 July 2020

## Congratulations FOR WINNING COMPLIANCE TEAM 2020 AWARD

**MOHITA GUPTA**  
Deccan Health Care Limited

Hosted by: **legosix**  
 Co-hosted by: **BSE**, **elephant**  
 Event Partners: **WITNESS**, **HDFC**, **VICTORINOX**

### BE YOUNG: LEVERAGES ITS PROFITABLE E-COMMERCE PLATFORM IN THE \$4BN INDIAN NUTRACEUTICAL INDUSTRY THROUGH INNOVATIVE FOOD PILLS AND NUTRITIONAL MEALS

**MOHITA GUPTA**  
Chief Marketing Officer, Deccan HealthCare & CPG, BE YOUNG

**BE YOUNG'S CONTRIBUTIONS**  
 • E-COMMERCE PLATFORM BE YOUNG STORES, 100% IN-PHYSICAL, 30%+ NEW CUSTOMERS REGISTERING EVERY MONTH  
 • NUTRACEUTICALS, FOOD PILLS AND MEALS PRODUCTS SHINE APPEAR TO MILLIONS & ARE MOST NUTRITIONAL, SUSTAINABLE

**BE YOUNG'S CONTRIBUTIONS**  
 • Rapid digitization and an increase in social media usage have increased awareness regarding nutrition and improved nutritional information.  
 • Changing of lifestyle is increasing the incidence of several diseases, such as diabetes, blood pressure, obesity and cardio-vascular problems among people, in urban areas. Higher income groups are the main consumers of preventive healthcare, and this will pose a considerable rise. Moreover, mental health consciousness, the rapid growth of the e-commerce market and online purchase, increase and driving the growth of their business model.

**BE YOUNG'S CONTRIBUTIONS**  
 • Employee teams in areas of food & health, specifically through nature like and their inspiration then, they there to the best and most sustainable. Employee products are innovated and designed by Dr. NP Gupta, her father who has spent decades working on nutrition and healthcare along with his team of doctors, PhD students, and functional nutritionists. Most agree with environmental responsibility and sustainable biological science approaches, practices. BE YOUNG's focus is functional food products, ingredients, and nutritional value to their natural origin.

**BE YOUNG'S CONTRIBUTIONS**  
 • Focused on the large market opportunity of USA & India.  
 • Training and development of young talent, better ways engaging in training and sales of BE YOUNG products.  
 • Value & Cost driven.  
 • A technology and data driven to create digital journey experiences.

**BE YOUNG'S CONTRIBUTIONS**  
 • Focused on the large market opportunity of USA & India.  
 • Training and development of young talent, better ways engaging in training and sales of BE YOUNG products.  
 • Value & Cost driven.  
 • A technology and data driven to create digital journey experiences.





# AWARDS & RECOGNITION

## AWARDS AND ACCOLADES

Award For The Fastest Growing Nutraceutical Brand, Zee Business - National Healthcare Leadership Congress & Awards

Sustainable Product Innovation Award, World Federation of CSR and World Sustainability Congress

Brand of the Year Health Supplements, The CEO Magazine

Fastest growing online nutrition store, ASSOCHAM Nutraceutical Excellence Award

Best Wellness Brand - by ASSOCHAM Nutraceutical Excellence Award

Fastest Growing Online Nutraceutical Store, CIMS Medica Nutrition & Wellness Awards



**DECCAN HEALTH CARE LIMITED**  
STAY WISE. STAY HEALTHY WITH DECCAN HEALTHCARE LIMITED THAT ENSURES QUALITY OF LIFE

**Deccan Health Care Limited**  
I Stay WISE

**Deccan Health Care Limited**  
I Stay WISE

**Deccan Health Care Limited**  
I Stay WISE

What we eat influences our body to a great extent that can either add quality or subtract it from life, depending on conscious or unconscious choices. Deccan HealthCare Limited upholds the standards of life by providing qualitative nutraceutical products. The motto of the national organization never strayed from the founding philosophy - "We believe in ensuring Quality of Life to its fullest in as simple as eating an apple every day". Building foundation on this ideology, they work hard every day to make quality nutraceutical products and services, which help people to live life up to its full potential every day. Quality Of Life (QOL) lies at the heart of their philosophy.

They devote life into their commitment innovation, technology based on age or life of 10000 days with each life stage of 8000 days. They meet stringent product guidelines defined by WHO and their products are formulated and manufactured within the ambit of the international guidelines laid out by FDA with stringent quality control measures. This ensures that their products meet the highest industry standards.

**DIFFERENT FROM THE REST**  
DHCL sources high quality ingredients in all its products and source food based materials from farms, which are organic. Many of these farms are in high altitude areas of the Himalayas where sustainable farming practices are followed, thereby reducing the chances of contamination. They bring in pure raw material from the best of farming practices. DHCL sources, growing, harvesting and processing plants, roots and seeds on farms where no pesticides are used. Many of these farms use organic growth promoters like plant leavers, etc. Their safety and potency are assured through strict quality control and manufacturing practices. The quality and reach of products lie in its high concentration of beneficial active ingredients and nutritional value ingredients, which are extracted right from the raw materials. Their products have extracts from traditionally known herbs and food, which contain unique and assured levels of active ingredients and nutrients based on RDA, which provide the nutritional health benefits in just one or two soft gels a day. All of this makes their nutraceutical solutions truly potent.

**WHY DHCL NUTRACEUTICALS WORK AND WHY?**  
Everyone irrespective of age or physical state should take nutraceutical pills. They need a variety of nutrients each day to stay healthy, including calcium and vitamins. To protect their bones, help aid to produce and maintain new cells, and vitamins A to preserve a healthy immune system and vision.

DHCL Nutraceutical Pills contain vitamins and other healthy substances not found regular food diet, which works together to keep us healthy. We can't get all

some synergistic effect from daily food alone. Taking various vitamins or minerals in higher quantities recommended alone may even interfere with nutrient absorption or cause side effects that's why they have researched nutraceutical solutions based on RDA that is the most essential indicator.

**HOW WE BELIEVE IN THE COMPANY**  
As an one of the best brands by Deccan Health Care Nutrition Food Pills and Meals, who they believe in the Company every day, and you are bound to hear "STAY WISE, STAY HEALTHY". These simple words define the inherent belief that drives them. People have believed to be trusted to lead with the biggest responsibility but the biggest responsibility as well.

"STAY WISE" reflects its commitment to WHO - Health Care Wellness in their time, changing material sources and spending results in medical expenses to retain the quality of life as we grow. Success at the cost of quality of life is no success. Utilizing technology with pure and innovation ensures that all business should focus the quality of life with their Nutraceutical Food Pills and Meals.

**RESEARCH AND DEVELOPMENT**  
From state-of-art innovation centre and manufacturing facilities to state-of-art laboratories, DHCL sources the best to sustain through science, helping all consumers connect to nature every day. This helps them formulate to closely evaluate the Recommended Dietary Allowance (RDA) to provide nutritional solutions just on the path toward optimal nutrition. And all the improved Quality of Life has to offer.

DHCL sources the advanced goodness of nature through the brilliance of advanced science to help them all connect to nature and provide the right nutrients you need every day to achieve improved Quality of Life. Since 1996, they have innovated and scientific processes to become based on the recommendations of the scientific panel and scientific committees in respect of the RDA values for various nutraceuticals.

**MISSIONS BELIEVE IN THE BUSINESS**  
To inspire the wisdom of Business (Entrepreneur), Adhik says, "The fastest way to build your business is to build your confidence. Why? Because when you develop a true confident mindset, you're able to take huge and make a vision when you're excited. You're able to slow up, increase your visibility, and put out your offers consistently without worrying about judgment or rejection. When I focused on the facts, I discovered a sense of confidence, which I'd never experienced before. After helping hundreds of clients not only experience the same but also increase their revenue than other times. I've discovered an strategy will work as well as that being the confidence to adapt that strategy."



# AWARDS & RECOGNITION



ASSOCHAM NUTRACEUTICAL  
EXCELLENCE AWARDS 25.07.2018

**Best Wellness Brand  
&  
Best Fastest Growing Online  
Nutrition Store**



BEST FASTEST GROWING ONLINE NUTRITION STORE



Best Wellness Brand



**Woman Entrepreneur  
of the year 2018  
Future Woman Leader  
Summit & Awards**



**Sustainable Product  
Innovation Award**  
October-2018  
World Federation of CSR  
and World Sustainability Congress





# AWARDS & RECOGNITION

THE WEDNESDAY 3 JULY 2019

Forecast: Partly cloudy. Temp: 30-29°C. Min: 24°C. Humidity: 60% Rainfall: 0-25

# HANS INDIA

• Simultaneously published from Hyderabad | Warangal | Tirupati | Amaravati | Visakhapatnam | Khammam | Kurnool | Delhi •



Mohita Gupta, COO, Deccan HealthCare receiving top 50 Brands Transforming India in London

## Deccan HealthCare among top brands

### HANS BUREAU

Hyderabad: Deccan HealthCare Ltd, a wellness products company on Tuesday said it is recognised as one of the top 50 Brands Transforming India, by The Westminster Church House Conference in London. The award was given by WCRC, an

agency of the UK's House of Lords, in recognition of its purpose and quality of the products.

The city-based company is in the wellness space from 1996. DHCL has an offering of over 1,500 products along with food supplements extracted from natural ingredients, available under the brand name 'Be

Young'. The company has an initiative called as Be-YoungBharat, which aims to spread awareness on undernourishment of women and children in India.

Mohita Gupta, COO, Deccan HealthCare, said: "It was a proud moment for our company, but I felt great because we won it for the country".

Dear Ms. Mohita Gupta,

Greetings from Women Entrepreneurship Platform (WEP), NITI Aayog!

Please accept our congratulations for making it to top 200 out of more than 2300 nominations considered for WTI Awards 2018. It's indeed a great achievement.

**RANKED IN TOP 200 WOMEN  
TRANSFORMING INDIA AWARDS 2018  
WOMEN ENTREPRENEURSHIP PLATFORM,  
NITI AAYOG GOVERNMENT OF INDIA**




**NEWS MOMENT  
ENGLISH WEEKLY**












---

## STATUTORY SECTION





## NOTICE

Notice is hereby given that the 26<sup>th</sup> Annual General Meeting (AGM) of members of Deccan Healthcare Limited will be held on Friday the 30<sup>th</sup> September, 2022 at 12:00 PM through Video Conferencing (VC) or Other Audio Visual Means (OAVM), to transact the following businesses:

### ORDINARY BUSINESSES

1. To receive, consider and adopt the Standalone and Consolidated Audited Financial Statements containing the Balance Sheet as at 31st March, 2022, the Statement of Profit & Loss, Cash Flow, and notes thereto of the Company for the Financial Year ended 31st March 2022 and the reports of the Board of Directors and Auditors thereon as on that date.
2. To appoint a director in place of Mr. Hitesh Patel (DIN: 02080625) who retires by rotation at this Annual General Meeting and being eligible offers himself for re-appointment.

### SPECIAL BUSINESSES

3. TO CHANGE THE DESIGNATION OF MRS. MEENAKSHI GUPTA FROM WHOLE TIME DIRECTOR (DIN: 00574624) TO NON EXECUTIVE DIRECTOR.

To consider and if thought fit to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

**“RESOLVED THAT** in suppression of all the earlier resolutions approved by the shareholders at

the 21<sup>st</sup> Annual General Meeting of the company, and upon the recommendation of the Board of Directors, Mrs. Meenakshi Gupta, who was appointed as the whole time director of the company for a period of three years from 30<sup>th</sup> August, 2020 till 31<sup>st</sup> August, 2023 be and is hereby re designated and appointed as a non-executive director with effect from the date of this meeting i.e. 30<sup>th</sup> September, 2022 whose term of office shall be liable to determination by retirement of directors by rotation.

**RESOLVED FURTHER THAT** all the terms and conditions as were applicable to a whole time director stands withdrawn w.e.f. 30th September, 2022 with respect to the payment of remuneration and others.

**RESOLVED FURTHER THAT** the Board of Directors be and is hereby authorised to modify the designation of Mrs. Meenakshi Gupta, from time to time.

**RESOLVED FURTHER THAT** the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things and to take all such steps as may be considered necessary to give effect to the aforesaid resolution.”

4. TO APPROVE THE TRANSACTIONS/CONTRACTS/ARRANGEMENTS WITH RELATED PARTIES UNDER REGULATION 23 OF THE SEBI (LODR) REGULATIONS, 2015:

To consider and if thought fit, to convey assent or dissent to the following **Special Resolution**:

**RESOLVED THAT** pursuant to the provisions of Regulation 23 of the SEBI (LODR) Regulations, 2015 (“SEBI Listing Regulations”) read with the



provisions of section 188 read with section 185 of the Companies Act, 2013 and other applicable provisions, if any, (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and the Company's policy on Related Party Transactions, consent of the members of the company be and is hereby accorded to enter into transactions/ contracts / arrangement, in the ordinary course of its business and on arm's length basis, for purchase, sale or deal in the products, goods, stock in trade, Transfer of Resources including receiving/ providing loans and advances or such other transactions, on such terms and conditions as may be mutually agreed upon between the company and all related party for an amount upto Rs.100 Crores (Rupees One Hundred Crore only) in each financial year.

**RESOLVED FURTHER THAT** the Board of Directors of the company, jointly and/or severally, be and is hereby authorized to do or cause to be done all such acts, deeds and things, settle any queries, difficulties, doubts that may arise with regard to any transaction with the related party, finalize the terms and conditions as may be considered necessary, expedient or desirable and execute such agreements, documents and writings and to make such filings as may be necessary or desirable, in order to give effect to this Resolution in the interest of the company."

---

**5. TO GIVE AUTHORITY TO MAKE LOANS, GIVE SECURITY OR PROVIDE CORPORATE GUARANTEE UNDER SECTION 186 OF THE COMPANIES ACT, 2013.**

---

To consider and, if thought fit, to pass, with or without modification(s), the following resolution, as **Special Resolution** for authority to the Board to make loans, give security or provide corporate guarantee to companies/ body corporate in which directors are concerned or interested under section 186 of the Companies Act, 2013:

**"RESOLVED THAT** pursuant to provisions of section 185 read with section 186 and 188 and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Meetings of Board and its Powers) Rules, 2014 (including any amendment, modification or re-enactment thereof) the approval of Members of the Company, be and is hereby accorded for authority to the Board of directors and/ or committee thereof for providing any advance(s), loan(s), any loan represented by book debts, and/ or to give guarantee or to provide any security on the assets of the Company in connection with loan taken

by the companies/bodies corporate in which any director of the company is directly or indirectly concerned and/or interested from time to time subject to the maximum amount of Loans/ Advances and or guarantee and securities not exceeding 50.00 crores (Fifty Crores) at any point of time at an interest rate as may be mutually agreed."

---

**6. TO RATIFY THE APPOINTMENT OF MR. RAVI RAMPRASAD (DIN: 03077288) AS DIRECTOR.**

---

To consider and if thought fit to pass with or without modification(s), the following resolution as an **Ordinary Resolution:**

**"RESOLVED THAT**, pursuant to the provisions of section 161, 152 and other applicable provision of the Companies Act, 2013 read with Companies (Appointment and Qualification of Directors) Rules, 2014 (including any modification, re enactments made thereof for the time being in force), Mr. Ravi Ramprasad (DIN: 03077288), who was appointed as additional director by the Board of Directors in their meeting held on 02.09.2022 on the recommendation of Nomination & remuneration Committee and who holds office upto the date of ensuing annual general meeting only , be and is hereby appointed as Non-executive Director of the company, whose period of office shall be liable to determination by retirement of directors by rotation.

**RESOLVED FURTHER THAT**, the Board of Directors of the company be and is hereby authorized to do all such acts, deeds and things and take all such steps as may be considered necessary and expedient to give effect to the aforesaid resolution."

---

**7. TO REVISE THE REMUNERATION OF THE MANAGING DIRECTOR MR. MINTO PURSHOTAM GUPTA (DIN: 00843784).**

---

To consider and if thought fit to pass with or without modification(s), the following resolution as a **Special resolution:**

**"RESOLVED THAT** pursuant to the provisions of Section 197 read with Part I and Section I of Part II of Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof), applicable clauses of the Articles of Association of

the Company and recommendation of the Nomination and Remuneration Committee and Audit Committee, approval of the Company be and is hereby accorded for revision in the remuneration of Mr. Minto Purshotam Gupta [DIN:00843784], Managing Director of the Company, from existing Rs. 90 Lakhs p.a. to Rs. 1.50 Crores p.a.

**RESOLVED FURTHER THAT** except the above revision in the remuneration, the other terms and conditions remain unchanged as specified in the explanatory statement annexed with this notice.”

**8. TO REAPPOINT DR. MINTO PURSHOTAM GUPTA (DIN: 00843784) AS THE MANAGING DIRECTOR**

To consider and if thought fit to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Sections 197, 196 and 203 read with Schedule V and other applicable provisions of the Companies Act, 2013, and the Companies (appointment and remuneration of Managerial personnel) Rules, 2014 (including any statutory modification (s) thereto or re-enactment thereof for time being in force), the consent of the Members be and is hereby accorded for the re-appointment of Dr. Minto P. Gupta as the Managing Director of Company for a period of 5 Years with effect from 31st August, 2023 to 30th August, 2028, on the terms and conditions including Remuneration as set out in the Statement annexed to this Notice, with the liberty to the Board of Directors to alter and vary the terms and conditions including

the Remuneration so as not to exceed the limits specified in the Act, including any statutory modification(s) or re-enactment(s) thereof for the time being in force or any amendments and modifications that may hereafter be made and as may be agreed to between the Board of Directors and Dr. Minto P. Gupta.

**RESOLVED FURTHER THAT** the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things and to take all such steps as may be considered necessary to give effect to the aforesaid resolution.”

By order of the Board of Directors of  
Deccan Healthcare Limited

Sd/-

Date: 02.09.2022  
Place: Hyderabad

Apeksha Baisakhiya  
Company Secretary  
M.No.A53813



## NOTES:

1. In view of the massive outbreak of the COVID-19 pandemic, social distancing is a norm to be followed and pursuant to Circular No. 14/2020 dated 8<sup>th</sup> April, 2020, Circular No.17/2020 dated 13<sup>th</sup> April, 2020 issued by the Ministry of Corporate Affairs (MCA) followed by Circular No. 20/2020 dated 5<sup>th</sup> May, 2020, Circular No. 2/2021 dated 13<sup>th</sup> January, 2021 and Circular No. 2/2022 dated 5<sup>th</sup> May, 2022, physical attendance of the Members to the AGM venue is not required and Annual General Meeting (AGM) be held through Video Conferencing (VC) or Other Audio Visual Means (OAVM). Hence, Members can attend and participate in the ensuing AGM through VC/OAVM only and no physical presence at the meeting is required.
2. Pursuant to the Circular No. 14/2020 dated 8<sup>th</sup> April, 2020 followed by Circular No. 2/2021 dated 13<sup>th</sup> January, 2021, issued by the MCA, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC/ OAVM and participate thereat and cast their votes through e-voting.
3. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. However, this number does not include the large Shareholders holding 2% or more share capital, Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors, Secretarial Auditors, Scrutinizers, etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
4. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under section 103 of the Companies Act, 2013.
5. Pursuant to the provisions of section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended), and the Circulars issued by the MCA dated 8<sup>th</sup> April, 2020, 13<sup>th</sup> April, 2020, 5<sup>th</sup> May, 2020 13<sup>th</sup> January, 2021 and Circular No. 2/2022 dated 5<sup>th</sup> May, 2022 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has made an arrangement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, and independent agency for providing necessary platform for Video Conference/OAVM and necessary technical support as may be required. Therefore, the facility of casting votes by a member using remote e-voting system as well as e-voting on the day of the AGM will be provided by CDSL.
6. The Notice calling the AGM along with complete Annual Report has been uploaded on the website of the Company. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Ltd. at [www.bseindia.com](http://www.bseindia.com), and the AGM Notice is also available on the website of CDSL (agency for providing the Remote e-Voting facility and providing necessary platform for Video Conference/OAVM) i.e. [www.evotingindia.com](http://www.evotingindia.com).
7. This AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated 8<sup>th</sup> April, 2020 and MCA Circular No. 17/2020 dated 13<sup>th</sup> April, 2020, MCA Circular No. 20/2020 dated 5<sup>th</sup> May, 2020 Circular No. 2/2021 dated 13<sup>th</sup> January, 2021 and MCA Circular No. 2/2022 dated 5<sup>th</sup> May, 2022.
8. In compliance with the aforesaid MCA Circulars dated 5<sup>th</sup> May, 2020 and SEBI Circular dated May 12, 2020 followed by May 13, 2022, Notice of the AGM along with the Annual Report 2021-22 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/ Depositories. Members may note that the Notice and Annual Report 2021-22 will also be available on the Company's website - <http://www.deccanhealthcare.co.in>, websites of the Stock Exchanges i.e. BSE Limited at [www.bseindia.com](http://www.bseindia.com), and on the website of CDSL <https://www>.

evotingindia.com. However, if any specific request received from the members for demanding of the physical copy of the Annual Report will be provided by the company but subject to time taken by the courier and Postal Department looking at Covid-19.

9. Members joining the meeting through VC, who have not already cast their vote by means of remote e-voting, shall be able to exercise their right to vote through e-voting at the AGM. The Members who have cast their vote by remote e-voting prior to the AGM may also join the AGM through VC but shall not be entitled to cast their vote again.
10. The Explanatory Statement pursuant to section 102 of the Companies Act, 2013, which sets out details relating to special business at the meeting is annexed and forms part of the Notice.
11. Register of Members and Share Transfer Books of the Company will remain closed from Saturday, 24<sup>th</sup> September, 2022 to Friday, 30<sup>th</sup> September, 2022 (both days inclusive) for the Annual General Meeting. The voting rights of members shall be in proportion to their shares of the paid-up equity share capital of the Company as on the cut-off date 23<sup>rd</sup> September, 2022, (Friday).
12. CS Monika Bhatia, Practicing Company Secretary (M. No. ACS 10397 & C.P. No. 13348) and Proprietor of M/s. M.R Bhatia & Co., Company Secretaries, Ahmedabad has been appointed as the Scrutinizer to scrutinize the voting at the AGM and remote e-voting process in a fair and transparent manner.
13. Members desirous of obtaining any information concerning Accounts and Operations of the Company are requested to address their questions in writing to the Company at least 7 days before the date of the Meeting at its email ID [companysecretary@deccanhealthcare.co.in](mailto:companysecretary@deccanhealthcare.co.in) so that the information required may be made available at the Meeting.
14. The Members are requested to: a) - Intimate changes, if any, in their registered addresses immediately. b) - Quote their ledger folio number in all their correspondence. c) - Send their Email address to us for prompt communication and update the same with their D.P to receive softcopy of the Annual Report of the Company.
15. Members are requested to notify immediately any change in their address and also intimate their active E-Mail ID to their respective Depository Participants (DPs) in case the shares are held in demat form and in respect of shares held in physical form to the Registrar and Share Transfer Agent Bigshare Services Pvt. Ltd., having email Id [amarendranath.r@bigshareonline.com](mailto:amarendranath.r@bigshareonline.com) and [bsshyd@bigshareonline.com](mailto:bsshyd@bigshareonline.com) to receive the soft copy of all communication and notice of the meetings etc., of the Company.
16. The report on Management Discussion and Analysis also form part to the report of the Board Report.
17. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under the Companies Act, 2013 will be available for inspection by the Members electronically during the 26<sup>th</sup> AGM. Members seeking to inspect such documents can send an email to [companysecretary@deccanhealthcare.co.in](mailto:companysecretary@deccanhealthcare.co.in).
18. As per SEBI Circular dated 20th April, 2018 such shareholders holding shares of the company in the physical form are required to provide details of the Income Tax Permanent Account No. and Bank Account Details to the Share Transfer Agent of the Company, Big share services Pvt. Ltd., Bharat Tin Works Building, 1st Floor, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East ,Mumbai,Maharashtra,400059 having email Id [amarendranath.r@bigshareonline.com](mailto:amarendranath.r@bigshareonline.com) and [bsshyd@bigshareonline.com](mailto:bsshyd@bigshareonline.com).
19. SEBI has mandated submission of PAN by every participant in the securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN details to their depository participants. Members holding shares in physical form are requested to submit their PAN details to the company's RTA.
20. Members are requested to intimate changes, if any, pertaining to their name, postal address, e-mail address, telephone/mobile numbers, Permanent Account Number ('PAN'), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc., For shares held in electronic form: to their Depository Participant only and not to the Company's RTA. Changes intimated to the Depository Participant will then be automatically



reflected in the Company's records which will help the Company and its RTA provide efficient and better service to the Members. For shares held in physical form: to the Company's RTA in prescribed Form ISR -1 and other forms pursuant to SEBI circular SEBI/HO/MIRSD/MIRSD\_RTAMB/P/ CIR/2021/655 dated November 3, 2021, as per instructions mentioned in the form. The said form can be downloaded from the Members' Reference available on the Company's website <http://kritiindustries.com> under Standard documents for Investors and is also available on the website of the RTA.

21. Members may please note that SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD\_RTAMB/P/CIR/2022/8 dated January 25, 2022 has mandated the listed companies to issue securities in dematerialized form only while processing service requests, viz., Issue of duplicate securities certificate; claim from unclaimed suspense account; renewal/ exchange of securities certificate; endorsement; sub-division/splitting of securities certificate; consolidation of securities certificates/ folios; transmission and transposition. Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR-4. The said form can be downloaded from the Standard documents for Investors available on the Company's website <http://www.deccanhealthcare.co.in> and is also available on the website of the RTA. It may be noted that any service request can be processed only after the folio is KYC Compliant.

22. SEBI vide its notification dated January 24, 2022 has amended Regulation 40 of the SEBI Listing Regulations and has mandated that all requests for transfer of securities including transmission and transposition requests shall be processed only in dematerialized form. In view of the same and to eliminate all risks associated with physical shares and avail various benefits of dematerialization, Members are advised to dematerialize the shares held by them in physical form. Members can contact the Company or RTA, for assistance in this regard.

### 23. Voting through electronic means

1. Members are requested to carefully read the below mentioned instructions for remote e-voting before casting their vote.

Step 1: Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2: Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and nonindividual shareholders in demat mode.

- i. The voting period begins on 27<sup>th</sup> September, 2022 at 9.00 AM and ends on 29<sup>th</sup> September, 2022 at 5.00 PM. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date 23<sup>rd</sup> September, 2022 (Friday) of may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- ii. Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- iii. Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/ CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level. Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders. In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1: Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode. iv. In terms of SEBI circular no. SEBI/HO/CFD/CMD/ CIR/P/2020/242



dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts

in order to access e-Voting facility. Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings for Individual shareholders holding securities in Demat mode CDSL/ NSDL is given below:

Type of Shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	<p>Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are <a href="https://web.cdslindia.com/myeasi/home/login">https://web.cdslindia.com/myeasi/home/login</a> or visit <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on Login icon and select New System Myeasi. Individual Shareholders holding securities in Demat mode with CDSL Depository</p> <p>2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the e-Voting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME, so that the user can visit the e-Voting service providers' website directly.</p> <p>3. If the user is not registered for Easi/Easiest, option to register is available at <a href="https://web.cdslindia.com/myeasi/Registration/EasiRegistration">https://web.cdslindia.com/myeasi/Registration/EasiRegistration</a></p> <p>4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page or click on <a href="https://evoting.cdslindia.com/Evoting/EvotingLogin">https://evoting.cdslindia.com/Evoting/EvotingLogin</a>. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</p>

Type of Shareholders	Login Method
Individual Shareholders holding securities in Demat mode with NSDL Depository	<p>If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting. Individual Shareholders holding securities in demat mode with NSDL Depository</p> <p>2. If the user is not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>. Select “Register Online for IDeAS “Portal or click at <a href="https://eservices.nsdl.com/SecureWeb/ IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/ IdeasDirectReg.jsp</a></p>



3. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nSDL.com/> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Individual Shareholders (holding securities in demat mode) login through their Depository Participants (DP)	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
---	--

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login Type	Helpdesk Details
<b>Individual Shareholders holding securities in Demat mode with CDSL</b>	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free no. 1800 22 55 33.
<b>Individual Shareholders holding securities in Demat mode with NSDL</b>	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at toll free no.: 1800 1020 990 and 1800 22 44 30.

Step 2: Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

v. Login method for e-Voting and joining virtual meetings for Physical shareholders and shareholders other than individual holding in Demat form.

1. The shareholders should log on to the e-voting website [www.evotingindia.com](http://www.evotingindia.com).
2. Click on “Shareholders” module.
3. Now enter your User ID a. For CDSL: 16 digits beneficiary ID, b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID, c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
4. Next enter the Image Verification as displayed and Click on Login.
5. If you are holding shares in demat form and had logged on to [www.evotingindia.com](http://www.evotingindia.com) and voted on an earlier e-voting of any company, then your existing password is to be used.
6. If you are a first-time user follow the steps given below:

Login Type	For Physical shareholders and other than individual shareholders holding shares in Demat
<b>PAN</b>	Enter your 10-digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> <li>• Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence</li> </ul>

	number sent by Company/RTA or contact Company/RTA.
<b>Dividend Bank Details OR Date of Birth (DOB)</b>	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ul style="list-style-type: none"> <li>If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field</li> </ul>

vi. After entering these details appropriately, click on “SUBMIT” tab.

vii. Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

viii. For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.

ix. Click on the **EVSN for the relevant Deccan Healthcare Limited** on which you choose to vote.

x. On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/ NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.

xi. Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.

xii. After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.

xiii. Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.

xiv. You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.

xv. If a demat account holder has forgotten the login password, then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

xvi. There is also an optional provision to upload BR/ POA if any uploaded, which will be made available to scrutinizer for verification.

xvii. Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.

a. Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to [www.evotingindia.com](http://www.evotingindia.com) and register themselves in the “Corporates” module.

b. A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com).

c. After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.

d. The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.

e. It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

f. Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address [companysecretary@deccanhealthcare.co.in](mailto:companysecretary@deccanhealthcare.co.in), if they have voted from individual tab & not uploaded



same in the CDSL e-voting system for the scrutinizer to verify the same.

**Instructions for Shareholders Attending the AGM Through VC/ OAVM & E-Voting During Meeting Are as Under:**

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast 7 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at [companysecretary@deccanhealthcare.co.in](mailto:companysecretary@deccanhealthcare.co.in). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 7 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote

through e-Voting system available during the AGM.

10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders may be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

**PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.**

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to Company/RTA email id.
2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP).
3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository. If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or contact at toll free no. 1800 22 55 33 All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL, ) Central Depository Services (India) Limited, A Wing, 25thFloor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or call toll free no. 1800 22 55 33.
4. Members can also update their mobile number and e-mail id in the user profile details of the folio which may be used for sending future communication(s). Any person, who acquires shares of the Company and become member of the Company after mailing of the notice and holding shares as on the cut-off date i.e. 23<sup>rd</sup> September, 2022 (Friday), may obtain the login ID and



password by sending a request at [amarendranath.r@bigshareonline.com](mailto:amarendranath.r@bigshareonline.com).

5. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date i.e. 23<sup>rd</sup> September, 2022 (Friday) only shall be entitled to avail the facility of remote e-voting as well as e- voting at the AGM.

6. The Chairman shall, at the AGM at the end of discussion on the resolutions on which voting is to be held, allow e-voting to all those members who are present/logged in at the AGM but have not cast their votes by availing the remote e-voting facility.

7. The Results of the voting on the resolutions along with the report of the Scrutinizer shall be declared and placed on the website of the Company - <http://www.deccanhealthcare.co.in> and on the

website of CDSL immediately after the declaration of result by the Chairman or a person authorized by him in writing. The results shall also be immediately forwarded to the BSE Ltd.

8. For any other queries relating to the shares of the Company, you may contact the Share Transfer Agents at the following address:

M/s. Big Share Services Pvt Ltd. Bharat Tin Works Building, 1st Floor, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai, Maharashtra, 400059 Tel: 022 – 62638200 Fax - 022 - 62638299 E-mail: [amarendranath.r@bigshareonline.com](mailto:amarendranath.r@bigshareonline.com).

---

**EXPLANATORY STATEMENT IN RESPECT OF SPECIAL BUSINESS PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013.**

---

**Item No.3**

In view of the re-constitution of the Board of Directors of the company, the nomination and remuneration committee of the company has decided to re-designate Mrs. Meenakshi Gupta as the non-executive director, who was originally re-appointed as the whole time director for a period of three years w.e.f 30<sup>th</sup> August, 2020 till 31<sup>st</sup> August, 2023.

The proposed re-designation shall be effective from the date of this meeting i.e. 30<sup>th</sup> September, 2022 and she shall not be entitled to receive any remuneration after this re-designation.

None of the Directors (other than Mrs. Meenakshi Gupta and her husband Dr. Minto P. Gupta), Managers or Key Managerial Personnel or any of the relatives of any of the Directors, Managers or Key Managerial Personnels are interested or deemed to be interested, financial or otherwise, in the proposed Resolution and the proposed Resolution does not relates to or affects any other company.

**Item No.4:**

Based upon the recommendation of Audit Committee, the Board recommends the ordinary resolution set forth at item no.4 of notice for approval by the members for the related party transactions upto the amount of Rs.100 Crores.

The Members may note that in terms of the provisions of the SEBI Listing Regulations, no Related Party shall vote to approve the Special Resolution set forth at Item No. 4 of the Notice, whether the entity is a Related Party to the particular transaction or not.

None of the other Directors, KMPs and/ or their respective relatives are in any way, concerned or interested, financially or otherwise, in the Resolution mentioned at Item No. 4 of the Notice.

**Item No.5:**

As per sub section (2) & (3) of section 186 of the Companies Act, 2013, a company is required to obtain the prior approval of the members through a special resolution, in case the company wants to –

(a) give any loan to any person or other body corporate;(b) give any guarantee or provide any security in connection with a loan to any other body corporate or person; and

(c) acquire by way of subscription, purchase or otherwise, the securities of any other body corporate,

Exceeding 60% of the paid up share capital, free reserves and securities premium account or 100% of its free reserves and securities premium account, whichever is more.

Your company is growing and therefore in order to capitulate the various opportunities prevailing in the industry, the Board of Directors are seeking approval of the members pursuant to section 186 provisions over and above the limit as specified in the resolution at item no.5.

The said approval is sought keeping in mind the fund requirements of the company and its group companies to meet urgent needs from time to time to yield and grow in business segment.

None of the other Directors, KMPs and/ or their respective relatives are in any way, concerned or interested, financially or otherwise, in the Resolution mentioned at Item No. 5 of the Notice.

The Board commends to passing of the Special Resolution as set out at item No.5.

**Item No.6:**

Members are hereby informed that upon the recommendation of Nomination & Remuneration Committee, the Board of Directors at their meeting held on 02.09.2022, have appointed Mr. Ravi Ramprasad as Additional Director (DIN:03077288) to hold the office upto the date of this Annual General Meeting.

The Company received his consent to act as director on 8<sup>th</sup> July, 2022 and who was appointed by the Board of Directors as an Additional Director on 02.09.2022.

Further Mr. Ravi Ramprasad has been long associated with media industry and has launched the first ever shipping and logistics magazine Maritime Gateway and many more. He is well qualified and experienced for this designation.

His appointment as additional director needs to be ratified under the provisions of section 161 of the Companies Act, 2013 by shareholders in the General Meeting. Thus the members approval is solicited for the resolution set out at Item No.6 of the Notice by way of Ordinary Resolution.



His appointment shall be subject to such terms & conditions as may be decided by the Board of Directors.

None of the Directors, Key Managerial Personal or their relatives are concerned or interested financial or otherwise in the aforesaid resolution.

#### Item No. 7

Dr. Minto Purshotam Gupta was last re-appointed as Managing Director of the Company with effect from 30th August, 2020 for a period of 3 year at a remuneration of Rs. 90 Lakhs p.a..

The Remuneration & Nomination Committee and the Board of Directors at their respective meetings held on 02<sup>nd</sup> September, 2022 depending upon the performance and contributions made by Dr. Minto Purshotam Gupta have unanimously recommended revision in the remuneration payable to Dr. Minto Purshotam Gupta, who was last re-appointed as Managing Director of the Company for a term of 3 years with effect from 30<sup>th</sup> August, 2020 to 31<sup>st</sup> August, 2023, for the remaining part of his tenure from 1<sup>st</sup> September, 2022 to 31<sup>st</sup> August, 2023 and his further re-appointment as well on the payment of remuneration as proposed in the resolution, subject to the approval of the Members of the Company in General Meeting.

Except Mrs. Meenakshi Gupta, no other Directors are interested in the aforesaid resolution.

#### Item No. 8

The tenure of Dr. Minto P. Gupta, as the Managing Director of the Company, will expire on 30th August, 2023. On the recommendation of Nomination & Remuneration committee of the Board, the Board of Directors, at its Meeting held on 02<sup>nd</sup> Sept, 2022, proposed the re-appointment of Dr. Minto P. Gupta as the Managing Director for a further period of Five years commencing from 31st August, 2023 to 30th August, 2028, on the terms and conditions set out in the disclosures made herein pursuant to Section 197 the Companies Act 2013, subject to approval by the Members of the Company at this Annual General Meeting.

Dr. Minto P. Gupta, the founder of the Company passed his B.Sc and M.Sc from Bombay University. He also has a Certified Packing Course with the Indian Institute of Packing, Bombay. He participated in the Thirteenth Management Development Programme conducted by Bombay Management Association and was a Visiting Lecturer at Sophia College during the academic years 1979-1981. He was a part of the Research Study with Chemical Physics Group at Tata Institute of Fundamental Research (TIFR). He also experimented on a possible overlap of the binding regions of BPB (bromophenol blue) or BPR (bromophenol red) and BBS (Biebrich Scarlett) on the lysozymes molecules. Additionally, he worked on for preparation of polysaccharides by hydrolysis of chitin.

The terms and conditions on which Dr. Minto P. Gupta is proposed to be reappointed as Managing Director are as under:

Salary – Rs. 1.50 Crores per annum

The following perquisites shall not be included in the ceiling on perquisites.

- i. Contribution to provident fund, superannuation fund or annuity fund to the extent these either singly or put together are not taxable under the Income Tax Act, 1961;
- ii. Gratuity payable at a rate not exceeding half a month's salary for each completed year of service; and
- iii. Leave encashment at the end of tenure.

None of the Directors other than Dr. Minto P. Gupta and his wife Mrs. Meenakshi Gupta, Managers or Key Managerial Personnel or any of the relatives of any of the Directors, Managers or Key Managerial Personnels are interested or deemed to be interested, financial or otherwise, in the proposed Resolution and the proposed Resolution does not relate to or affects any other company.

**DETAILS OF DIRECTOR SEEKING APPOINTMENT/REAPPOINTMENT/CONTINUANCE OF APPOINTMENT AT FORTHCOMING ANNUAL GENERAL MEETING**

<b>Particulars</b>	<b>1.</b>	<b>2.</b>	<b>3.</b>	<b>4.</b>
<b>Name</b>	<b>Mr. Minto P Gupta</b>	<b>Mrs. Meenakshi Gupta</b>	<b>Mr. Ravi Ramprasad.</b>	<b>Mr. Hitesh Patel</b>
<b>Category of Directorship</b>	Managing Director not liable to retire by rotation.	Non Executive Director liable to retire by rotation.	Non-Executive Director liable to retire by Rotation.	Non-Executive Director liable to retire by rotation
<b>DIN</b>	00843784	00574624	03077288	02080625
<b>Date of Birth</b>	09.08.1958	26.03.1960	28.09.1960	14 <sup>th</sup> June, 1975
<b>Age</b>	64 years	62 years	62 years	47 years
<b>Date of Appointment on the Board</b>	06.02.2000	29.10.2014	02.09.2022	30.05.2019
<b>Qualification</b>	MS in Biochemistry.	Masters Degree in Science (MSc.)	Bachelors Degree	Higher Secondary
<b>Experience</b>	20 years of Experience in the field in which company operates.	Corporate Development, training & education and human resource management	Expertise in media industry.	He is the guiding force behind every strategic decision of the company.
<b>No. of other Directorships in public ltd companies</b>	Nutricircle Limited	NIL	Mapworld Technologies Limited	Nutricircle Limited
<b>Chairman/Member of the Committees of the Board of Directors of the Company.</b>	Chairman of Corporate Social Responsibility Committee	NIL	NIL	Member of Audit Committee, NRC, Corporate Social Responsibility Committee and Stakeholder Relationship Committee.
<b>No. of equity shares held</b>	21,06,467	16,71,333	-	14,814



## DIRECTORS' REPORT

To,  
The Members of  
**DECCAN HEALTH CARE LIMITED**

Your Directors' are pleased to present Twenty Sixth Annual Report on the affairs of the Company, along with the Standalone & Consolidated Audited Financial Statements for the Financial Year ended on March 31, 2022.

### Financial Highlights:

The summarized financial highlights for the year vis-a-vis the previous year are as follows:

(Rs. in Lakhs except EPS)

Particulars	Standalone		Consolidated	
	FY 2021-22	FY 2020-21	FY 2021-22	FY 2020-21
<b>Revenue from Operations</b>	3317.12	3,377.58	3317.12	3,377.58
<b>Other Income</b>	22.07	5.54	22.07	5.54
<b>Total Revenue</b>	<b>3339.19</b>	<b>3,383.12</b>	<b>3339.19</b>	<b>3,383.12</b>
<b>Expenses:</b>				
<b>Cost of Material Consumed</b>	398.09	2,273.90	398.09	2,273.90
<b>Changes in Inventories of Finished Goods and Work-in-Progress</b>	1036.69	(430.88)	1036.69	(430.88)
<b>Employee Benefit Expenses</b>	291.52	291.76	291.52	291.76
<b>Other Expenses</b>	1128.04	1,039.04	1128.19	1,039.04
<b>Finance Cost</b>	15.18	10.79	15.18	10.79
<b>Depreciation and Amortization Expenses</b>	147.27	146.60	147.27	146.60
<b>Total Expenses</b>	<b>2944.94</b>	<b>3,331.21</b>	<b>2944.94</b>	<b>3,331.21</b>
<b>Profit / (Loss) Before Tax</b>	<b>54.40</b>	<b>51.91</b>	<b>54.25</b>	<b>51.91</b>
<b>Tax Expenses:</b>				
<b>Provision for Income Tax</b>	25.13	13.91	25.13	13.91
<b>Less: MAT Credit Entitlement</b>				
<b>Deferred Tax</b>	(3.14)	(0.99)	(3.14)	(0.99)
<b>Profit / (Loss) for the period</b>	<b>32.41</b>	<b>39.00</b>	<b>32.26</b>	<b>39.00</b>
<b>Earnings Per Share:</b>				
<b>Basic</b>	0.21	0.25	0.21	0.25
<b>Diluted</b>	0.21	0.25	0.21	0.25



### Operational Performance:

On a standalone basis, your Company recorded net sales of Rs.3339.19 Lakhs during the financial year 2021-22 as compared to Rs. 3,383.12 Lakhs in the previous financial year 2020-21, whereas the Net Profit during the financial year 2021-22 stood at Rs. 32.41 Lakhs as compared to a net profit of Rs 39 Lakhs in financial year 2020-21 leading to the Basic Earnings Per Share of Rs. 0.21 for the financial year 2021-22 as compared to Rs. 0.25 in financial year 2020-21 due to negative impact of heavy rains and floods caused in Uttarakhand last year

On a Consolidated basis, your Company recorded net sales of Rs. 3339.19 Lakhs during the financial year 2021-22 as compared to Rs. 3,383.12 Lakhs in the previous financial year 2020-21, whereas the Net Profit during the financial year 2021-22 stood at Rs. 32.26 Lakhs as compared to a net profit of Rs 38.99 Lakhs in financial year 2020-21 leading to the Basic Earnings Per Share at Rs. 0.21 for the financial year 2021-22 as compared to Rs. 0.25 in financial year 2020-21 due to negative impact of heavy rains and floods on the business of the Company.

### FY 2021-22

Your Company remained growth oriented during the financial year 2021-22, but also faced challenges. Apart from the outbreak of covid -19 and its repeated waves, your company also faced challenges due to heavy rains and floods caused in Uttarakhand, where the innovation hub and manufacturing unit of the Company is situated.

To deal with this scenario, your company focused on ensuring the safety of its employees and all other stakeholders and also managed to perform well and achieve adequate profits.

Your Company has constituted a committee of senior management personnels to monitor the events happening in the external environment and take suitable preventive and corrective measures to ensure continued safety of employees. The committee has prepared a business continuity plan, disaster management plan. We are happy to mention that we have been doing whatever possible for the country in terms of fight against Covid-19.

During this pandemic the Company has launched Germa Free hand sanitizer so that consumers can take protective measures for safeguarding themselves from Covid-19, Company has also launched Royal Tea Tree Body Wash; omega 3 hair oil Sachets, Ubtan Body wash, Nurovit MC Total, Sonehaldi and Orthomega during the FY 221-22 as addition to its existing list of products.

Our manufacturing facility is operating at a reasonable capacity utilization and we are ensuring that our products are available to consumers without

interruptions. However it faced challenges due to the flood and heavy rains caused in Uttarakhand but managed maintain the supply chain with a specific focus on helping parties in surviving the difficult times. We have taken several steps aimed at ensuring the safety, which include social distancing in the office premises, sanitization of our office premises; plant location, thermal screening for employees working at sites, providing sanitizers, masks, gloves etc. to employees.

### Transfer to Reserves:

The Company has not transferred any amount to reserves for the period under review.

### Dividend:

In view of the future expansion plans, Board of Directors have not recommended any dividend for the financial year ended 31<sup>st</sup> March, 2022.

### Issue of Equity Shares and changes in Share Capital:

There was no change in the Share Capital of the Company during the financial year under review.

### Change in the Nature of Business:

There is no change in the nature of business during the financial year 2021-22.

### Material Changes and Commitments:

No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

### Management Discussion and Analysis [MDA]:

Management Discussion and Analysis Report as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 forms part of this Annual Report.

### Directors and Key Managerial Personnel:

The Composition of the Board of Directors during the year under review were as follows and changes that took place in the Board composition during the year under review.

Name of the Director	Category
Mr. Minto Purshotam Gupta*	Managing Director (Promoter)

<b>Ms. Meenakshi Gupta**</b>	Executive (Promoter)	Director
<b>Mr. Hitesh Patel***</b>	Non-executive (Promoter)	Director
<b>Ms. Ruchi Khattar</b>	Independent Director	
<b>Ms. Kandlakunta Samhitha</b>	Independent Director	
<b>Ms. Savita Bhutani****</b>	Independent Director	

\* Mr. Minto Purshotam Gupta will be reappointed as Managing Director of the Company for the period of 5 (five) years, w.e.f. 31<sup>st</sup> August, 2023 by the members of the Company at the 26<sup>th</sup> Annual General Meeting (AGM) to be held on 30<sup>th</sup> September, 2022.

\*\*Mrs. Meenakshi Gupta will also be re-designated as the non-executive director of the company from her existing designation of Whole Time Director by the members of the Company at the 26<sup>th</sup> Annual General Meeting (AGM) to be held on 30<sup>th</sup> September, 2022.

\*\*\*Mr. Hitesh Patel (DIN 02080625) shall retire by rotation at the ensuing Annual General Meeting and being eligible, offers himself for re-appointment. The Board hereby recommends his re-appointment for approval of shareholders in the ensuing Annual General Meeting.

\*\*\*\*Mrs. Savita Bhutani has resigned from her office w.e.f 28<sup>th</sup> July, 2021.

#### Key Managerial Personnel:

1. Mr. Mohak Gupta – Chief Financial Officer.
2. Ms. Sheena Jain, Company Secretary.

#### Remuneration of Directors, Key Managerial Personnel & Particulars of Employees:

The information required under Section 197 of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms an integral part of this Report is attached as Annexure – III.

The statement containing particulars of employees as required under section 197 of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, will be provided upon request. In terms of Section 136 of the Companies Act, 2013, the Report and accounts are being sent to the members and others entitled thereto.

#### Board Meeting:

During the year under review, the Board of Directors met 6 times i.e. 31<sup>st</sup> July, 2021, 21<sup>st</sup> August, 2021, 06<sup>th</sup>

September, 2021, 25<sup>th</sup> October, 2021 and 13<sup>th</sup> November, 2021, 18<sup>th</sup> February, 2022 respectively.

The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013.

#### Attendance at the Board Meetings held during the FY 2021-22:

Name of Director	31.07.21	21.08.21	06.09.21	25.10.21	13.11.21	18.02.22
					1	2

Minto Purshotam Gupta	Yes	Yes	Yes	Yes	Yes	Yes
Meenakshi Gupta	Yes	Yes	Yes	Yes	No	Yes

Hitesh Patel	Yes	Yes	Yes	Yes	Yes	Yes
Ruchi Khattar	Yes	Yes	Yes	Yes	Yes	No

Samhitha Kandlakunta	Yes	Yes	Yes	Yes	Yes	No
Savita Bhutani*	No	N.A.	N.A.	N.A.	N.A.	N.A.

\*Mrs. Savita Bhutani has resigned from the Directorship of the Company w.e.f. 28<sup>th</sup> July, 2021.

#### Attendance at the Last AGM of the Company held on 30th September, 2021:

Particulars	Minto P Gupta	Meenakshi Gupta	Hitesh Patel	Ruchi Khattar	Samhitha Kandlakunta
25 <sup>th</sup> Annual General Meeting	Yes	Yes	Yes	Yes	Yes

#### Declaration by Independent Directors:

Ms. Ruchi Khattar and Ms. Kandlakunta Samhitha and Ms. Savita Bhutani (Resigned w.e.f. 28<sup>th</sup> July, 2021) are the Independent Directors on the Board of your Company. In the opinion of the Board and as confirmed by these Directors, they fulfil the conditions specified in Section 149(6) of the Act and the Rules made thereunder about their status as Independent Directors of the Company.

#### Performance Evaluation:

Pursuant to the provisions of Companies Act, 2013 and the Listing Regulations, the Board has carried out the annual performance evaluation of the Directors

individually as well as evaluation of the working of the Board and the committees of the Board, by way of individual and collective feedback from the Directors.

The following were the Evaluation Criteria:

**(a) For Independent Directors:**

- Knowledge and Skills
- Professional conduct
- Duties, Role and functions

**(b) For Executive Director:**

- Performance as Team Leader/Member
- Evaluating Business Opportunity and analysis of Risk Reward Scenarios
- Key Set Goals and Achievements
- Professional Conduct and Integrity
- Sharing of Information with the Board

The Directors expressed their satisfaction with the evaluation process.

**Board Committees:**

During the year under review, the Board of Directors of your Company had constituted and re-constituted following Committees and approved the terms of reference / role in compliance with the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015.

**1. Audit Committee:**

In accordance with the provisions of section 177 of the Companies Act, 2013 and regulation 18 of SEBI (Listing Obligation & Disclosure Requirement) Regulations, 2015, the company has constituted an Audit Committee to perform the roles, responsibilities and functions as specified under Schedule II of the SEBI (LODR) Regulations and Companies Act, 2013.

The Composition of the Committee is as under:

S. No.	Name of Director	Designation
1.	Mrs. Ruchi Khattar	Independent Director & Chairman of the Committee
2.	Ms. Smahitha Kandlakunta	Independent Director & Member of Committee
3.	Mr. Hitesh M Patel	Non – Executive Director & Member
4.	Mrs. Savita Bhutani #	Member of Committee

# Mrs. Savita Bhutani has resigned w.e.f 28<sup>th</sup> July, 2021.

During the Financial Year under review, the Audit Committee met four (4) times on 31<sup>st</sup> July, 2021, 21<sup>st</sup> August, 2021, 25<sup>th</sup> October, 2021 and 13<sup>th</sup> November, 2021 respectively and the requisite quorum was present at the Meeting.

**2. Nomination & Remuneration Committee:**

In accordance with the provisions of the Companies Act, 2013 and regulation 19 of SEBI (Listing Obligation & Disclosure Requirement) Regulations, 2015, the company has constituted a Stakeholder Relationship Committee to perform the roles, responsibilities and functions as specified under Schedule II of the SEBI (LODR) Regulations and Companies Act, 2013.

The Composition of the Committee is as under:

S. No.	Name of Director	Designation
1.	Ms. Smahitha Kandlakunta	Independent Director & Chairman of the Committee
2.	Mrs. Ruchi Khattar	Independent Director & Member of Committee
3.	Mr. Hitesh M Patel	Non – Executive Director & Member

During the Financial Year under review, the Nomination & Remuneration Committee met only once i.e. 21<sup>st</sup> August, 2021 and the requisite quorum was present at the Meeting.

**3. Stakeholder Relationship Committee:**

In accordance with the provisions of the Companies Act, 2013 and regulation 20 of SEBI (Listing Obligation & Disclosure Requirement) Regulations, 2015, the company has constituted a Stakeholder Relationship Committee to perform the roles, responsibilities and functions as specified under Schedule II of the SEBI (LODR) Regulations and Companies Act, 2013.



The Composition of the Committee is as under:

S. No.	Name of Director	Designation
1.	Mrs. Ruchi Khattar	Independent Director & Chairman of the Committee
2.	Ms. Smahitha Kandlakunta	Independent Director & Member of Committee
3.	Mr. Hitesh M Patel	Non – Executive Director & Member

During the Financial Year under review, No Stakeholder Relationship Committee meetings were held.

#### **4. Corporate Social Responsibility Committee:**

In accordance with provisions of section 135 of the Companies Act, 2013 and the rules made thereunder the company has formed a Corporate Social Responsibility committee to oversee and monitor CSR activities to be undertaken by the Company and frame a policy for the same.

The composition of the committee is as under:

S. No.	Name of Director	Designation
1.	Mrs. Ruchi Khattar	Independent Director & Chairman of the Committee
2.	Ms. Smahitha Kandlakunta	Independent Director & Member of Committee
3.	Mr. Hitesh M Patel	Non – Executive Director & Member

During the Financial Year ended 31st March, 2022, the Corporate Social Responsibility Committee met once i.e. on 01<sup>st</sup> March, 2022 and the requisite quorum was present at the Meeting.

Company Secretary act as the Secretary to all the above four constituted Committees.

All decisions pertaining to the constitution of Committees, appointment of members and fixing of terms of reference / role of the Committees are taken by the Board of Directors.

#### **Subsidiary Companies:**

The Company has one wholly owned subsidiary i.e. Beyoungstore Private Limited.

Pursuant to the provisions of Section 129(3) of the Companies Act, 2013, a statement containing the salient features of financial statements is annexed in Form AOC-1 as Annexure I to this report.

However, the company does not have any joint ventures or associate companies during the year under the review.

#### **Consolidated Financial Statements:**

The Consolidated Financial Statements have been prepared by the Company in accordance with applicable provisions of the Companies Act, 2013, Accounting Standards and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The audited consolidated financial statements together with Auditors' Report form part of the Annual Report. The Auditor's Report does not contain any qualification, reservation or adverse remark

#### **Details about Related Party Transactions:**

No material Related Party Transactions i.e. transactions exceeding ten percent of the annual consolidated turnover as per the last audited financial statements were entered during the financial year of the Company. Accordingly, the disclosure of Related Party Transactions as required under Section 134(3)(h) of the Companies Act, 2013 in Form AOC-2 is not applicable.

#### **Details about Loans, Guarantee & Investment Under Section 186:**

During the year under review, the Company has complied with the provisions of the Section 186 of the Companies Act, 2013 and rules made thereunder.

#### **Internal Control / Internal Financial Control Systems and Adequacy Thereof:**

Your Company has in place an adequate system of internal controls. The effectiveness of internal controls is reviewed through the internal audit process. Reports of internal auditors are reviewed by management and Audit Committee of the Company from time to time

and desired actions are initiated to strengthen the control and effectiveness of the system.

**Human Resources:**

The Company believes that quality of its employees is the key to success in long run. The Company continues to have cordial relations with its employees.

**Conservation Of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo:**

The information with regard to Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo in accordance with the provisions of Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is given as **Annexure-II** forming part of this Report.

**Auditors:**

**a. Statutory Auditor**

In the Annual General Meeting (AGM) of the Company held on 30<sup>th</sup> September, 2019, M/s. Keyur Shah & Co., Chartered Accountants, Ahmedabad, (FRN: 141173W), were appointed as the Statutory Auditors of the Company to hold office as the Statutory Auditors until the conclusion of the 28<sup>th</sup> Annual General Meeting (AGM) of the Company to be held in the year 2024.

Pursuant to the notification dated 7th May, 2018 issued by Ministry of Corporate Affairs, the requirement for ratification of appointment of Auditors by the shareholders at every Annual General Meeting has been done away with. Further, the Auditors have confirmed their eligibility under section 141 of the Companies Act, 2013 and the rules made thereunder.

Further, the report of the Statutory Auditors along with notes is enclosed to this report. The remarks in the Report are already explained in the Notes to Accounts and as such does not call for any further explanation or elucidation.

No fraud has been reported by the Statutory Auditors under Section 143(12) of the Companies Act, 2013 and the rules made thereunder.

**B. Secretarial Audit**

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company had appointed M/s. M. R. Bhatia & Co., a firm of Company Secretaries in Practice to undertake the Secretarial Audit of the Company for the Financial Year 2021-22. The Secretarial Audit Report is annexed herewith as **Annexure-IV**.

The Secretarial Audit Report does not contain any qualification, reservation or adverse remark. No fraud has been reported by the Secretarial Auditors under

Section 143 (12) of the Companies Act, 2013 and the rules made thereunder.

**Corporate Social Responsibility (CSR):**

During the year, the CSR provisions were not applicable on the company, however the company has constituted the CSR Committee and framed CSR Policy. Hence the Annual Report on Corporate Social Responsibility is not required to be annexed to this Report as.

**Disclosure as per the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:**

The Company has zero tolerance towards sexual harassment at the workplace and has set up Internal Complaints Committee (ICC) for prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder. During the year 2020-21, the Company has not received any complaint of sexual harassment.

**Credit Rating:**

During the Financial Year, there was no credit rating being obtained by the Company.

**Public Deposits:**

The Company has not accepted any deposits from the public/members under section 73 of the Companies Act, 2013, read with Companies (Acceptance of Deposits) Rule, 2014 during the year.

**Directors' Responsibility Statement:**

To the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors make the following statements in terms of Section 134 (5) of the Companies Act, 2013;

(a) That in the preparation of the annual accounts, the applicable accounting standards read with requirements set out under Schedule III to the Companies Act, 2013 have been followed along with proper explanation relating to material departures;

(b) That such accounting policies as mentioned in Notes to the Financial Statements have been selected and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2022 and of the profit of the Company for the year ended on that date;

(c) That proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) That the annual financial statements have been prepared on a going concern basis;

(e) That proper internal financial controls were in place and that the financial controls were adequate and were operating effectively;

(f) That systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

**Significant and Material Orders passed by the Regulators or Courts or Tribunals impacting the Going Concern Status of the Company:**

There has been no significant and material Order passed by the Regulators or Courts or Tribunals in the FY 2021-22, impacting the going concern status of the Company's operations.

**Extract of Annual Return U/S 92 (3) in MGT-9:**

As per the provisions of Section 92(3) of the Companies Act, 2013 ('the Act') read with Rule 12(1) of the Companies (Management and Administration) Rules, 2014, the extract of the Annual Return in Form MGT-9 is given in **Annexure "V"**, forming part of this report.

**Insider Trading:**

In compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (Regulations), your Company has adopted the following:

- i) Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders- The said Code lays down guidelines, which advise Insiders on the procedures to be followed and disclosures to be made in dealing with the shares of the Company and cautions them on consequences of non-compliances.
- ii) Code of Practices and Procedures of Fair Disclosures of Unpublished Price Sensitive Information- The Code ensures fair disclosure of events and occurrences that could impact price discovery in the market.
- iii) Policy for dealing with Unpublished Price Sensitive Information (UPSI) and Whistle Blower Policy for employees to report any leak or suspected leak of UPSI- The policy aims to enable the employees of the Company to report any leak or

suspected leak of UPSI, procedures for inquiry in case of leak of UPSI or suspected leak of UPSI and initiate appropriate action and informing the SEBI promptly of such leaks, inquiries and results of such inquiries.

iv) Internal Control Mechanism to prevent Insider Trading-The Internal Control Mechanism is adopted to ensure compliances with the requirements given in the regulations and to prevent Insider Trading. The Audit Committee reviewed and found the same in order.

**Vigil Mechanism:**

The Company has adopted a Whistle Blower Policy establishing vigil mechanism, to provide a formal mechanism to the Directors and Employees to report their concerns about unethical behaviour, actual or suspected fraud or violation of the Company's Code of Conduct or ethics policy. The Policy provides for adequate safeguards against victimization of employees who avail of the mechanism.

**Acknowledgements:**

Your Directors wish to place on record their appreciation of the contribution made by the employees at all level, towards the continued growth and prosperity of your company. Your Directors also wish to place on record their sincere thanks to the Banks and various Government Authorities for the support and co-operation extended to the Company. Your Directors are especially grateful to the shareholders for reposing their trust and confidence in the Company.

**By order of the Board of Directors  
For DECCAN HEALTH CARE LIMITED**

**Minto Purshotam Gupta**  
Managing Director  
DIN:00843784

**Hitesh Patel**  
Director  
DIN:0208625



**ANNEXURE I**

**FORM AOC-1**

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

**STATEMENT CONTAINING SALIENT FEATURES OF THE FINANCIAL STATEMENT OF  
SUBSIDIARIES/ASSOCIATE COMPANIES/JOINT VENTURES AS ON 31.03.2022**

**Part "A": Subsidiaries**

(Information in respect of each subsidiary to be presented with amount in Rs.)

S.No.	Name of Subsidiary	Beyoungstore Private Limited
1.	The date since when subsidiary acquired	12/05/2020
2.	Reporting period for the subsidiary concerned, if different from the holding company's reporting period NA.	NA
3.	Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries.	NA
4.	Paid up Capital	1,00,000
5.	Reserves & Surplus	(15,000)
6.	Total Assets	14,85,308
7.	Total Liabilities	14,85,308
8.	Investments	-
9.	Turnover including other income	-
10.	Profit/(Loss) before taxaion	(15,000)
11.	Profit/(Loss) before taxation from Discontinued Operations	-
12.	Provision for taxation	-
13.	Profit/(loss) after taxation	(15,000)
14.	Proposed Dividend	-
15.	% of shareholding	100%
16.	Names of subsidiaries which are yet to commence operations	NA
17.	Names of subsidiaries which have been liquidated or sold during the year	NA

**Part "B": Associate and Joint ventures**

Statement pursuant to section 129(3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures

**NOT APPLICABLE** - The Company does not have any Associates and Joint Ventures as on 31<sup>st</sup> March, 2022.

## ANNEXURE - II

### **PARTICULARS OF ENERGY CONSERVATION, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO AS PER SECTION 134(3)(M) OF THE COMPANIES ACT, 2013 AND RULE 8 OF THE COMPANIES (ACCOUNTS) RULES, 2014.**

#### **A. ENERGY CONSERVATION**

Deccan Health Care Limited has always been a frontrunner in continually improving its operational performance in all areas, like productivity, yield, utilization and a host of other operating metrics, while reducing the consumption of fuel, power, stores and others. This is done by adopting an approach of continual improvement of process metrics across all energy consuming facilities.

The Company is continuously putting its efforts to improve Energy Management by way of monitoring energy related parameters on regular basis.

The Company is committed to transform energy conservation into a strategic business goal fully along with the technological sustainable development of Energy Management System. It is putting best endeavor to reduce energy consumption in its operations and activities.

#### **To achieve above objectives the following steps are being undertaken by the Company:**

- Continuously monitoring the energy parameters such as maximum demand, power factor, load factor on regular basis;
- Continuously replacing the inefficient equipment's with latest energy efficient technology & upgradation of equipment's continually;

- Increasing the awareness of energy saving within the organization to avoid the wastage of energy;
- To enhance utilization of Renewable Energy Resources;
- Exploring the feasibility of utilization of Solar Power at plant locations wherever possible;

#### **B. RESEARCH AND DEVELOPMENT (R& D)**

Research, Technology and innovation continue to be one of the key focus area to drive growth. In addition to developing new design, pattern and styles of Company's product, it also works on building new capabilities. To support this, Company avails services of qualified and experienced professionals / consultants.

#### **C. TECHNOLOGY ABSORPTION**

The Company develops in-house Technology and is not dependent on any outside Technology/Source.

#### **D. FOREIGN EXCHANGE EARNINGS AND OUTGO**

During the financial year under review, there was no foreign exchange earnings and out go.

Any gains or loss arising on account of exchange difference either on settlement or on transactions is accounted for in the Statement of Profit & Loss.

**INFORMATION PURSUANT TO SECTION 197 (12) OF THE COMPANIES ACT, 2013 READ WITH RULE 5 OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014 AS AMENDED AND FORMING PART OF THE DIRECTORS' REPORT FOR THE YEAR ENDED 31STMARCH, 2022.**

(A) Particulars of Employees as per [Rule-5 of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

- (i) The ratio of the remuneration of each Executive Director to the median remuneration of the employees of the Company for the financial year 2021-22.

S.No.	Name of Director	Ratio of remuneration of each Director/ to median remuneration of employees (in times)
1.	Mr. Minto P Gupta	31.35:1
2.	Mrs. Meenakshi Gupta	18.81:1

- (ii) The percentage increase in remuneration of each Executive Director, Chief Financial Officer and Company Secretary in the financial year 2021-22.

S.No.	Name of Director /KMPs	Designation	% Increase in remuneration
1.	Mr. Minto P Gupta	Managing Director	(41.39)
2.	Mrs. Meenakshi Gupta	Whole Time Director	(41.19)
3.	Mr. Mohak Gupta	Chief Financial Officer	0.03%
4.	Ms. Sheena Jain	Company Secretary	(27.45)

- (iii) The percentage increase in the median remuneration of employees in the financial year 2021-22 was 38.24%.

- (iv) There were 85 permanent employees on the rolls of the Company as on 31<sup>st</sup> March, 2022.

- (v) The information of employees receiving salary in excess of the limits as prescribed under the provisions of Section 197 read with Rule 5, sub rule 2 & 3 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and the Companies (Appointment and remuneration of Managerial Personnel) Amendment Rules, 2016 under the Companies Act, 2013, who were employed throughout or for a part of the financial year under review. - **Nil**

- (vi) It is hereby affirmed that the remuneration paid is as per the Remuneration Policy of the Company.



**FORM NO. MR – 3**

**SECRETARIAL AUDIT REPORT**

For the financial year ended March 31, 2022

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies  
(Appointment and Remuneration Personnel) Rules, 2014]

**To,  
The Members,  
Deccan Health Care Limited, Hyderabad  
(L72200TG1996PLC024351)**

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Deccan Health Care Limited (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period ended on March 31, 2022, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the period ended on March 31, 2022 according to the provisions of:

- I. The Companies Act, 2013 ("the Act") and the Rules made thereunder;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder;
- III. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- IV. Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (Not Applicable to the Company during the Audit Period)
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') to the extent applicable to the Company :-
  - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
  - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
  - c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
  - d. The Securities and Exchange Board of India (Share based Employee Benefits) Regulations, 2014;
  - e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
  - f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
  - g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (Not Applicable to the Company during the Audit Period);
  - h. The Securities and Exchange Board of India (Buyback of Securities)

Regulations, 2018 (Not Applicable to the Company during the Audit Period)

- i. The Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015;

VI. Other laws applicable specifically to the Company, namely:

- The Environment Protection Act, 1986;
- The Water (Prevention & Control of Pollution) Act, 1974;
- The Air (Prevention & Control of Pollution) Act, 1981;
- The Hazardous Waste (Management, Handling & Transboundary Movement) Rules, 2008;
- Factories Act, 1948;
- Industrial Disputes Act, 1947;
- The Payment of Wages Act, 1948;
- The Employee State Insurance Act, 1948;
- The Employee Provident Fund and Miscellaneous Provision Act, 1952;
- The Payment of Bonus Act, 1965;
- The Payment of Gratuity Act, 1972;
- The Income Tax Act, 1961;
- Contract Labor (Regulation and Abolition) Act, 1970;
- The Industrial Employment (Standing Orders) Act, 1946;
- The Goods and Service Tax Act, 2017;

We have also examined compliance with the applicable clauses of the following:

- i) Secretarial Standards (SS-1 and SS-2) issued by The Institute of Company Secretaries of India; and
- ii) The Listing Agreements entered into by the Company with the BSE Limited (SME Exchange).

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, Listing Agreements etc mentioned above.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings. Except where consent of the directors was received for scheduling meeting at a Shorter Notice, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings were carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committees of the Board, as the case may be.

The Company has obtained all necessary approvals under the various provisions of the Act; and there was no prosecution initiated and no fines or penalties were imposed during the year under review under the Act, SEBI Act, SCRA, Depositories Act, Listing Agreement and Rules, Regulations and Guidelines framed under these Acts against / on the Company, its Directors and Officers.

We further report that compliance of applicable financial laws including Direct and Indirect Tax laws by the Company has not been reviewed in the Audit since the same has been subject to review by the Statutory Auditors and other designated professionals.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

**For M. R. Bhatia & Co.  
Practicing Company Secretaries**

Sd/-

**Monika R. Bhatia  
Company Secretary**

**Proprietor**

**M. No. 10397**

**C.P. No.13348**

**Place: Ahmedabad**

**Date: 02<sup>nd</sup> Sept 2022**

**Peer Review Cer No: 2167/2022**

**UDIN: F010397D000894821**

*Note: This report is to be read with our letter of even date which is annexed as "ANNEXURE A" and forms an integral part of this report.*

---

**“ANNEXURE A”**

---

**To,  
The Members,  
Deccan Health Care Limited, Hyderabad  
(L72200TG1996PLC024351)**

Our report of even date is to be read along with this letter.

1. Maintenance of Secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on the test basis to ensure that correct facts are reflected in Secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
4. We have obtained the Management representation about compliance of laws, rules and regulations and happenings of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of the management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of efficacy or effectiveness with which the management has conducted the affairs of the Company.

**For M. R. Bhatia & Co.  
Practicing Company Secretaries**

**Monika R. Bhatia  
Company Secretary  
Proprietor**

**M. No. 10397**

**C.P. No.13348**

**Place: Ahmedabad**

**Date: 02<sup>nd</sup> Sept 2022**

**Peer Review Cer No: 2167/2022**

**UDIN: F010397D000894821**

---



**Form No. MGT-9  
EXTRACT OF ANNUAL RETURN  
as on the financial year ended on 31.03.2022**

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

**i) REGISTRATION & OTHER DETAILS:**

i	<b>CIN</b>	L72200TG1996PLC024351
ii	<b>Registration Date</b>	14/06/1996
iii	<b>Name of the Company</b>	DECCAN HEALTH CARE LIMITED
iv	<b>Category / Sub-Category of the Company</b>	Company Limited By Shares Non-Government Indian Company
v	<b>Address of the Registered office and contact details</b>	H.No. 6-3-348/4, Dwarkapuri Colony, Punjagutta, Hyderabad TG – 500082
vi	<b>Website</b>	<a href="http://www.deccanhealthcare.co.in">www.deccanhealthcare.co.in</a>
vii	<b>Whether listed company</b>	Yes (Bombay Stock Exchange)
viii	<b>Name, Address and Contact details of Registrar and Transfer Agent, if any</b>	Big Share Services Private Limited 1st Floor, Bharat Tin Works Building, Opposite Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai- 400059 Tel No : +91 22 62638200; Fax No. : +91 22 62638299

**ii) PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:**

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the Company
1	Manufacture of Fast moving consumer health products (FMCHP)	21003	100%

iii) PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S. No.	Name and address of the company	CIN/GLN	Holding/ Subsidiary/Associate Company	% of shares held	Applicable section
1	<b>Beyoungstore Private Limited</b>	U74999TG2020PTC140313	Wholly Owned Subsidiary	100%	2(87)

iv) SHARE HOLDING PATTERN  
(Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change During the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
<b>A. Promoters</b>									
(1) <b>Indian</b>	56,10,214	-	56,10,214	35.70%	43,37,414	-	43,37,414	27.60%	-8.10%
a) Individual /HUF	-	-	-	-	-	-	-	-	-
b) Central Govt	-	-	-	-	-	-	-	-	-
c) State Govt (s)	-	-	-	-	-	-	-	-	-
d) Bodies Corp.	-	-	-	-	-	-	-	-	-
e) Banks / FI	-	-	-	-	-	-	-	-	-
f) Any Other	-	-	-	-	-	-	-	-	-
<b>Sub-total (A) (1):-</b>	<b>56,10,214</b>	<b>-</b>	<b>56,10,214</b>	<b>35.70%</b>	<b>43,37,414</b>	<b>-</b>	<b>43,37,414</b>	<b>27.60%</b>	<b>-8.10%</b>
(2) <b>Foreign</b>									
a) NRIs - Individuals	-	-	-	-	-	-	-	-	-
b) Other –Individuals	-	-	-	-	-	-	-	-	-
c) Bodies Corp.	-	-	-	-	-	-	-	-	-
d) Banks / FI	-	-	-	-	-	-	-	-	-
e) Any Other....	-	-	-	-	-	-	-	-	-
<b>Sub-total (A) (2):-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total shareholding of Promoter</b>	<b>56,10,214</b>	<b>0</b>	<b>56,10,214</b>	<b>35.70%</b>	<b>43,37,414</b>	<b>0</b>	<b>43,37,414</b>	<b>27.60%</b>	<b>-8.10%</b>

<b>(A) =(A)(1)+(A)(2)</b>									
<b>B. Public Shareholding</b>									
<b>1. Institutions</b>									
a) Mutual Funds	-	-	-	-	-	-	-	-	-
b) Banks / FI	-	-	-	-	-	-	-	-	-
c) Central Govt	-	-	-	-	-	-	-	-	-
d) State Govt(s)	-	-	-	-	-	-	-	-	-
e) Venture Capital Funds	-	-	-	-	-	-	-	-	-
f) Insurance Companies	-	-	-	-	-	-	-	-	-
g) FIIs	-	-	-	-	-	-	-	-	-
h) Foreign Venture Capital unds	-	-	-	-	-	-	-	-	-
i) Others (specify)	-	-	-	-	-	-	-	-	-
<b>Sub-total (B)(1):-</b>	-	-	-	-	-	-	-	-	-
<b>2. Non-Institutions</b>	-	-	-	-	-	-	-	-	-
a) Bodies Corp.	-	-	-	-	-	-	-	-	-
i) Indian	14,04,000	-	14,04,000	8.94%	11,05,200	-	11,05,200	7.03%	-1.91%
ii) Overseas	-	-	-	-	-	-	-	-	-
b) Individuals	-	-	-	-	-	-	-	-	-
i) Individual shareholders holding nominal share capital upto Rs1 lakh	2204843	-	2204843	14.03%	21,16,627	-	21,16,627	13.47%	-0.56%
ii) Individual shareholders holding nominal share capital in excess of Rs 1lakh	5654389	-	5654389	35.98%	72,12,389	-	72,12,389	45.90%	+9.92%
c) Others (specify)	8,39,984	-	8,39,984	5.35%	9,41,880	-	9,41,880	6.00%	+0.65%
<b>Sub-total (B)(2):-</b>	<b>1,01,03,26</b>	-	<b>1,01,03,26</b>	<b>64.3%</b>	<b>113,76,06</b>	-	<b>113,76,096</b>	<b>72.4%</b>	<b>+8.10</b>
<b>Total Public Shareholding (B)=(B)(1)+(B)(2)</b>	<b>1,01,03,26</b>	-	<b>1,01,03,26</b>	<b>64.3%</b>	<b>113,76,06</b>	-	<b>113,76,096</b>	<b>72.4%</b>	<b>+8.10</b>
<b>C. Shares held by Custodian for GDRs &amp; ADRs</b>	-	-	-	-	-	-	-	-	-
<b>Grand Total (A+B+C)</b>	<b>1,57,13,40</b>	-	<b>1,57,13,40</b>	<b>100</b>	<b>1,57,13,40</b>	-	<b>1,57,13,40</b>	<b>100</b>	<b>0</b>



ii) Shareholding of Promoters

Sl. No	Shareholder's Name	Shareholding at the beginning of the year (01.04.2021)			Share holding at the end of the year (31.03.2022)			% change In shareholding during the year
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	
1	Dr. Minto Purshotam Gupta	21,07,667	13.41%	0	21,06,467	13.41%	0	0
2	Mr. Hitesh Mohanbhai Patel	17,98,014	11.44%	0	5,24,014	3.33%	0	-8.11

iii) Change in Promoters' Shareholding (please specify, if there is no change): As above.

iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.	Name of Shareholders	Shareholding at the beginning of the year 01-04-2021		Increase/ Decrease in shareholding, if any	Shareholding at the end of the Year 31-03-2022	
		No. of shares	% of total shares of the company		No. of shares	% of total Shares of the company
1	RITIKA BHANDARI	0	0.00%	+7,75,200	7,75,200	4.93%
2	VISHAL BHANDARI	2,46,200	1.57%	+1,86,000	4,32,200	2.75%
3	VIKRAM SHARAD SETH	0	0.00%	+3,51,600	3,51,600	2.23%
4	PRASAD RAJNIKANTH SETH	2,36,400	1.50%	+1,14,000	3,50,400	2.22%
5	NIHIR CHANDRAKANT SHAH	3,08,400	1.96%	+37,200	3,45,600	2.19%
6	HIRAL JAGDISH MALEKAR	3,00,000	1.91%	-	3,00,000	1.91%
7	VIKAS BHANDARI	1,02,123	0.64%	+1,55,600	2,57,723	1.64%
8	NIKHIL GARG	1,99,600	1.27%	-	1,99,600	1.27%
9	GITA KIRTI AMBANI	1,96,600	1.25%	-	1,96,600	1.25%
10	SHAH SAURABH NARESHKUMAR HUF	1,94,400	1.23%	-	1,94,400	1.23%

v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.	For each of the Directors and KMP	Shareholding at the beginning of the year 01-04-2021		Increase/ Decrease in shareholding, if any	Shareholding at the end of the Year 31-03-2022	
		No. of shares	% of total shares of the company		No. of shares	% of total Shares of the company
1	Dr. Minto Purshotam Gupta	21,07,667	13.41%	-1200	21,06,467	13.41%
2	Mrs. Meenakshi Gupta	16,71,333	10.64%	-	16,71,333	10.64%
3	Mr. Hitesh Mohanbhai Patel	17,98,014	11.44%	-1274000	5,24,014	3.33%

vi) Indebtedness:

Indebtedness of the Company including interest outstanding/accrued but not due for payment:

Particulars	(Amount in Rs.)			
	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
<b>Indebtedness at the beginning of the financial year</b>				
i) Principal Amount	81,94,905	21,25,000	-	1,03,19,905
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
<b>Total (i+ii+iii)</b>	<b>81,94,905</b>	<b>21,25,000</b>	<b>-</b>	<b>1,03,19,905</b>
<b>Change in Indebtedness during the financial year</b>				
• Addition	30,40,875	-	-	+30,40,875
• Reduction	-	8,50,000	-	-8,50,000
<b>Net Change</b>				
<b>Indebtedness at the end of the financial year</b>				
i) Principal Amount	1,12,35,780	12,75,000	-	1,25,10,780
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
<b>Total (i+ii+iii)</b>	<b>1,12,35,780</b>	<b>12,75,000</b>	<b>-</b>	<b>1,25,10,780</b>

vii) Remuneration of Directors and Key Managerial Personnel:

**Remuneration to Chairman, Managing Director & Whole-time Directors:**

(Amount in Rs.)

SN.	Particulars of Remuneration	Minto P. Gupta Managing Director	Meenakshi Gupta Whole Time Director
1	Gross salary	30,00,000	18,00,000
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	0	0
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	0	0
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	0	0
2	Stock Option	0	0
3	Sweat Equity	0	0
4	Commission - as % of profit - others, specify...	0	0
5	Others, please specify	0	0
	<b>Total (A)</b>	<b>30,00,000</b>	<b>18,00,000</b>
	Ceiling as per the Act	(Being 10% of the net profit of the Company calculated as per sec 198 of the Companies Act, 2013)	

**A. Remuneration to Other Directors:**

(Amount in Rs.)

SN.	Particulars of Remuneration	Mr. Hitesh M Patel	Mrs. Ruchi Khattar	Mrs. Samhith Kamndlakunta
1	<b>Independent Directors</b>	-	-	-
	Fee for attending board/committee meetings	-	-	-
	Commission	-	-	-
	Others, please specify	-	-	-
	<b>Total (1)</b>	-	-	-



<b>2</b>	<b>Other Non Executive Directors</b>	-	-	-
	Fee for attending board/committee meetings	-	-	-
	Commission	-	-	-
	Others, please specify	-	-	-
	Total (2)	-	-	-
	Total (B)=(1+2)	-	-	-
	<b>Overall Ceiling as per the Act (Rs. In Lakh)</b>	<b>Ceiling of Rs. 1, 00, 000/- (Rupees One Lakh only) sitting fees per meeting as per the Companies Act, 2013.</b>		

**B. Remuneration to Key Managerial Personnel (other than MD/Manager/WTD):**

(Amount in Rs.)

SN	Particulars of Remuneration	Key Managerial Personnel	
		Mr. Mohak Gupta (Chief Financial Officer)	Ms. Sheena Jain Company Secretary
1	Gross salary	17,98,200	5,17,438
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	0	0
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	0	0
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	0	0
2	Stock Option	0	0
3	Sweat Equity	0	0
4	Commission	0	0
	- as % of profit	0	0
	others, specify...	0	0
5	Others, please specify	0	0
	<b>Total</b>	<b>17,98,200</b>	<b>5,17,438</b>

viii) PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
<b>A. COMPANY</b> Penalty Punishment Compounding	-	-	-	-	-
<b>B. DIRECTORS</b> Penalty Punishment Compounding	-	-	-	-	-
<b>C. OTHER OFFICERS IN DEFAULT</b> Penalty Punishment Compounding	-	-	-	-	-

For DECCAN HEALTH CARE LIMITED

Place: Hyderabad  
Date: 02.09.2022

**MINTO PURSHOTAM GUPTA**  
Managing Director (DIN 00843784)

**HITESH PATEL**  
Director (DIN 02080625)



## MANAGEMENT DISCUSSION AND ANALYSIS REPORT

### Industry structure and developments:

Nutraceutical markets are born as innovative and transversal segments to the Pharmaceutical, Nutrition and Personal Care, blurring the boundaries among traditional Segments.

Healthcare (Nutrition and Pharmaceutical) and Personal Care markets have evolved in recent years, extending the focus of their business to new areas and addressing common consumer needs.

The expansion of the business, together with the latest industry trends, has developed transversal and innovative market segments, focused on offering health and wellness benefits using natural ingredients and resources (e.g. food, herbs, roots, oils, vitamins).


Among the cross and innovative segments, Nutraceutical products are positioned as food with specific organoleptic properties able to prevent and / or reduce certain diseases. Vitamins and Dietary Supplements cover the 26% of the nutraceuticals market worldwide. They are used as a diet aid for specific needs, from those related to a disease to sports needs

### Prospective growth of the vitamins and food supplements market:

Nutraceuticals is one of the rapidly emerging sectors.

The prospective growth of the Vitamins and Food Supplements market is forecast at 4.4% (CAGR 2018 -2023), driven by exogenous factors and the evolution of consumption preferences

Vitamins and Dietary Supplements – Global market (2018 – 2023, €B, %)



### Impact of Nutraceutical sector in post covid era:

India's nutraceutical market is poised to be a global leader at USD 4 pandemic proving 5 billion. Experts and reports suggested that it will grow to approximately USD 18 billion by 2025. The dietary supplements market in India is valued at USD 3924.44 million in 2020 and reports say that it will reach USD 10,198.57 million by 2026. It puts the industry at a 22 per cent growth rate year on year.

This industry has risen in the past few years and recently a boost due to the ongoing pandemic. The focus on preventive healthcare has contributed to the growth of this sector. The population across India has begun to believe in immunity boosting supplements and has led to a significant shift in buying patterns and market behavior. Vitamin capsules, chewable tablets and gummies are examples of the open healthcare products. Vitamin capsules, chewable tablets and gummies are the examples of the open minded buying behavior of consumers of healthcare products. Vitamin and zinc supplements are also those commonly prescribed



by doctors during the pandemic. Making a growth path for the nutraceuticals market in India.

Preventive healthcare has become an important line of defense during the pandemic proving the nutraceuticals sector to be a strong economic partner to the people. Even after the intensity of the pandemic dropped, nutraceuticals continued to be preferred. The second wave and third waves too has seen that the nutraceutical sector has built and will continue to grow its presence in the market.

#### Year 2021-22 for the company:

Your company is making gradual but real progress in its efforts to achieve the goal of consistent and sustainable balanced growth and value creation including shareholder returns.

During the year under review your company made efforts to improve the pipeline and R&D productivity, sharpening commercial execution and expenses discipline and tackling the Company's structure, underpinned by a shift in culture.

Targets for sustained performance - As well as performance in-year, we maintain a clear focus and oversight on the company's strategy and plans to expand into retail, new geographies which are proposed, subject to approvals, to happen in 2022.

Further there had been a continuous innovations across products: During 2021-22, amidst the ongoing pandemic crisis, the Company's Marketing and R&D teams worked relentlessly on innovation which were more relevant to the current times and which could fit into the consumer's need for healthier products. Some of the key new products which the Company launched in 2021-22 are as follows:

- Royal Tea Tree Body Wash;
- Omega 3 Hair Oil (Sachets).
- Ubtan Body Wash.
- Sonchaldi.
- Nurovit MC Total.
- Orthomega.

B. Strong Go to Market reaching the consumer directly - capacity and capability building: the Company embarked on Project BeYoungBharat aimed to take direct reach of the Company to health conscious wellness consumers which the Company successfully managed to achieve by end of the financial year. The company established Home Shoppes in high-demand locations to improve the delivery time by catering to the pin codes serviced by this Home Shoppee. The Company also plans to supplement it with digitization of front end SI and

PIP with hand held devices and geotag its direct Home Shoppes under its coverage.

C. Growth for emerging channels and markets: E-commerce has emerged as the one bright spot for the Company as the channel grew substantially. There is no denying that as the consumers become more adaptive to shopping online across categories and products, E-commerce will play a significant role in driving the future growth of the Company. As the Company continues to expand its footprints in new markets, international business has seen a growth opportunity. With the focus to further expand share of revenue from the international market, the Company has served its clients and consumers in Mauritius, Nepal and Africa.

#### **Material development in Human resources:**

Company has remained very committed to the safety of all its employees and partners. The company has taken steps to improve processes for better talent acquisition, performance evaluation, merit recognition, and higher productivity. The Company's employee strength as on 31<sup>st</sup> March, 2022 was 85. The Company has also undertaken initiatives to build stronger employee engagement and talent retention. Core policies to enhance efficiencies have been implemented. Company has remained very committed to the safety of all its employees and partners. We focus on enhancing employee well-being and potential. The company provides an invigorating workplace environment, attractive career growth, fair performance management and compensation and operational transparency.

#### **Impact of Flood:**

The company has its innovation hub & Manufacturing unit situated at Udham Singh Nagar, Uttarakhand.

Uttarakhand witnessed unusually high and unprecedented rainfall in some places on 17 and 18<sup>th</sup> October, 2021 resulting in floods causing loss of lives and severe damage to the infrastructure and public utilities in many districts and due to which your company has to face difficulties and uncertain consequences like loss of inventory, damage to valuable machinery, hinderance in transportation and manufacturing of its products.

#### **Growth patterns and emerging opportunities in Nutraceuticals:**

The Nutraceutical industry presents immense possibilities not only for growth, but for innovation,

experimentation, and market expansion. It is an industry full of entrepreneurial opportunities.

Noteworthy trends keeping the sector on the growth path are as follows:

- The changing consumer preferences and shift towards preventive care are making the sector sustainable. The stable growth is thanks to the onset of the pandemic.
- It is preventive care for all age groups with no side effects. It provides adequate nutrition to children who have trouble with eating green leafy vegetables for example. It is available in different shapes, colors, and sizes to make it appealing to children.

**Threats and key challenges faced by Nutraceutical segment in India:**

- The lack of clear regulatory framework: Nutraceuticals as a segment has been a major challenge to the growth and wide spread acceptance of nutraceuticals in India.
- Trust worthiness: There have been instances fake or counterfeit products which are unregistered and unapproved, and it has led to skepticism from consumers as well as industry trade community
- Pricing: Being a preventive approach to health, pricing has been a key player for deciding the acceptance of nutraceuticals across socio-economic classes.

**Outlook and future trends:**

According to statistics, 15 per cent of our population is undernourished. Various initiatives such as Integrated Child Development Services (ICDS) program, National Health Mission (NHM), and the mid day meal scheme are helping with nourishment reaching all. The World Bank has said that the country loses about US\$12 billion in Gross Domestic Product (GDP) to malnourishment. Nutraceuticals can play a vital role in eradicating malnutrition and paving a bridge between government efforts and the population.

The current situation paints a brighter picture for the future where the Indian nutraceutical industry could help the global pharmaceutical industry grow. It is an industry that is regulated by the Food Safety and Standards Authority of India (FSSAI) which comes under the Ministry of Food Processing Industries (MOFPI). Due to the limited attention

given by the FSSAI, the sector cannot achieve its full potential in the export market.

Since the Government is unable to support the exponential growth of the industry. It may give rise to the need of creating a supporting organization that can promote resolutions for grievances, Harmonized System of Nomenclature (HSN) treasury and export promotion initiatives by a comprehensive strong regulatory body to promote the sector.

Special financial assistance or packages, HSN code structure, and tax breaks for analysis and experimentation during clinical studies. It will boost the industry and contribute positively to public health. The public private partnership (PPP) model will also help drive growth and penetration of markets across the country to enhance nutrition among unprivileged segments of society.

While US, Europe and Japan currently account for over 90 percent of the total global nutraceutical market, India, China and other Southeast Asian countries are rising as new and emerging markets for nutraceuticals. As this trend is becoming more and more pronounced, several international, well-reputed, and certified players from US, Japan, and European countries are venturing into the Indian market, ready to leverage the potential by launching their products and expanding their portfolio according to the needs of Indian consumers. Thus, apart from the forecast growth of the industry, nutraceuticals are set to become widely accepted and a common part of Indian households in the near future!

**Future Trends:**

- Nutraceutical manufacturers and marketers are taking up the responsibility of educating the consumers by sharing detailed information about the product and its benefits and roles, while also bringing about a transparency and credibility among the consumers. This will go a long way to build a stronger category for Nutraceuticals as a health and wellness segment.
- Industry players are also undertaking a number of initiatives on their own, including a renewed focus on improved quality standards of the product, enhanced transparency, and competitive pricing for innovations.
- Nutraceuticals in the form of capsules will gain wider popularity, given their ease of

consumption and the flexibility for diverse formulation.

Your company will align its activities and goals with these changing scenarios to keep abreast with the latest developments in this sector and take competitive advantages.

**Risks and Concerns:**

The analysis shown above clearly depicts the major risks and concerns involved in nutraceutical segment. The strategy of your Company to de-risk against these factors is also outlined in the said Sections.

**Internal Control Systems and their adequacy:**

The Company has established a well-defined process of risk management, wherein the identification, analysis and assessment of the various risks, measuring the probable impact of such risks, formulation of risk mitigation strategy and implementation of the same takes place in a structured manner. Though the various risks associated with the business cannot be eliminated completely, all efforts are made to minimize the impact of such risks on the operations of the Company. Necessary internal control systems are also put in place by the Company on various activities across the board to ensure that business operations are directed towards attaining the stated organizational objectives with optimum utilization of resources. Apart from these internal control procedures, a well-defined and established system of internal audit is in operation. The results of operations and financial conditions are affected by numerous factors including the following: Supply and availability of raw material/traded goods; Competition from existing and new entrants; Performance of our distribution channel; Brand image; Rate of interest policies; Economic and Demographic conditions; and Changes in laws and regulations that apply to Nutraceutical Industry in domestic and overseas market.

**Discussion on Financial Performance with respect to the Operational Performance:**

On a standalone basis, your Company recorded net sales of Rs. 3339.19 Lakhs during the financial year 2021-22 as compared to Rs. 3,383.12 Lakhs in the previous financial year 2020-21, whereas the Net Profit during the financial year 2021-22 stood at Rs. 32.41 Lakhs as compared to a net profit of Rs 39 Lakhs in financial year 2020-21 leading to the Basic Earnings Per Share of Rs. 0.21/- for the financial year 2021-22 as compared to Rs.0.25/- in financial year 2020-21 due to negative impact of

flood caused in Uttarakhand on the business of the Company.

On a Consolidated basis, your Company recorded net sales of 3339.19 Lakhs during the financial year 2021-22 as compared to 3,383.12 Lakhs in the previous financial year 2020-21, whereas the Net Profit during the financial year 2021-22 stood at Rs. 32.26 Lakhs as compared to a net profit of Rs 38.99 Lakhs in financial year 2020-21 leading to the Basic Earnings Per Share of Rs.0.21/- for the financial year 2021-22 as compared to Rs. 0.25/- in financial year 2020-21 due to negative impact of heavy rains and flood caused in Uttarakhand on the business of the Company.

**Significant changes (i.e. change of 25% or more as compared to the immediately previous financial years) in Key Financial Ratios, along with explanation are as under:**

Ratios	FY 2021-22	FY 2020-21
<b>Debtor turnover ratio</b>	<b>2.62</b>	<b>2.05</b>
<b>Inventory turnover ratio</b>	<b>0.31</b>	<b>0.44</b>
<b>Interest coverage ratio</b>	<b>4.58</b>	<b>5.81</b>
<b>Current ratio</b>	<b>6.47</b>	<b>5.23</b>
<b>Debt- Equity Ratio</b>	<b>0.08</b>	<b>0.07</b>
<b>Operating Profit margin</b>	<b>1.43</b>	<b>1.69</b>
<b>Net Profit Margin</b>	<b>0.98</b>	<b>1.15</b>
<b>Return on Net worth</b>	<b>0.42</b>	<b>0.51</b>

**References:**

- [www.fssai.gov.in](http://www.fssai.gov.in)
- [www.biovoicenews.com](http://www.biovoicenews.com)
- PwC reports on Vitamins and Dietary Supplements market trends – overview.





# STANDALONE FINANCIAL STATEMENTS



FOR FINANCIAL YEAR 2021-22



---

# INDEPENDENT AUDITOR'S REPORT

---

To  
The Members of  
DECCAN HEALTH CARE LIMITED

## Report on the Audit of the Standalone Financial Statements

### Opinion

We have audited the standalone financial statements of **DECCAN HEALTH CARE LIMITED** (“the Company”), which comprise the balance sheet as at 31<sup>th</sup> March 2022, and the statement of Profit and Loss, and statement of cash flows for the period ended 31<sup>th</sup> March 2022, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its profit/loss, and its cash flows for the period ended March 31, 2022.

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters and there is no any Key Audit Matters which need to be reported.

### Information Other than the financial statements and Auditor's report thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### Responsibility of Management for Standalone

## Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can

arise from fraud or error and are considered material if,

individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### Report on other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure A' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - (c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
  - (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
  - (e) On the basis of the written representations received from the directors as on 31<sup>st</sup> March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
  - (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
    - i. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of

the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- ii. The Company has not any pending litigation which should require to disclose on its financial position. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
  - iv. The management has represented that, to the best of its knowledge and belief, as disclosed in to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall:
    - directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or
    - provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
    - The management has represented, that, to the best of its knowledge and belief, as disclosed in the accounts, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall:
      - directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Party or
      - provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries.
      - Based on such audit procedures as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (d) (i) and (d) (ii) contain any material misstatement.
  - v. The Company has not declared or paid any dividend during the year.
- (g) **With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:**

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

**For Keyur Shah & Co.**

**Chartered Accountants  
FRN.: 141173W**

**Sd/-**

**Keyur Shah**

**Proprietor**

**Membership No.: 153774**

**Date: 30<sup>th</sup> May, 2022**

**UDIN –22153774AJXPMQ5055 Place: Ahmedabad**

---

---

## “Annexure A” to the Independent Auditors’ Report

---

Referred to in paragraph 1 under the heading ‘Report on Other Legal & ‘Regulatory Requirement’ of our report of even date to the financial statements of the Company for the period ended March 31, 2022:

**i. Property, Plant, Equipment and intangible Assets:**

- a. The Company is maintaining proper records showing full particulars, including quantitative details and situation of Property, Plant, Equipment and intangible Assets;
- b. The Property, Plant, Equipment and intangible Assets are physically verified by the management according to a phased programme, designed to cover all the items over a period of three years which, in our opinion, is reasonable having regard to the size of the company and nature of its assets. Pursuant to the programme, a portion of the Property, Plant, Equipment and intangible Assets has been physically verified by the management during the year and no material discrepancies have been noticed on such verification.
- c. The title deeds of all the immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee), as disclosed in Note 10 on Property, plant and equipment and Intangible assets to the standalone financial statements, are held in the name of the Company.
- d. The Company has not revalued its Property, Plant, Equipment and intangible Assets during the year. Accordingly, the reporting under clause 3(i)(d) of the Order is not applicable to the company.
- e. Based on the information and explanations furnished to us, no proceedings have been initiated on or are pending against the Company for holding Benami property under Benami Transactions (Prohibitions) Act, 1988(as

amended in 2016) (formerly the Benami Transaction (Prohibition) Act, 1998(45 of 1988) and Rules made thereunder, and therefore the question of our commenting on whether the company has appropriately disclosed the details in its standalone financial statements does not arise.

**ii. Inventory:**

- a. The physical verification of inventory (excluding stocks with third parties) has been conducted at reasonable intervals by the Management during the year and, in our opinion, the coverage and procedures of such verification by Management is appropriate. The discrepancies noticed on physical verification of inventory as compared to book records were not 10% or more in aggregate for each class of inventory.
- b. The Company does not have any working capital limits in excess of five crores rupees (at any point of time during the year), in aggregate from banks or financial institutions on the basis of security of current assets. Accordingly, the provisions of clause 3(ii) of the Order are not applicable.

**iii. Loans given by the Company:**

According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any security or granted advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnership or any other parties during the year. The Company has made investments, granted loans and provided guarantees to companies and other parties in respect of which the requisite information is provided in clause (a) to (f) as below to the extent applicable. The Company has not made any investments in or provided any guarantee or security

to firms or limited liability partnership Except as mentioned below :

Company has provided loans or stood guarantee, as below:

- a) Based on the audit procedures carried out by us and as per the information and explanations given to us, the

(INR in Lakhs)

Particulars	Guarantees	Loans - Unsecured
<b>Aggregate amount granted/Provided during the year</b>		
<b>-Subsidiary</b>		
<b>-Be Youngstore Private Limited</b>	0.00	0.00
<b>Balance outstanding as at balance sheet date</b>		
<b>-Subsidiary</b>		
<b>- Be Youngstore Private Limited</b>	0.00	1.00

- b) According to the information and explanations given to us and based on the audit procedures carried out by us, in our opinion the investments made during the year and the terms and conditions of the grant of loans provided during the year are prima facie, not prejudicial to the interest of the Company.

- f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment.

- c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans given, in our opinion, the repayment of principal and payment of interest has been stipulated and the repayments or receipts have been regular.

#### **iv. Loans to directors & Investment by the Company:**

In our opinion, and according to the information and explanations given to us, the Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of the loans and investments made, and guarantees and security provided by it, as applicable.

- d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no overdue amount for more than ninety days in respect of loans given.

#### **v. Deposits**

The Company has not accepted any deposits or amounts which are deemed to be deposits within the meaning of Sections 73, 74, 75 and 76 of the Act and the Rules framed there under to the extent notified.

- e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted falling due during the year, which has been renewed or extended or fresh loans granted to settle the over dues of existing loans given to same parties.

#### **vi. Cost records:**

To the best of our knowledge and belief, the Central Government has not specified maintenance of cost records under sub-section (1) of Section 148 of the



Act, in respect of activities carried on by the company. Accordingly, the provision of clause 3(vi) of the Order are not applicable.

**Vii. Statutory Dues:**

- a. According to the information and explanations given to us and the records of the Company examined by us, in our opinion, the Company is generally regular

in depositing undisputed statutory dues in respect of provident fund, employees' state insurance, income tax, goods and services tax and Labour welfare fund, though there were no delay in depositing undisputed statutory dues, including sales tax, service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues, as applicable, with the appropriate authorities.

Name of the Statute	Nature of Dues	Amount (Rs. In Lakhs)	Period to which the amount relates	Due Date of Payment	Date of Payment
<b>The Employees' State Insurance Act, 1948</b>	Employer and Employee Contribution	0.41	April, 2019	15 <sup>th</sup> May, 2019	-
		0.18	May, 2019	15 <sup>th</sup> June, 2019	-
		0.16	June, 2019	15 <sup>th</sup> July, 2019	-
		0.10	July, 2019	15 <sup>th</sup> August, 2019	-
		0.10	August, 2019	15 <sup>th</sup> Sept, 2019	-
		0.10	Sept, 2019	15 <sup>th</sup> Oct, 2019	-
		0.09	Oct, 2019	15 <sup>th</sup> Nov, 2019	-
		0.07	Nov, 2019	15 <sup>th</sup> Dec, 2019	-
		0.07	Dec, 2019	15 <sup>th</sup> Jan, 2020	-
		0.07	Jan, 2020	15 <sup>th</sup> Feb, 2020	-
		0.11	Feb, 2020	15 <sup>th</sup> April, 2020	-
		0.10	March, 2020	15 <sup>th</sup> May, 2020	-
		0.03	April, 2020	15 <sup>th</sup> May, 2020	-
		0.03	May, 2020	15 <sup>th</sup> June, 2020	-
		0.03	June, 2020	15 <sup>th</sup> July, 2020	-
		0.05	July, 2020	15 <sup>th</sup> August, 2020	-
		0.05	August, 2020	15 <sup>th</sup> Sept, 2020	-
		0.05	Sep, 2020	15 <sup>th</sup> Oct, 2020	-
		0.04	Oct, 2020	15 <sup>th</sup> Nov, 2020	-
		0.04	Nov, 2020	15 <sup>th</sup> Dec, 2020	-
		0.04	Dec, 2020	15 <sup>th</sup> Jan, 2021	-
		-	Jan, 2021	15 <sup>th</sup> Feb, 2021	-
		0.04	Feb, 2021	15 <sup>th</sup> March, 2021	-
0.07	March, 2021	15 <sup>th</sup> April, 2021	-		
0.02	April, 2021	15 <sup>th</sup> of May, 2021	27/05/2021		
0.02	May, 2021	15 <sup>th</sup> of June, 2021	23/06/2021		
0.02	June, 2021	15 <sup>th</sup> of July, 2021	20/07/2021		
0.02	July, 2021	15 <sup>th</sup> of Aug, 2021	24/08/2021		
0.02	Aug, 2021	15 <sup>th</sup> of Sep, 2021	07/10/2021		
-	Sep, 2021	15 <sup>th</sup> of Oct, 2021	-		
<b>Income Tax Act, 1961</b>	Tax Deducted At Source and Tax Collected at Source	40.25	April 2020 to March, 2021	7 <sup>th</sup> of next month & for the March'2021 the date would be 30 <sup>th</sup> April, 2021	6.14 paid in July, 2021
<b>EPF &amp; MP Act, 1952</b>	Employer Contribution And Employee	0.18	Oct, 2019	15 <sup>th</sup> of Nov, 2019	-
		0.18	Nov, 2019	15 <sup>th</sup> of Dec, 2019	-
		0.16	Dec, 2019	15 <sup>th</sup> of Jan, 2020	-

	Contribution	0.16	Jan,2020	15th of Feb,2020	-
		0.32	Feb,2020	15th of March,2020	-
		0.30	March,2020	15th of May,2020	-
		0.08	April,2020	15th of May,2020	-
		0.08	May,2020	15th of June,2020	-
		0.08	July,2020	15th of Aug,2020	-
		0.08	Aug,2020	15th of Sep,2020	-
		0.09	Sep, 2020	15 <sup>th</sup> of Oct, 2020	-
		0.09	Oct, 2020	15 <sup>th</sup> of Nov, 2020	-
		0.08	Nov, 2020	15 <sup>th</sup> of Dec, 2020	-
		0.08	Dec, 2020	15 <sup>th</sup> of Jan, 2021	-
		0.08	Feb, 2021	15 <sup>th</sup> of March, 2021	-
		0.15	March, 2021	15 <sup>th</sup> of April, 2021	-
		0.03	April, 2021	15 <sup>th</sup> of May, 2021	26/05/2021
		0.03	May, 2021	15 <sup>th</sup> of June, 2021	24/06/2021
		0.03	June, 2021	15 <sup>th</sup> of July, 2021	20/07/2021
		0.03	July, 2021	15th of August, 2021	24/08/2021
		0.03	August, 2021	15 <sup>th</sup> of Sept, 2021	07/10/2021
<b>Income Tax Act, 1961</b>	Income Tax	3.70	AY 2001-02		-
<b>Income Tax Act, 1961</b>	Income Tax	1.10	AY 2009-10		-
<b>Income Tax Act, 1961</b>	Income Tax	1.50	AY 2018-19		-

- b. According to the information and explanation given to us, there have been no dues of Income Tax, Sales Tax, Goods & Service Tax, Duty of Customs, Duty of Excise, Value Added Tax outstanding on account of any dispute except as mentioned below:

(Rs. In Lakhs)				
Nature of Statute	Nature of Dues	Forum where Dispute is Pending	Period to which the Amount Relates (Assessment Year)	Amount
<b>Income Tax Act, 1961</b>	Income Tax	Jurisdictional AO	2010-11	8.77/-
<b>Income Tax Act, 1961</b>	Income Tax	CIT(A) 5- Hyderabad	2017-18	451.12/-
<b>Income Tax Act, 1961</b>	Income Tax	CIT (Appeal)	2018-19	525.35/-
<b>Income Tax Act, 1961</b>	Income Tax	CIT(Appeal)	2019-20	505.91/-

#### **viii. Unrecorded income**

According to the information and explanations given to us and the records of the Company examined by us, there are no transactions in the books of account that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.

#### **ix. Repayment of Loans:**

a. According to the records of the Company examined by us and the information and explanations given to us, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest to any lender during the year.

b. According to the information and explanations given to us and on the basis of our audit procedures, we report that

the Company has not been declared Willful Defaulter by any bank or financial institution or government or any government authority.

- c. In our opinion, and according to the information and explanations given to us, the company has obtained term loans during the year and term loans were applied for the purpose for which the loans were obtained.
- d. According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the standalone financial statements of the Company, we report that the Company has not used funds raised on short-term basis for the long-term purposes.
- e. According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.
- f. According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.

**x. Utilization of IPO & FPO and Private Placement and Preferential issues:**

- a. The Company has not raised money by way of initial public offer or further public offer (including debt instruments) during the year;
- b. According to the information and explanation given to us, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year.

**xi. Reporting of Fraud:**

- a. During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of material fraud by the Company or on the Company, noticed or reported during the year, nor have we been

- b. informed of any such case by the Management.
- b. During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, no report under Section 143(12) of the Act, in Form ADT-4, as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 has been filed with the Central Government. Accordingly, the reporting under Clause 3(xi) (b) of the Order is not applicable to the Company.
- c. During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, the Company has not received whistle-blower complaints during the year, which have been considered by us for any bearing on our audit and reporting.

**xii. NIDHI Company:**

As the Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to it, the reporting under Clause 3(xii) of the Order is not applicable to the Company.

**xiii. Related Party Transaction:**

The Company has entered into transactions with related parties in compliance with the provisions of Sections 177 and 188 of the Act. The details of such related party transactions have been disclosed in the standalone financial statements as required under Indian Accounting Standard 24 “Related Party Disclosures” specified under Section 133 of the Act.

**xiv. Internal Audit**

- a) In our opinion and according to the information and explanation given to us, the Company has an internal audit system commensurate with the size and nature of its business.
- b) The reports of the Internal Auditor for the period under audit have been considered by us.

**xv. Non-Cash Transaction:**

The Company has not entered into any non-cash

transactions with its directors or persons connected with him. Accordingly, the reporting on compliance with the provisions of Section 192 of the Act under Clause 3(xv) of the Order is not applicable to the Company.

**xvi. Register under RBI Act, 1934:**

According to the information and explanations given to us, we are of the opinion that the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 and the company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India, accordingly the provisions of clause 3(xvi) of the Order are not applicable;

**xvii. Cash Losses**

According to the information and explanation given to us and based on the audit procedures conducted we are of opinion that the company has not incurred any cash losses in the financial year and the immediately preceding financial year;

**xviii. Auditor's resignation**

There has been no resignation of the statutory auditors during the year and accordingly, the provisions of clause 3(xviii) of the Order is not applicable.

**xix. Financial Position**

According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and

payment of financial liabilities, other information accompanying the standalone financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

**xx. Corporate Social Responsibility**

The Provision of Section 135 of the Companies Act 2013 in relation to Corporate Social Responsibility are not applicable to the Company during the year and hence reporting under this clause is not applicable.

**For Keyur Shah & Co.  
Chartered Accountants  
FRN.: 141173W**

**Keyur Shah  
Proprietor  
Membership No.: 153774      Date: 30<sup>th</sup> May, 2022  
UDIN -22153774AJXPMQ5055      Place: Ahmedabad**



---

**“Annexure B” to the Independent Auditor’s Report of even date on the Financial Statements of DECCAN HEALTH CARE LIMITED**

---

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of **DECCAN HEALTH CARE LIMITED** (“the Company”) as of March 31, 2022 in conjunction with our audit of the financial statements of the Company for the period ended on that date.

**Management’s Responsibility for Internal Financial Controls**

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditor’s Responsibility**

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

**Meaning of Internal Financial Controls over Financial Reporting**

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

**Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting

were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For Keyur Shah & Co.  
Chartered Accountants  
FRN.: 141173W**

**Sd/-  
Keyur Shah  
Proprietor  
Membership No.: 153774  
UDIN :- 22153774AJXPMQ5055**

**Date: 30<sup>th</sup> May, 2022**

---

**Deccan Healthcare Limited**  
CIN: L72200TG1996PLC024351

## Balance Sheet as on 31.03.2022

(Rs in Lakhs)

Sr. No.	Particulars	Note No.	As at 31st March, 2022	As at 31st March, 2021
<b>I.</b>	<b>EQUITY AND LIABILITIES</b>			
<b>(1)</b>	<b>Shareholder's Funds</b>			
	(a) Share Capital	2	1,571.34	1,571.34
	(b) Reserves and Surplus	3	6,123.28	6,090.87
<b>(2)</b>	<b>Share Application Money pending allotment</b>		-	-
<b>(3)</b>	<b>Non-Current Liabilities</b>			
	(a) Long-Term Borrowings	4	95.70	66.63
	(b) Deferred Tax Liability	5	209.53	212.68
	(c) Long Term Provisions	6	14.07	14.08
<b>(4)</b>	<b>Current Liabilities</b>			
	(a) Trade Payables	7		
	- Due to Micro and Small Enterprise		56.21	-
	- Due to other than Micro and Small Enterprise		517.90	565.64
	(b) Other Current Liabilities	8	421.90	505.45
	(c) Short-Term Provisions	9	52.67	200.07
	<b>TOTAL</b>		<b>9,062.60</b>	<b>9,226.76</b>
<b>II.</b>	<b>ASSETS</b>			
<b>(1)</b>	<b>Non-Current Assets</b>			
	(a) Property, Plant & Equipments & Intangible Assets	10		
	(i) Tangible Assets		1,851.35	1,987.41
	(ii) Intangible Assets		1.72	-
	(iii) Intangible Assets Under Development		-	6.66
	(b) Long-Term Loans and Advances	11	175.94	176.87
	(c) Other Non-Current Assets	12	237.75	410.08
	(d) Non-Current Investment	13	1.00	1.00
<b>(2)</b>	<b>Current Assets</b>			
	(a) Inventories	14	4,650.32	4,497.95
	(b) Trade Receivables	15	1,282.31	1,246.59
	(c) Cash and Cash Equivalents	16	265.72	321.15
	(d) Short-Term Loans and Advances	17	596.49	579.05
	<b>TOTAL</b>		<b>9,062.60</b>	<b>9,226.76</b>

The accompanying notes 1 to 33 form an integral part of the Standalone Financial Statements

As per our Report of even date attached

For **Keyur Shah & Co.**  
Chartered Accountants  
(FRN: 141173W)

Sd/-

**Keyur Shah**  
Proprietor  
M.No.:153774

Sd/-  
**Minto P Gupta**  
(Managing Director)  
DIN: 00843784

Sd/-  
**Hitesh M Patel**  
(Director)  
DIN:02080625

Sd/-  
**Mohak Gupta**  
(Chief Financial officer)  
PAN: ARTPG3989Q

Sd/-  
**Apeksha Baisakhiya**  
(Company Secretary)  
PAN:CTXPB8692K

For and on behalf of the Board of Director

Date: 30<sup>th</sup> May, 2022  
Place: Ahmedabad

**Deccan Healthcare Limited**  
CIN: L72200TG1996PLC024351

## Statement of Profit & Loss for the period ended 31.03.2022

(Rs. In Lakhs)

	Particulars	Note No	For the Year Ended 31st March, 2022	For the Year Ended 31st March, 2021
<b>I.</b>	Revenue from Operations	18	3,317.12	3,377.58
<b>II.</b>	Other Incomes	19	22.07	5.54
<b>III.</b>	<b>Total Revenue (I + II)</b>		<b>3,339.19</b>	<b>3,383.12</b>
<b>IV.</b>	Expenses:			
	Cost of Materials Consumed	20	398.09	2,273.90
	Changes in Inventories of Finished Goods and Work-in-Progress	21	1,036.69	(430.88)
	Employee Benefit Expenses	22	219.52	291.76
	Depreciation and Amortization Expense	10	147.27	146.60
	Finance Costs	23	15.18	10.79
	Other Expenses	24	1,128.04	1,039.04
	<b>Total Expenses</b>		<b>2,944.79</b>	<b>3,331.21</b>
<b>V.</b>	<b>Profit/ Loss before Exceptional Items and Tax (III - IV)</b>		<b>394.40</b>	<b>51.91</b>
<b>VI</b>	Exceptional Items (Loss due to flood at manufacturing facility in Uttarakhand)		(340.00)	-
<b>VII</b>	<b>Profit before Tax (V-VI)</b>		<b>54.40</b>	<b>51.91</b>
<b>VIII</b>	Tax Expense:			
	(1) Provision for Income Tax			
	Income Tax		25.13	13.91
	(2) Deferred Tax		(3.14)	(0.99)
<b>IX</b>	<b>Profit/ (Loss) for the period (VII-VIII)</b>		<b>32.41</b>	<b>38.99</b>
<b>X</b>	<b>Earnings Per Equity Share</b>			
	(1) Basic	25	0.21	0.25
	(2) Diluted	25	0.21	0.25

The accompanying notes 1 to 33 form an integral part of the Standalone Financial Statements

As per our Report of even date attached

For **Keyur Shah & Co.**  
Chartered Accountants  
(FRN: 141173W)

For and on behalf of the Board of Director

Sd/-

**Keyur Shah**

Proprietor

M.No.:153774

Sd/-

**Minto P Gupta**

(Managing Director)

DIN: 00843784

Sd/-

**Hitesh M Patel**

(Director)

DIN:02080625

Sd/-

**Mohak Gupta**

(Chief Financial officer)

PAN: ARTPG3989Q

Sd/-

**Apeksha Baisakhiya**

(Company Secretary)

PAN:CTXPB8692K

Date: 30<sup>th</sup> May, 2022

Place: Ahmedabad



Deccan Healthcare Limited  
CIN: L72200TG1996PLC024351

## Cash Flow Statement as on 31.03.2022

(Rs. In Lakhs)

	PARTICULARS	For the Year Ended 31st March, 2022	For the Year Ended 31st March, 2021
<b>A</b>	<b>Cash Flows from Operating Activities</b>		
	Net Profit before tax and Extraordinary items	394.40	51.91
	<b>Adjustments for :</b>		
	Depreciation	147.27	146.60
	Exceptional Loss	(340.00)	
	Interest Expense	15.18	10.79
	Interest Income	(0.39)	(0.76)
	<b>Operating Profit before Working Capital Changes</b>	<b>216.46</b>	<b>208.54</b>
	<b>Adjustments for :</b>		
	(Increase)/Decrease in Trade Receivables	(35.72)	809.51
	(Increase)/Decrease in Inventory	(152.37)	(707.90)
	Increase/(Decrease) in Provisions	(147.42)	8.31
	(Increase)/Decrease in Other Non Current Asset	172.33	(6.68)
	(Increase)/Decrease in Short Term Loans and Advances	(17.45)	(183.76)
	Increase/(Decrease) in Trade Payables	8.47	(140.33)
	Increase/(Decrease) in Current Liabilities	(76.39)	48.04
	<b>Cash Generated from Operations</b>	<b>(32.09)</b>	<b>35.73</b>
	<b>Tax Paid</b>	<b>(25.13)</b>	<b>(13.91)</b>
	<b>Net Cash from Operating Activities</b>	<b>(57.22)</b>	<b>21.82</b>
<b>B</b>	<b>Cash Flows from Investing Activities</b>		
	(Increase)/Decrease in Capital Work in Progress	4.94	(6.66)
	Purchase of Fixed Assets	(11.20)	(9.18)
	Interest Income	0.39	0.76
	(Increase)/Decrease in Non Current Investment	-	(1.00)
	(Increase)/Decrease in Long Term Loans and Advances	0.93	7.91
	<b>Net Cash from Investing Activities</b>	<b>(4.94)</b>	<b>(8.17)</b>
<b>C</b>	<b>Cash Flows from Financing Activities</b>		
	Interest Expense	(15.18)	(10.79)
	Increase/(Decrease) in Long Term Borrowing	21.91	(26.24)
	<b>Net Cash from Financing Activities</b>	<b>6.73</b>	<b>(37.03)</b>
<b>D</b>	<b>Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>(55.43)</b>	<b>(23.38)</b>
<b>E</b>	Cash and Cash Equivalents at the beginning	321.15	344.53
<b>F</b>	<b>Cash and Cash Equivalents at the end (D+E)</b>	<b>265.72</b>	<b>321.15</b>

Notes: 1. Cash Flow Statement has been prepared using the indirect method in accordance with Accounting Standard AS 3-"Cash Flow Statement" notified under section 133 of the Companies Act,2013

2. Represent Cash and Cash Equivalents as given in Note 16 to the Financial Statement.

For Keyur Shah & Co.  
Chartered Accountants  
(FRN: 141173W)

Sd/-

**Keyur Shah**

Proprietor

M.No.:153774

Sd/-

**Minto P Gupta**

(Managing Director)

DIN: 00843784

Sd/-

**Hitesh M Patel**

(Director)

DIN:02080625

Sd/-

**Mohak Gupta**

(Chief Financial officer)

PAN: ARTPG3989Q

Sd/-

**Apeksha Baisakhiya**

(Company Secretary)

PAN:CTXPB8692K

For and on behalf of the Board of Director

Date: 30<sup>th</sup> May, 2022

Place: Ahmedabad

## Note No: 1

### A. Significant Accounting Policies:

The Accounting policies set out below have been adopted in preparation and presentation of financial statement and applied consistently to the period presented in this financial statement.

### B. Disclosure of Accounting Policies:

#### a. Basis of Preparation:

These financial statement have been prepared to comply in all material aspects with applicable accounting principles in India, the applicable accounting standards prescribed under section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified) and other accounting principles generally accepted in India, to the extent applicable. The accounting policies have been consistently applied by the Company and are consistent with those used in the previous year.

#### b. Use of Estimates:

The preparation of financial statements in conformity with generally accepted accounting principles require the management to make estimates and assumptions that affect the reported amounts of Assets and Liabilities and disclosure of Contingent Liabilities at the date of the financial statements and the result of operations during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates.

Significant estimates used by the management in the preparation of these financial statements include provisions for bad and doubtful debts. Any revision to accounting estimates is recognized prospectively.

#### c. Accounting Convention and Revenue Recognition:

The Financial Statements have been prepared on a going concern basis in accordance with historical cost convention except for such fixed assets which are revalued. Both Income and Expenditure are recognized on accrual basis.

Revenue from Sales is recognized when practically all risks and rewards of ownership are transferred to the buyer and there is no effective control of the seller as the owner, this usually occurs upon dispatch of the goods. Gross sales shown in the Statement of Profit & Loss are inclusive of Excise duty but exclude discounts, CST, VAT & Goods & Service Tax. Net Sales are shown after

deducting Excise duty which is disclosed at appropriate places. Interest income is recognized on receipt basis, and not on a time proportion basis, taking into accounts the amount outstanding and rate applicable.

Revenue are accounted Net of Goods & Service Tax (GST), Excise Duty, Taxes and Sales Returns.

Other Items of Revenue are recognized in accordance with AS-9.

#### d. Cash Flow Statement: AS-3

The Company has prepared Cash Flow Statement as per the AS-3.

Cash flows are reported using the Indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the group are segregated.

#### e. Retirements Benefits:

Staff benefits arising out of retirements / death, comprising of contributions to Provident Fund, Superannuation & Gratuity Schemes, accrued Leave Encashment and other post-separation benefits are accounted for on the basis of an independent actuarial valuation, in accordance with AS-15. The actuarial liability is determined with reference to employees at the end of each financial year.

Expenses for defined benefit gratuity payment plans are calculated as at the balance sheet date by independent actuaries in the manner that distributes expenses over the employees working life. These commitments are valued at the present value of the expected future payments, with consideration for calculated future salary increases, using a discounted rate corresponding to the interest rate estimated by the actuary having regard to the interest rate on Government Bonds with a remaining term i.e. almost equivalent to the average balance working period of employees.

The Company has adopted accounting standard 15 on Employee Benefits as per Actuarial Valuation carried out by an independent actuary in the Book of Account of the Company and the Disclosure relating to same which is envisaged under the standard are disclosed under the notes to financial Statement.

#### f. Property, Plant & Equipment:

Property, plant and equipment are stated at cost, net of recoverable taxes, trade discount and rebates less accumulated depreciation and impairment losses, if any. Such cost includes purchase price, borrowing cost and any cost directly attributable to bringing the assets to its working condition for its intended use, net charges on foreign exchange contracts and arrangements arising from exchange rate variations attributable to the assets. Expenditure on additions, improvements and renewals is capitalized and expenditure for maintenance and repairs is charged to profit and loss account.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow the entity and the cost can be measured reliably.

Depreciation on property, plant and equipment is provided using Straight Line Method over the useful life of the Asset.

Depreciation in respect of addition to assets has been charged on pro rata basis with reference to the period of use of such asset.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Gains or losses arising from de recognition of a property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Statement of Profit and Loss when the asset is derecognized.

#### g. Accounting for Investments:

Long term investments are stated at cost. However, provision for diminution is made to recognize any decline, other than temporary, in the value of long term investments. Current Investments are stated at the lower of cost and fair value.

#### h. Accounting for Intangible Assets:

Intangible assets are capitalized at cost if:

- a. It is probable that the future economic benefits that are attributable to the asset will flow to the company;
- b. The company will have control over the assets;
- c. The cost of these assets can be measured reliably and is more than 10,000/- & this is in accordance with AS-26.

#### i. Accounting for Borrowing Costs:

Borrowing cost relating to acquisition/ construction of qualifying assets are capitalized until the time all substantial activities necessary to prepare the qualifying assets for their intended use are complete. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use/sale. Borrowing costs that are attributable to the projects are charged to the respective projects. All other borrowing costs, not eligible for capitalization, are charged to revenue accounts.

#### j. Accounting & Valuation for Inventories:

- Materials, Stores & Spares, Tools and Consumables are valued at Cost or Market Value, whichever is lower, on the basis of First in First Out method reflecting the fairest possible approximation to the cost incurred in bringing the items of Inventory to their present location and condition.
- Finished Stock of completed products is valued at lower of Cost or Net Realizable Value on the basis of actual identified units. Cost being determined by including cost of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. Net realizable value determined by excluding all payable statutory dues and direct sales expenses.
- Scrap is valued at Net Realizable Value.
- Work in process in respect of activities is valued at estimated cost.

#### k. Accounting for Taxes on Income:

- Provision for tax for the year comprises current Income Tax and Deferred Tax and is provided as per the Income Tax Act, 1961.
- Deferred tax resulting from timing differences between the book and the tax profits is accounted for, at the current rate of tax, to the extent that the timing differences are expected to crystallize. Deferred tax assets are recognized only to the extent there is reasonable certainty that the assets can be realized in the future; however where there is unabsorbed depreciation or carried forward

loss under taxation laws, deferred tax assets are recognized only if there is a virtual certainty of realization of such assets. Deferred tax assets/liabilities are reviewed as at each balance sheet date.

#### **I. Provisions, Contingent Liabilities and Contingent Assets:**

Provisions are recognized for liabilities that can be measured only by using a substantial degree of estimation, if

- The Company has a present obligation as a result of a past event;
- A probable outflow of resources is expected to settle the obligation; and
- The amount of the obligation can be reliably estimated.
- Reimbursement expected in respect of expenditure required to settle a provision is recognized only when it is virtually certain that the reimbursement will be received.

Contingent Liability is disclosed in the case of:

- A present obligation arising from a past event, when it is not probable that an outflow of resources will be required to settle the obligation;
- A possible obligation, unless the probability of outflow of resources is remote. Contingent Assets are neither recognized nor disclosed.

#### **m. Earnings per Share:**

The earnings considered in ascertaining the companies earning per share comprise net profit after tax and includes the post-tax effect of any extraordinary/exceptional item is considered. The number of shares used in computing basic earnings per share is the weighted average number of shares outstanding during the year.

The no. of shares used in computing diluted earnings per share comprises the weighted average no. of shares considered for deriving basic earnings per share and also the weighted average no. of equity shares that could have been issued on the conversion of all dilutive potential equity shares.

#### **n. Accounting for Impairment of Assets:**

Management periodically assesses using external and internal sources whether there is an indication that an asset may be impaired. Impairment occurs where the carrying value exceeds the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. The impairment loss to be expensed is determined as the excess of carrying amount over the higher of the asset's net sale price or present value as determined above.

#### **o. Related Party Disclosures:**

The Company as required by AS-18 furnishes the details of Related Party Disclosures in the notes to financial statements.



### 10. Property Plant & Equipment

SL NO	PARTICULARS	GROSS BLOCK				DEPRECIATION				NET BLOCK	
		AS AT 01.04.2021	ADDITIONS DURING THE YEAR	(SALE)/ Adjustment DURING THE YEAR	TOTAL AS AT 31.03.2022	UPTO 01.04.2021	FOR THE YEAR	ADJUSTMENT	UPTO 31.03.2022	NET CARRYING AMOUNT AS AT 31.03.2022	NET CARRYING AMOUNT AS AT 31.03.2021
1	Land (Lease Hold)	28.41	-	-	28.41	-	-	-	-	28.41	28.41
2	Factory Building	1,432.97	-	-	1,432.97	354.78	47.86	-	402.64	1,030.34	1,078.20
3	Plant & Machinery	1,154.92	-	-	1,154.92	613.76	54.86	-	668.61	486.31	541.17
4	R&D (Machinery)	85.96	-	-	85.96	37.16	4.08	-	41.24	44.71	48.79
5	Furniture & Fixture	104.93	-	-	104.93	72.44	6.64	-	79.08	25.85	32.49
6	Electrical Appliances	47.99	0.10	-	48.09	7.26	2.28	-	9.54	38.54	40.73
7	Computer & Software	102.67	2.29	-	104.96	98.50	4.37	-	102.88	2.08	4.17
8	Office Equipments	43.02	-	-	43.02	21.88	2.72	-	24.61	18.42	21.14
9	Air Conditions	15.41	-	-	15.41	10.04	0.98	-	11.02	4.40	5.37
10	Vehicles	344.13	67.17	82.66	328.64	157.18	23.47	24.30	156.34	172.30	186.95
	<b>Sub Total</b>	<b>3,360.41</b>	<b>69.56</b>	<b>82.66</b>	<b>3,347.31</b>	<b>1,373.00</b>	<b>147.27</b>	<b>24.30</b>	<b>1,495.96</b>	<b>1,851.35</b>	<b>1,987.41</b>
	Previous Year	<b>3,351.23</b>	<b>9.18</b>	<b>-</b>	<b>3,360.41</b>	<b>1,226.40</b>	<b>146.60</b>	<b>-</b>	<b>1,373.00</b>	<b>1,987.41</b>	<b>2,124.83</b>

## Notes forming part of Balance Sheet and Profit & Loss Accounts

### 2. Share Capital

(Rs. In Lakhs)

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
Authorised Capital		
<b>18000000 Equity Shares of Rs.10/- each (PY.18000000 Equity Share of Rs.10 /- each)</b>	1,800.00	1,800.00
	<b>1,800.00</b>	<b>1,800.00</b>
Issued, Subscribed and Paid up		
<b>1,57,13,430 Equity Shares of Rs.10/- each (PY.1,57,13,430 Equity Shares of Rs. 10/- each)</b>	1,571.34	1,571.34
<b>Total</b>	<b>1,571.34</b>	<b>1,571.34</b>

- A) The company has only one class of equity share having at par value of Rs.10/- per share.  
 B) During the year 31st March, 2022 ,the amount of share dividend recognised to equity share holder was "nil" (P.Y. "nil")  
 C) Reconciliation of number of shares outstanding and amount of share capital

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	Amounts	No. of Shares	Amounts
Shares outstanding at the beginning of the year	1,57,13,430	15,71,34,300	1,57,13,430	15,71,34,300
Shares issued during the year	-	-	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	1,57,13,430	15,71,34,300	1,57,13,430	15,71,34,300

- D) Detail of shareholder & Promoters holding more than 5% share in the company is given below :-

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Minto Pursottam Gupta	21,06,467	13.41	21,07,667	13.41
Meenakshi Gupta	16,71,333	10.64	16,71,333	10.64
Hitesh M Patel	5,24,014	3.33	17,98,014	11.44
Kent RO System Limited	9,68,800	6.17	9,68,800	6.17
Total	<b>52,70,614</b>	<b>33.54</b>	<b>65,45,814</b>	<b>41.66</b>

E) Details of Promoters holding of Equity Share Capital of Company

Shares held by Promoters at the end of the year			% Change during the year	Shares held at the beginning of the year	
Promoter Name	No. of Shares	% of Total Shares		No of shares	% of Total Shares
Minto Pursottam Gupta	21,06,467	13.41	0.01	21,07,667.00	13.41
Hitesh Mohan Patel	5,24,014	3.33	8.11	17,98,014.00	11.44

3. Reserves & Surplus:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
Security Premium		
<b>Opening Balance</b>	5,373.59	5,373.59
<b>Add: During the year</b>	-	-
<b>Less : Issue Exps / Transaction Cost regarding Initial Public Offer</b>	-	-
Closing Balance (A)	5,373.59	5,373.59
Profit & Loss Account		
<b>Opening balance</b>	717.26	678.27
<b>Add: Profit For the year</b>	32.41	38.99
<b>Less : Other Adjustment</b>	-	-
Closing Balance (B)	749.67	717.26
Total(A+B)	6,123.28	6,090.87

4. Long Term Borrowing:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
(a) Term Loan (Secured)		
From Bank		
<b>Axis Bank (Refer Note No. 33)</b>	-	27.04
<b>HDFC Bank - I (Refer Note No. 33)</b>	4.89	18.11
<b>HDFC Bank - II (Refer Note No. 33)</b>	15.96	19.40
<b>HDFC Bank - III (Refer Note No. 33)</b>	9.85	13.67
<b>HDFC Bank - IV (Refer Note No. 33)</b>	3.01	3.73
<b>Kotak Mahindra Bank (Refer Note No. 33)</b>	78.64	-
<b>Less:- Current Maturity</b>	(29.41)	(36.57)
	82.95	45.38
(b) Loan and Advances from Directors and Related Parties		
<b>(i) From Directors</b>	-	8.50
	-	8.50

(c) Loan from Member / Share Holders		
<b>Value Worth Capital Management Pvt Ltd</b>	12.75	12.75
	<b>12.75</b>	<b>12.75</b>
Total	<b>95.70</b>	<b>66.63</b>

#### 5. Deferred Tax Liability:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
Opening Balance of Deffered tax Laibility	212.68	213.68
<b>Add: Provision for the year</b>	(3.14)	(0.99)
Closing Balance of Deffered tax Laibility	209.53	212.68
Total	<b>209.53</b>	<b>212.68</b>

#### 6. Long-Term Provisions:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
<b>Provision for Employee Benefits (Non Current)</b>	14.07	14.08
Total	<b>14.07</b>	<b>14.08</b>

#### 7. Trade Payable:

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021
Payable for Goods and Services received		
<u>Trade Payable - MSME:</u>		
<b>Trade Payable Less than year from the due date for payment</b>	22.25	-
<b>Trade Payable More than one year but Less than two year from the due date for payment</b>	-	-
<b>Trade Payable More than two year but Less than three year from the due date for payment</b>	13.28	-
<b>Trade Payable More than three year from the due date for payment</b>	20.68	-
	56.21	-
<u>Trade Payable - Other than MSME:</u>		
<b>Trade Payable Less than year from the due date for payment</b>	218.15	76.33
<b>Trade Payable More than one year but Less than two year from the due date for payment</b>	26.46	307.29
<b>Trade Payable More than two year but Less than three year from the due date for payment</b>	91.56	169.18
<b>Trade Payable More than three year from the due date for payment</b>	181.73	12.84
	517.90	565.64
Disputed due to Micro, small and Medium Enterprises	-	-



Disputed due to other than Micro, Small and Medium Enterprises	-	-
<b>Total</b>	<b>574.11</b>	<b>565.64</b>

**8. Other Current Liabilities:**

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
<b>Current Maturities of Long-Term Debt</b>	29.41	36.57
<b>Advance from Customers</b>	28.38	28.93
<b>Duties &amp; Taxes</b>	57.31	72.52
<b>Other Current Liabilities</b>	306.80	367.43
<b>Total</b>	<b>421.90</b>	<b>505.45</b>

**9. Short Term Provisions:**

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
<b>Provision for Employee Benefits</b>	1.25	3.75
<b>Provision for Income Tax</b>	45.69	190.38
<b>Provision for Others</b>	5.73	5.94
<b>Total</b>	<b>52.67</b>	<b>200.07</b>

**11. Long-Term Loans and Advances:**

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
<b>Security Deposits (Unsecured considered good)</b>	19.34	20.28
<b>Loans and advances to Related Parties</b>	156.60	156.60
<b>Total</b>	<b>175.94</b>	<b>176.87</b>

**12. Other Non – Current Assets:**

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
<b>R&amp;D Product Development Expenses</b>	236.92	236.92
<b>TDS/ MAT recoverable</b>	0.83	173.17
<b>Total</b>	<b>237.75</b>	<b>410.08</b>

**13. Non- Current Investments:**

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.

Investment in Subsidiary Co.		
Beyoungstore Private Limited	1.00	1.00
<b>Total</b>	<b>1.00</b>	<b>1.00</b>
Note Related to Investment:-		
(a) Aggregate Amount of Unquoted Investment :	-	1.00

#### 14. Inventories:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
Raw Materials and Components	3,682.27	2,373.21
Work-in-Progress	413.82	1,667.03
Finished Goods	554.23	457.70
<b>Total</b>	<b>4,650.32</b>	<b>4,497.95</b>

Note: Inventory is taken as certified by Management.

#### 15. Trade Receivables:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
<b>Unsecured, Considered Good</b>		
- Receivables Outstanding for a period exceeding three years from the due date for payment.	122.77	193.57
- Receivables outstanding for a period exceeding two year but less than three years, from the due date for payment.	32.72	45.27
- Receivables outstanding for a period exceeding one year but less than two years, from the due date for payment.	13.91	16.25
- Receivables outstanding for a period exceeding six months, from the due date for payment.	841.14	852.12
- Receivables outstanding for a period not exceeding six months, from the due date for payment.	271.77	139.38
Disputed Trade Receivables considered Goods	-	-
Disputed Trade Receivables considered Doubtful	-	-
<b>Total</b>	<b>1,282.31</b>	<b>1,246.59</b>

#### 16. Cash & Cash Equivalents:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
Balances with banks (Inclusive of bank deposit)	4.87	12.06
Cash on hand/Imprest	260.87	309.09
<b>Total</b>	<b>265.72</b>	<b>321.15</b>

**17. Short Term Loans & Advances:**

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
Advance To Creditors	595.04	576.11
Prepaid Exps	1.46	2.25
Other Current Assets	-	0.69
<b>Total</b>	<b>596.49</b>	<b>579.05</b>

**18. Revenue From Operations:**

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Sale of Products - Domestic	3,303.86	3,369.76
- Export	13.27	7.82
<b>Total</b>	<b>3,317.12</b>	<b>3,377.58</b>

**19. Other Income:**

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Interest Income	0.39	0.76
Discount Received	1.08	0.25
Balances Written off	12.27	2.19
Other Non-Operating Income	8.33	2.34
<b>Total</b>	<b>22.07</b>	<b>5.54</b>

**20. Cost of Material Consumed:**

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Opening Stock	2,373.21	2,096.20
Purchases	1,927.15	2,550.91
Less Closing Stock	3,902.27	2,373.21
<b>Total</b>	<b>398.09</b>	<b>2,273.90</b>

**21. Changes in Inventories of Finished goods & Work in progress:**

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31-03-2021 Rs.
-------------	--	--

Opening Stock (Finished Goods & WIP )	2,124.74	1,693.86
Closing Stock (Finished Goods & WIP )	1,088.05	2,124.74
<b>Total</b>	<b>1,036.69</b>	<b>(430.88)</b>

#### 22. Employee Benefit Expenses:

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Salaries and Wages	209.34	275.10
Contribution to Provident Fund and Other funds & Staff Welfare Exps	10.18	16.66
<b>Total</b>	<b>219.52</b>	<b>291.76</b>

#### 23. Finance Cost:

Particulars	For The Year Ended on 31-03- 2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Interest On Long Term Borrowing	11.26	7.61
Other Borrowing Charges	3.92	3.18
<b>Total</b>	<b>15.18</b>	<b>10.79</b>

#### 24. Other Expenses:

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Administration Charges	4.14	8.08
Auditors' Remuneration	3.00	2.50
Casual Labour Charges & Wages	145.46	82.36
Communication, Courier & Telephone Expenses	4.32	10.64
Consumable & Manufacturing Expenses	6.21	6.71
Directors Sitting Fees	-	0.15
Freight , Cartage & Packing	23.27	18.01
Insurance Expenses	4.41	



		-
Licenses & Fees	6.09	6.77
Loss on sale of Asset	28.35	-
Membership Expenses	0.45	1.12
Misc Expenses	5.19	-
Power & Fuel	44.38	41.56
Professional & Legal Expenses	22.32	7.71
R&D Expenses	1.27	4.73
Rent, Rates & Taxes	6.30	27.87
Repair & Maintenance Expenses	13.56	26.03
Security Expenses	4.17	6.37
Selling & Distribution Expenses	781.85	677.26
Software and Hardware Expenses	6.99	3.10
Stationery & Printing Expenses	2.15	1.83
Travelling & Conveyance Expenses	14.15	10.68
Balances Written off	-	95.57
<b>Total</b>	<b>1,128.04</b>	<b>1,039.04</b>

**25. In compliance to Accounting Standard 20 on “Earning per share”, the calculation of Earnings per Share (Basic and diluted) is as under:**

Particulars	Year Ended 31.03.2022	Year Ended 31.03.2021
A. Profit/Loss attributable to Equity Shareholders	32.41	38.99
B. Weighted average No. of Shares	15713430	15713430
C. Nominal value of equity share	10	10
D. Basic EPS (Rs.) (A)/(B)	0.21	0.25
E. Diluted EPS(Rs.)	0.21	0.25

**26. Contingent Liabilities:  
(Not provided for, as provided by the management)**

Particulars	Year Ended 31.03.2022	Year Ended 31.03.2021
Corporate Social Responsibility	74.59	67.13
Income Tax Laws	1502.24	1497.45

27. In the opinion of the Management, Current Assets, Loans and Advances shall have the value on realization, in the ordinary course of the business, equal to the amount at which they are stated in the Balance Sheet.

28. In compliance of Accounting Standard 17 (AS-17) on “Segment Reporting” as notified under Companies Accounting Standard Rules, 2006, the company is engaged in manufacturing of Fast Moving Consumer Health Products (FMCHP). Considering the nature of business and financial reporting of the company, the company is operating only one segment and hence the segment reporting is not applicable.

28. The Company has adopted Accounting Standard 15 on Employee Benefits as per Actuarial Valuation carried out by an independent actuary in the Book of Account of the Company and the Disclosure relating to same which is envisaged under the standard are disclosed as under :

### 1. Amount of Liability in respect of Gratuity

Particulars	Year Ended 31.03.2022	Year Ended 31.03.2021
<b>Opening Balance of Obligation</b>	<b>17.84</b>	<b>15.82</b>
Add:		
<b>Current Service Cost</b>	<b>3.02</b>	<b>3.26</b>
<b>Past Service Cost</b>	<b>-</b>	<b>-</b>
<b>Interest Cost</b>	<b>1.25</b>	<b>1.03</b>
<b>Benefits Paid</b>	<b>-</b>	<b>-</b>
<b>Actuarial Gain (Loss)</b>	<b>(6.78)</b>	<b>(2.27)</b>
<b>Closing Balance</b>	<b>15.33</b>	<b>17.84</b>

### 2. Amount of obligation recognized in statement of

Particulars	Year Ended 31.03.2022	Year Ended 31.03.2021
<b>Current Service Cost</b>	<b>3.02</b>	<b>3.26</b>
<b>Past Service Cost</b>	<b>-</b>	<b>-</b>
<b>Interest Cost</b>	<b>1.25</b>	<b>1.03</b>
<b>Expected Return on plan assets</b>	<b>-</b>	<b>-</b>
<b>Net Actuarial Losses (Gain)</b>	<b>(6.78)</b>	<b>(2.27)</b>
<b>Recognised in the Year</b>		
Expenses Recognised In Statement of Profit & Loss	<b>(2.51)</b>	<b>2.01</b>

30. Previous years' figures are restated or regrouped or rearranged wherever necessary in order to confirm to the current years' grouping and classifications.

### 31. Additional Information

#### a) Reporting under Micro, small & Medium Enterprise Development Act, 2016

The Company has initiated the process of identification of Creditors which falls under category of MSME, the disclosure relating to amount due to MSME are made to the extent information received.

#### b) Payment to Auditors:

(in Lakhs)

Particulars	Year Ended 31.03.2022	Year Ended 31.03.2021
<b>Payment to statutory Auditor as Audit Fees</b>	<b>3.00</b>	<b>2.50</b>

### 32. Details of Long Term Borrowings (Secured):

Sr. No.	Lender	Nature of facility	Loan Amount	Amount outstanding as at March 31, 2022	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	Axis Bank	Car Loan	Rs. 69.00 Lakhs	-	9.15%	Repayable in 60 Monthly Installment of Rs.1,43,735/- Each	Hypothecation of BMW car Purchased through Loan
2	HDFC Bank-I	Car Loan	Rs. 52.13 Lakhs	-	10.00%	Repayable in 60 Monthly Installment of Rs.1,10,78	Hypothecation of Benz car Purchased through Loan

3	HDFC Bank-II	Car Loan	Rs. 21.25 Lakhs	Rs.12.00 Lakhs	13.50%	7/- Each Repayable in 60 Monthly Installment of Rs.48,900/- Each	Hypothecation of Mercedes car Purchased through Loan
4	HDFC Bank-III	Car Loan	Rs. 18.14 Lakhs	Rs. 6.05 Lakhs	9.50%	Repayable in 60 Monthly Installment of Rs.38,087/- Each	Hypothecation of Toyota car Purchased through Loan
5	HDFC Bank-IV	Car Loan	Rs. 4.13 Lakhs	Rs. 2.22 Lakhs	8.50%	Repayable in 60 Monthly Installment of Rs.8434/- Each	Hypothecation of Maruti Eco car Purchased through Loan
6	HDFC Bank-V	Car Loan	Rs. 88.60 Lakhs	Rs. 62.67 Lakhs	7.40%	Repayable in 60 Monthly Installment of Rs.1,77,113/- Each	Hypothecation of BMW car Purchased through Loan

### 33. Related Party Transactions:

Sr. No.		Nature of Relationship	Name of Related Parties
1		Key Management Personnel	Minto Purshotam Gupta Meenakshi M Gupta Hitesh Mohanalal Patel Yezdi Jal Batliwala Narinder Singh Savita Bhutani Mohak M Gupta Sheena Jain
2		Relatives of Key Person	Mohita M Gupta
3		Subsidiary	Beyoung Store Private Limited
4	Associates /Sister Concern/Enterprise		Nutricircle Limited Mintokashi Associates And Investments Private Limited Mintakashi FMCH Products India (OPC) Private Limited

Calmour US Private Limited

Note: Related parties are identified by the Management and relied up on by the Auditor.

Sr. No.	Nature of Transaction	Associates /Sister Concern/Enterprise	Key Management Personnel & Relatives of Such Personnel
		April'21 to March'22	April'21 to March'22
<b>(A)</b>	<b>Volume of Transactions</b>		
<b>1</b>	<b><u>Remuneration to KMP &amp; Relatives</u></b>		
	Minto Purshotam Gupta	--	30.00
	Meenakshi M Gupta	--	18.00
	Sheena Jain	--	5.17
	Mohak M Gupta	--	17.98
	Mohita M Gupta	--	12.61

Sr. No.	Nature of Transaction	Associates /Sister Concern/Enterprise	Key Management Personnel & Relatives of Such Personnel
		April'21 to March'22	April'21 to March'22
<b>2</b>	<b><u>Unsecured Loan</u></b>		
	<u>Hitesh N. Patel</u>		
	Loan accepted	--	25.00
	Loan repaid	--	25.00
	<u>Mohita Gupta</u>		
	Loan accepted	--	20.00
	Loan repaid	--	20.00
<b>3</b>	<b><u>Loans &amp; Advances</u></b>		
	<u>Beyoung Store Private Limited</u>		
	Loan accepted	0.89	--
	Loan repaid	1.03	--
<b>4</b>	<b><u>Investment</u></b>		
	Beyoung Store Private Limited	1.00	--

For **Keyur Shah & Co.**  
Chartered Accountants  
(FRN: 141173W)

For and on behalf of the Board of Director

Sd/-  
**Keyur Shah**  
Proprietor  
M.No.:153774

Sd/-  
**Minto P Gupta**  
(Managing Director)  
DIN: 00843784

Sd/-  
**Hitesh M Patel**  
(Director)  
DIN:02080625

Sd/-  
**Mohak Gupta**  
(Chief Financial officer)  
PAN: ARTPG3989Q

Sd/-  
**Apeksha Baisakhiya**  
(Company Secretary)  
PAN:CTXPB8692K

Date: 30<sup>th</sup> May, 2022  
Place: Ahmedabad



---

# CONSOLIDATED FINANCIAL STATEMENT

---

FOR FINANCIAL YEAR 2021-22



---

## INDEPENDENT AUDITOR'S REPORT

---

To  
**The Members of  
DECCAN HEALTH CARE LIMITED**

### Report on the Audit of the Consolidated Financial Statements

#### Opinion

We have audited the accompanying Consolidated Financial Statements of **DECCAN HEALTH CARE LIMITED** (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), which comprises of the Consolidated Balance sheet as at 31<sup>st</sup> March, 2022, and the Consolidated statement of Profit and Loss, and Consolidated Statement of Cash flows for the period then ended, and Notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the Consolidated Financial Statements").

In our opinion and to the best of our knowledge and according to the explanations given to us, the aforesaid Consolidated Financial Statements gives the information required by the Companies Act, 2013, in the manner so required, and gives true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31<sup>st</sup> March, 2022 of Consolidated statement of Profit and Loss, and Consolidated Statement of Cash flows for the period then ended.

#### Basis for Opinion

We have conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in India in terms of the Code of Ethics issued by the Institute of Chartered Accountants of India, the relevant provisions of the Companies Act, 2013, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon and we do not provide a separate opinion on these matters and there is no any Key Audit Matters which need to be reported.

#### Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation and presentation of these Consolidated Financial Statements in terms of the requirements of the Companies Act, 2013 that give a true and fair view of the Consolidated financial position and Consolidated financial performance and consolidated cash flows, of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the Company included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statement, that gives a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Statements,

the respective Board of Directors of the Companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Statements**

Our objective is to obtain reasonable assurance about whether the consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made

by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the Consolidated Financial Statements of which we are Independent Auditors. For the other entities included in the Consolidated Financial Statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audit carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and, where applicable, related safeguards.

## Other Matters

We did not audit the financial statements / financial information of subsidiary (Beyoungstore Private Limited), whose financial statements / financial information reflect total assets of Rs. 14,85,308 as at March 31, 2022, revenue from operation of Rs. NIL and net cash flows amounting to Rs. NIL for the period ended on March 31, 2022, as considered in the consolidated financial statements. This financial statements / financial information has been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiary and our report in terms of sub-sections (3) and (11) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiaries is based solely on the reports of the other auditors.

Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial statements / financial information certified by the Management.

## Report on other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, we report, to the extent applicable, that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Consolidated Financial Statements.
  - (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid Consolidated Financial Statement have been kept so far as it appears from our examination of those books and the reports of the other auditors.
  - (c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of the consolidated financial statement.
  - (d) In our opinion, the aforesaid Consolidated Financial Statements comply with the Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2022 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies incorporated in India, none of the directors of the Group companies incorporated in India is disqualified as on 31st March, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
  - (f) With respect to the adequacy of the internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
  - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
    - i. There were no pending litigations which would impact the consolidated financial position of the Group.
    - ii. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.
    - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company, and its Subsidiary companies incorporated in India. The management has represented that, to the best of its knowledge and belief, as disclosed in to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall:
      - directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company orprovide any guarantee, security or the like to or on



behalf of the Ultimate Beneficiaries.

- The management has represented, that, to the best of its knowledge and belief, as disclosed in the accounts, no funds have been received by the Company from any persons or entities, including foreign entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company shall:
- directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever (“Ultimate Beneficiaries”) by or on behalf of the Funding Party or
- provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries.
- Based on such audit procedures as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (d) (i) and (d) (ii) contain any material misstatement.

The Company has not declared or paid any dividend during the year.

- (h) With respect to the matter to be included in the Auditor’s Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

**For Keyur Shah & Co.  
Chartered Accountants  
FRN.: 141173W**

Sd/-

**Keyur Shah  
Proprietor  
MembershipNo.:153774  
UDIN – 22153774AJXQKU7805**

**Date: 30<sup>th</sup> May, 2022  
Place: Ahmedabad**

---

**With reference to the “Annexure A” referred to in the Independent Auditors’ Report to the members of the Holding Company, Subsidiary companies in incorporated in india on Consolidated Financial Statements for the year ended March 31, 2022**

---

**We report the Following:**

According to the information and explanations given to us, companies incorporated in India and included in the Consolidated Financial Statements, there have been no remarks included in their reports under Companies (Auditor’s Report) Order, 2020 (“CARO”), which have been reproduced as per the requirements of the Guidance Note on CARO 2020, issued by Institute of Chartered Accountants of India.

---

**“Annexure B” to the Independent Auditor’s Report of even date on the Consolidated Financial Statements of DECCAN HEALTH CARE LIMITED**

---

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

In conjunction with our audit of the Consolidated Financial Statements of DECCAN HEALTH CARE LIMITED as of and for the period ended March 31, 2022, we have audited the internal financial controls over financial reporting of DECCAN HEALTH CARE LIMITED (hereinafter referred to as the “Holding Company”) and its subsidiary, which are companies incorporated in India, as of that date.

**Management’s Responsibility for Internal Financial Controls**

The respective Board of Directors of the Holding Company, its subsidiaries, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective Company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

**Auditor’s Responsibility**

Our responsibility is to express an opinion on the Holding Company, its subsidiaries, which are companies incorporated in India, internal financial controls over financial reporting with reference to these Consolidated Financial Statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, both, issued by Institute of Chartered Accountants of India, and deemed to be prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting with reference to these Consolidated Financial Statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting with reference to these Consolidated Financial Statements and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting with reference to these Consolidated Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting with reference to these Consolidated Financial Statements.

#### **Meaning of Internal Financial Controls over Financial Reporting with Reference to these Consolidated Financial Statements**

A Company's internal financial control over financial reporting with reference to these Consolidated Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting with reference to these Consolidated Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

#### **Inherent Limitations of Internal Financial Controls over Financial Reporting with Reference to these Consolidated Financial Statements**

Because of the inherent limitations of internal financial controls over financial reporting with reference to these Consolidated Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these Consolidated Financial Statements to future periods are subject to the risk that the internal financial control

over financial reporting with reference to these Consolidated Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

#### **Opinion**

In our opinion, to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors, as referred to in Other Matters paragraph below, the Holding Company, its subsidiary, which are companies incorporated in India, have, maintained in all material respects, adequate internal financial controls over financial reporting with reference to these Consolidated Financial Statements and such internal financial controls over financial reporting with reference to these Consolidated Financial Statements were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

#### **Other Matters**

Other report under Section 143(3)(i) of Act on the adequacy and operating effectiveness of the internal financial controls over financial reporting with reference to those Consolidated Financial Statement of the Holding Company, in so far as it relates to separate financial statement of 1 subsidiary company, which are companies incorporated in India, is based on the corresponding reports of the auditors of such company incorporated in India.

**For Keyur Shah & Co.  
Chartered Accountants  
FRN.: 141173W**

**Sd/-  
Keyur Shah  
Proprietor  
M.No.:153774**

**Date:30<sup>th</sup> May, 2022  
Place: Ahmedabad**

**UDIN-22153774AJXQKU7805**

**Deccan Healthcare Limited**  
CIN: L72200TG1996PLC024351

## Balance Sheet as on 31.03.2022

(Rs in

Lakhs)

Sr. No.	Particulars	Note No.	As at 31st March, 2022	As at 31st March, 2021
<b>I.</b>	<b>EQUITY AND LIABILITIES</b>			
(1)	<b>Shareholder's Funds</b>			
	(a) Share Capital	2	1,571.34	1,571.34
	(b) Reserves and Surplus	3	6,123.13	6,090.87
(2)	<b>Share Application Money pending allotment</b>		-	-
(3)	<b>Non-Current Liabilities</b>			
	(a) Long-Term Borrowings	4	95.70	66.63
	(b) Deferred Tax Liability	5	209.53	212.68
	(c) Long Term Provisions	6	14.07	14.08
(4)	<b>Current Liabilities</b>			
	(a) Trade Payables	7		
	- Due to Micro and Small Enterprise		56.21	-
	- Due to other than Micro and Small Enterprise		524.42	565.64
	(b) Other Current Liabilities	8	415.41	505.45
	(c) Short-Term Provisions	9	52.82	200.07
	<b>TOTAL</b>		<b>9,062.63</b>	<b>9,226.77</b>
<b>II.</b>	<b>ASSETS</b>			
(1)	<b>Non-Current Assets</b>			
	(a) Property, Plant & Equipments & Intangible Assets	10		
	(i) Tangible Assets		1,851.35	1,987.41
	(ii) Intangible Assets		1.72	-
	(iii) Intangible Assets Under Development		-	6.66
	(b) Long-Term Loans and Advances	11	175.94	176.87
	(c) Other Non-Current Assets	12	237.75	410.08
(2)	<b>Current Assets</b>			
	(a) Inventories	13	4,650.32	4,497.95
	(b) Trade Receivables	14	1,282.31	1,246.59
	(c) Cash and Cash Equivalents	15	266.75	321.15
	(d) Short-Term Loans and Advances	16	596.49	579.05
	<b>TOTAL</b>		<b>9,062.63</b>	<b>9,226.77</b>

The accompanying notes 1 to 33 form an integral part of the Standalone Financial Statements

As per our Report of even date attached

For **Keyur Shah & Co.**  
Chartered Accountants  
(FRN: 141173W)

Sd/-

**Keyur Shah**  
Proprietor  
M.No.:153774

For and on behalf of the Board of Director

Sd/-

**Minto P Gupta**  
(Managing Director)  
DIN: 00843784

Sd/-

**Hitesh M Patel**  
(Director)  
DIN:02080625

Sd/-

**Mohak Gupta**  
(Chief Financial officer)  
PAN: ARTPG3989Q

Sd/-

**Apeksha Baisakhiya**  
(Company Secretary)  
PAN:CTXPB8692K

Date: 30<sup>th</sup> May, 2022  
Place: Ahmedabad



**Deccan Healthcare Limited**  
CIN: L72200TG1996PLC024351

## Statement of Profit & Loss for the period ended 31.03.2022

(Rs. In

Lakhs)

	Particulars	Note No	For the Year Ended 31st March, 2022	For the Year Ended 31st March, 2021
<b>I.</b>	Revenue from Operations	18	3,317.12	3,377.58
<b>II.</b>	Other Incomes	19	22.07	5.54
<b>III.</b>	<b>Total Revenue (I + II)</b>		<b>3,339.19</b>	<b>3,383.12</b>
<b>IV.</b>	Expenses:			
	Cost of Materials Consumed	20	398.09	2,273.90
	Changes in Inventories of Finished Goods and Work-in-Progress	21	1,036.69	(430.88)
	Employee Benefit Expenses	22	219.52	291.76
	Depreciation and Amortization Expense	10	147.27	146.60
	Finance Costs	23	15.18	10.79
	Other Expenses	24	1,128.19	1,039.04
	<b>Total Expenses</b>		<b>2,944.79</b>	<b>3,331.21</b>
<b>V.</b>	<b>Profit/ Loss before Exceptional Items and Tax (III - IV)</b>		<b>394.40</b>	<b>51.91</b>
<b>VI</b>	Exceptional Items (Loss due to flood at manufacturing facility in Uttarakhand)		(340.00)	-
<b>VII</b>	<b>Profit before Tax (V-VI)</b>		<b>54.25</b>	<b>51.91</b>
<b>VIII</b>	Tax Expense:			
	(1) Provision for Income Tax			
	Income Tax		25.13	13.91
	(2) Deferred Tax		(3.14)	(0.99)
<b>IX</b>	<b>Profit/ (Loss) for the period (VII-VIII)</b>		<b>32.26</b>	<b>38.99</b>
<b>X</b>	<b>Earnings Per Equity Share</b>			
	(1) Basic	25	0.21	0.25
	(2) Diluted	25	0.21	0.25

The accompanying notes 1 to 33 form an integral part of the Standalone Financial Statements

As per our Report of even date attached

For **Keyur Shah & Co.**  
Chartered Accountants  
(FRN: 141173W)

For and on behalf of the Board of Director

Sd/-  
**Keyur Shah**  
Proprietor  
M.No.:153774

Sd/-  
**Minto P Gupta**  
(Managing Director)  
DIN: 00843784

Sd/-  
**Hitesh M Patel**  
(Director)  
DIN:02080625

Sd/-  
**Mohak Gupta**  
(Chief Financial officer)  
PAN: ARTPG3989Q

Sd/-  
**Apeksha Baisakhiya**  
(Company Secretary)  
PAN:CTXPB8692K

Date: 30<sup>th</sup> May, 2022  
Place: Ahmedabad

Deccan Healthcare Limited  
CIN: L72200TG1996PLC024351

## Cash Flow Statement as on 31.03.2022

(Rs. In Lakhs)

	PARTICULARS	For the Year Ended 31st March, 2022	For the Year Ended 31st March, 2021
<b>A</b>	<b>Cash Flows from Operating Activities</b>		
	Net Profit before tax and Extraordinary items	394.25	51.91
	<b>Adjustments for :</b>		
	Depreciation	147.27	146.60
	Exceptional Loss	(340.00)	
	Interest Expense	15.18	10.79
	Interest Income	(0.39)	(0.76)
	<b>Operating Profit before Working Capital Changes</b>	<b>216.31</b>	<b>208.54</b>
	<b>Adjustments for :</b>		
	(Increase)/Decrease in Trade Receivables	(35.72)	809.51
	(Increase)/Decrease in Inventory	(152.37)	(707.90)
	Increase/(Decrease) in Provisions	(147.27)	8.31
	(Increase)/Decrease in Other Non Current Asset	172.33	(6.68)
	(Increase)/Decrease in Short Term Loans and Advances	(17.54)	(183.76)
	Increase/(Decrease) in Trade Payables	14.99	(140.33)
	Increase/(Decrease) in Current Liabilities	(82.90)	48.04
	<b>Cash Generated from Operations</b>	<b>(32.17)</b>	<b>35.84</b>
	<b>Tax Paid</b>	<b>(25.13)</b>	<b>(13.91)</b>
	<b>Net Cash from Operating Activities</b>	<b>(57.30)</b>	<b>21.93</b>
<b>B</b>	<b>Cash Flows from Investing Activities</b>		
	(Increase)/Decrease in Capital Work in Progress	4.94	(6.66)
	Purchase of Fixed Assets	(11.20)	(9.18)
	Interest Income	0.39	0.76
	(Increase)/Decrease in Non Current Investment	-	
	(Increase)/Decrease in Long Term Loans and Advances	0.93	7.91
	<b>Net Cash from Investing Activities</b>	<b>(4.94)</b>	<b>(8.17)</b>
<b>C</b>	<b>Cash Flows from Financing Activities</b>		
	Interest Expense	(15.18)	(10.79)
	Increase/(Decrease) in Long Term Borrowing	21.91	(26.24)
	<b>Net Cash from Financing Activities</b>	<b>6.73</b>	<b>(37.04)</b>
<b>D</b>	<b>Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>(55.51)</b>	<b>(22.27)</b>
<b>E</b>	Cash and Cash Equivalents at the beginning	322.26	344.53
<b>F</b>	<b>Cash and Cash Equivalents at the end (D+E)</b>	<b>266.75</b>	<b>322.26</b>

Notes: 1. Cash Flow Statement has been prepared using the indirect method in accordance with Accounting Standard AS 3-"Cash Flow Statement" notified under section 133 of the Companies Act,2013

2. Represent Cash and Cash Equivalents as given in Note 16 to the Financial Statement.

For Keyur Shah & Co.

Chartered Accountants

(FRN: 141173W)

Sd/-

**Keyur Shah**

Proprietor

M.No.:153774

For and on behalf of the Board of Director

Sd/-

**Minto P Gupta**

(Managing Director)

DIN: 00843784

Sd/-

**Hitesh M Patel**

(Director)

DIN:02080625

Sd/-

**Mohak Gupta**

(Chief Financial officer)

PAN: ARTPG3989Q

Sd/-

**Apeksha Baisakhiya**

(Company Secretary)

PAN:CTXPB8692K

Date: 30<sup>th</sup> May, 2022

Place: Ahmedabad

## Note No: 1

### A. Significant Accounting Policies:

The Accounting policies set out below have been adopted in preparation and presentation of financial statement and applied consistently to the period presented in this financial statement.

### B. Disclosure of Accounting Policies:

#### a. Basis of Preparation:

These financial statement have been prepared to comply in all material aspects with applicable accounting principles in India, the applicable accounting standards prescribed under section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified) and other accounting principles generally accepted in India, to the extent applicable. The accounting policies have been consistently applied by the Company and are consistent with those used in the previous year.

#### b. Principles of Consolidation:

The Consolidated Restated financial statements relate to Deccan Health Care Limited ("the Company") and its subsidiary entity viz Beyoungstore Private Limited. The Consolidated Financial Statements have been prepared on following basis:

I. The financial statements of the company and its subsidiary entity, used in the consolidation are drawn up to the same date as that of the company i.e. 31st March 2022.

II. The financial statements of the Company and its subsidiary entity have been combined on line- by-line basis by adding together like items of assets, liabilities, income and expenses, after eliminating intra-group balances, intra-group transactions and resulting unrealized profit or losses, unless cost cannot be recovered.

III. The excess of cost to the company of its investment in the subsidiary entity over its share of equity of the subsidiary entity, at the date on which the investment in the subsidiary entity were made, is

recognized as 'Goodwill' being an asset in the consolidated financial statement and is tested for impairment on annual basis.

IV. Goodwill arising on consolidation is not amortized but tested for impairment.

V. The consolidated financial statement have been prepared using uniform accounting policies for like transactions and other events in similar circumstances and are presented to the extent possible, in the same manner as the company's separate financial statements.

VI. Following subsidiary company/entity, associate and jointly controlled entities have been considered in the preparation of the consolidated financial statement:

#### c. Use of Estimates:

The preparation of financial statements in conformity with generally accepted accounting principles require the management to make estimates and assumptions that affect the reported amounts of Assets and Liabilities and disclosure of Contingent Liabilities at the date of the financial statements and the result of operations during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Significant estimates used by the management in the preparation of these financial statements include provisions for bad and doubtful debts. Any revision to accounting estimates is recognized prospectively.

d. Accounting Convention and Revenue Recognition: The Financial Statements have been prepared on a going concern basis in accordance with historical cost convention except for such fixed assets which are revalued. Both Income and Expenditure are recognized on accrual basis.

Revenue from Sales is recognized when practically all risks and rewards of ownership are transferred to the buyer and there is no effective control of the seller as the owner, this usually occurs upon dispatch of the goods. Gross sales shown in the Statement of

Profit & Loss are inclusive of Excise duty but exclude discounts, CST, VAT & Goods & Service Tax. Net Sales are shown after deducting Excise duty which is disclosed at appropriate places. Interest income is recognized on receipt basis, and not on a time proportion basis, taking into accounts the amount outstanding and rate applicable.

Revenue are accounted Net of Goods & Service Tax (GST), Excise Duty, Taxes and Sales Returns.

Other Items of Revenue are recognized in accordance with AS-9.

#### e. Cash Flow Statement: AS-3

The Company has prepared Cash Flow Statement as per the AS-3. Cash flows are reported using the Indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the group are segregated.

#### f. Retirements Benefits:

Staff benefits arising out of retirements / death, comprising of contributions to Provident Fund, Superannuation & Gratuity Schemes, accrued Leave Encashment and other post-separation benefits are accounted for on the basis of an independent actuarial valuation, in accordance with AS-15. The actuarial liability is determined with reference to employees at the end of each financial year.

Expenses for defined benefit gratuity payment plans are calculated as at the balance sheet date by independent actuaries in the manner that distributes expenses over the employees working life. These commitments are valued at the present value of the expected future payments, with consideration for calculated future salary increases, using a discounted rate corresponding to the interest rate estimated by the actuary having regard to the interest rate on Government Bonds with a remaining term i.e. almost equivalent to the average balance working period of employees.

The Company has adopted accounting standard 15 on Employee Benefits as per Actuarial Valuation carried out by an independent actuary in the Book of Account of the Company and the Disclosure relating to same which is envisaged under the standard are disclosed under the notes to financial

Statement.

#### g. Property, Plant & Equipment:

Property, plant and equipment are stated at cost, net of recoverable taxes, trade discount and rebates less accumulated depreciation and impairment losses, if any. Such cost includes purchase price, borrowing cost and any cost directly attributable to bringing the assets to its working condition for its intended use, net charges on foreign exchange contracts and arrangements arising from exchange rate variations attributable to the assets. Expenditure on additions, improvements and renewals is capitalized and expenditure for maintenance and repairs is charged to profit and loss account.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow the entity and the cost can be measured reliably.

Depreciation on property, plant and equipment is provided using Straight Line Method over the useful life of the Asset. Depreciation in respect of addition to assets has been charged on pro rata basis with reference to the period of use of such asset.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Gains or losses arising from de recognition of a property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Statement of Profit and Loss when the asset is derecognized.

#### h. Accounting for Investments:



Long term investments are stated at cost. However, provision for diminution is made to recognize any decline, other than temporary, in the value of long term investments. Current Investments are stated at the lower of cost and fair value.

#### i. Accounting for Intangible Assets:

Intangible assets are capitalized at cost if:

- a. It is probable that the future economic benefits that are attributable to the asset will flow to the company;
- b. The company will have control over the assets;
- c. The cost of these assets can be measured reliably and is more than 10,000/- & this is in accordance with AS-26.

#### j. Accounting for Borrowing Costs:

Borrowing cost relating to acquisition/ construction of qualifying assets are capitalized until the time all substantial activities necessary to prepare the qualifying assets for their intended use are complete. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use/sale. Borrowing costs that are attributable to the projects are charged to the respective projects. All other borrowing costs, not eligible for capitalization, are charged to revenue

accounts.

#### k. Accounting & Valuation for Inventories:

- i) Materials, Stores & Spares, Tools and Consumables are valued at Cost or Market Value, whichever is lower, on the basis of First In First Out method reflecting the fairest possible approximation to the cost incurred in bringing the items of Inventory to their present location and condition.
- ii) Finished Stock of completed products is valued at lower of Cost or Net Realizable Value on the basis of actual identified units. Cost being determined by including cost of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. Net realizable value determined by excluding all payable statutory dues and direct sales expenses.

iii) Scrap is valued at Net Realizable Value.

iv) Work in process in respect of activities is valued at estimated cost.

#### l. Accounting for Taxes on Income:

i) Provision for tax for the year comprises current Income Tax and Deferred Tax and is provided as per the Income Tax Act, 1961.

ii) Deferred tax resulting from timing differences between the book and the tax profits is accounted for, at the current rate of tax, to the extent that the timing differences are expected to crystallize. Deferred tax assets are recognized only to the extent there is reasonable certainty that the assets can be realized in the future; however where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognized only if there is a virtual certainty of realization of such assets. Deferred tax assets/ liabilities are reviewed as at each balance sheet date.

#### m. Provisions, Contingent Liabilities and Contingent Assets:

Provisions are recognized for liabilities that can be measured only by using a substantial degree of estimation, if

- i) The Company has a present obligation as a result of a past event;
- ii) A probable outflow of resources is expected to settle the obligation; and

iii) The amount of the obligation can be reliably estimated.

iv) Reimbursement expected in respect of expenditure required to settle a provision is recognized only when it is virtually certain that the reimbursement will be received.

Contingent Liability is disclosed in the case of:

- i) A present obligation arising from a past event, when it is not probable that an outflow of resources will be required to settle the obligation;

ii) A possible obligation, unless the probability of outflow of resources is remote. Contingent Assets are neither recognized nor disclosed.

n. Earnings per Share:

The earnings considered in ascertaining the companies earning per share comprise net profit after tax and includes the post-tax effect of any extraordinary/exceptional item is considered. The number of shares used in computing basic earnings per share is the weighted average number of shares outstanding during the year.

The no. of shares used in computing diluted earnings per share comprises the weighted average no. of shares considered for deriving basic earnings per share and also the weighted average no. of equity shares that could have been issued on the conversion of all dilutive potential equity shares.

o. Accounting for Impairment of Assets:

Management periodically assesses using external and internal sources whether there is an indication that an asset may be impaired. Impairment occurs where the carrying value exceeds the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. The impairment loss to be expensed is determined as the excess of carrying amount over the higher of the asset's net sale price or present value as determined above.

p. Related Party Disclosures:

The Company as required by AS-18 furnishes the details of Related Party Disclosures in the notes to financial statements.

---

### 10. Property Plant & Equipment

SL NO	PARTICULARS	GROSS BLOCK				DEPRECIATION				NET BLOCK	
		AS AT 01.04.2021	ADDITIONS DURING THE YEAR	(SALE)/ Adjustment DURING THE YEAR	TOTAL AS AT 31.03.2022	UPTO 01.04.2021	FOR THE YEAR	ADJUSTMENT	UPTO 31.03.2022	NET CARRYING AMOUNT AS AT 31.03.2022	NET CARRYING AMOUNT AS AT 31.03.2021
1	Land (Lease Hold)	28.41	-	-	28.41	-	-	-	-	28.41	28.41
2	Factory Building	1,432.97	-	-	1,432.97	354.78	47.86	-	402.64	1,030.34	1,078.20
3	Plant & Machinery	1,154.92	-	-	1,154.92	613.76	54.86	-	668.61	486.31	541.17
4	R&D (Machinery)	85.96	-	-	85.96	37.16	4.08	-	41.24	44.71	48.79
5	Furniture & Fixture	104.93	-	-	104.93	72.44	6.64	-	79.08	25.85	32.49
6	Electrical Appliances	47.99	0.10	-	48.09	7.26	2.28	-	9.54	38.54	40.73
7	Computer & Software	102.67	2.29	-	104.96	98.50	4.37	-	102.88	2.08	4.17
8	Office Equipments	43.02	-	-	43.02	21.88	2.72	-	24.61	18.42	21.14
9	Air Conditions	15.41	-	-	15.41	10.04	0.98	-	11.02	4.40	5.37
10	Vehicles	344.13	67.17	82.66	328.64	157.18	23.47	24.30	156.34	172.30	186.95
	<b>Sub Total</b>	<b>3,360.41</b>	<b>69.56</b>	<b>82.66</b>	<b>3,347.31</b>	<b>1,373.00</b>	<b>147.27</b>	<b>24.30</b>	<b>1,495.96</b>	<b>1,851.35</b>	<b>1,987.41</b>
	Previous Year	<b>3,351.23</b>	<b>9.18</b>	<b>-</b>	<b>3,360.41</b>	<b>1,226.40</b>	<b>146.60</b>	<b>-</b>	<b>1,373.00</b>	<b>1,987.41</b>	<b>2,124.83</b>

## Notes forming part of Balance Sheet and Profit & Loss Accounts

### 2. Share Capital

(Rs. In Lakhs)

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
Authorised Capital		
<b>1800000 Equity Shares of Rs.10/- each (PY.1800000 Equity Share of Rs.10 /- each)</b>	1,800.00	1,800.00
	<b>1,800.00</b>	<b>1,800.00</b>
Issued, Subscribed and Paid up		
<b>1,57,13,430 Equity Shares of Rs.10/- each (PY.1,57,13,430 Equity Shares of Rs. 10/- each)</b>	1,571.34	1,571.34
Total	<b>1,571.34</b>	<b>1,571.34</b>

A) The company has only one class of equity share having at par value of Rs.10/- per share.

B) B) During the year 31st March, 2022 ,the amount of share dividend recognised to equity share holder was "nil" (P.Y. "nil")

C) Reconciliation of number of shares outstanding and amount of share capital

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	Amounts	No. of Shares	Amounts
Shares outstanding at the beginning of the year	1,57,13,430	15,71,34,300	1,57,13,430	15,71,34,300
Shares issued during the year	-	-	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	1,57,13,430	15,71,34,300	1,57,13,430	15,71,34,300

D) Detail of shareholder & Promoters holding more than 5% share in the company is given below :-

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Minto Pursottam Gupta	21,06,467	13.41	21,07,667	13.41
Meenakshi Gupta	16,71,333	10.64	16,71,333	10.64
Hitesh M Patel	5,24,014	3.33	17,98,014	11.44
Kent RO System Limited	9,68,800	6.17	9,68,800	6.17
Total	<b>52,70,614</b>	<b>33.54</b>	<b>65,45,814</b>	<b>41.66</b>

Details of Promoters holding of Equity Share Capital of Company

Shares held by Promoters at the end of the year			% Change during the year	Shares held at the beginning of the year	
Promoter Name	No. of Shares	% of Total Shares		No of shares	% of Total Shares
Minto Pursottam Gupta	21,06,467	13.41	0.01	21,07,667.00	13.41
Hitesh Mohan Patel	5,24,014	3.33	8.11	17,98,014.00	11.44



### 3. Reserves & Surplus:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
Security Premium		
<b>Opening Balance</b>	5,373.59	5,373.59
<b>Add: During the year</b>	-	-
<b>Less : Issue Exps / Transaction Cost regarding Initial Public Offer</b>	-	-
Closing Balance (A)	<b>5,373.59</b>	<b>5,373.59</b>
Profit & Loss Account		
<b>Opening balance</b>	717.28	678.27
<b>Add: Profit For the year</b>	32.26	38.99
<b>Less : Other Adjustment</b>	-	-
Closing Balance (B)	<b>749.67</b>	<b>717.26</b>
Total(A+B)	<b>6,123.13</b>	<b>6,090.87</b>

### 4. Long Term Borrowing:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
(a) Term Loan (Secured)		
From Bank		
<b>Axis Bank (Refer Note No. 33)</b>	-	27.04
<b>HDFC Bank - I (Refer Note No. 33)</b>	4.89	18.11
<b>HDFC Bank - II (Refer Note No. 33)</b>	15.96	19.40
<b>HDFC Bank - III (Refer Note No. 33)</b>	9.85	13.67
<b>HDFC Bank - IV (Refer Note No. 33)</b>	3.01	3.73
<b>Kotak Mahindra Bank (Refer Note No. 33)</b>	78.65	-
<b>Less:- Current Maturity</b>	(29.41)	(36.57)
	<b>82.95</b>	<b>45.38</b>
(b) Loan and Advances from Directors and Related Parties		
<b>(i) From Directors</b>	-	8.50
	-	<b>8.50</b>
(c) Loan from Member / Share Holders		
<b>Value Worth Capital Management Pvt Ltd</b>	12.75	12.75
	<b>12.75</b>	<b>12.75</b>
Total	<b>95.70</b>	<b>66.63</b>

### 5. Deferred Tax Liability:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
Opening Balance of Deffered tax Laibility	212.68	213.68
<b>Add: Provision for the year</b>	(3.14)	(0.99)
Closing Balance of Deffered tax Laibility	209.53	212.68
Total	<b>209.53</b>	<b>212.68</b>

#### 6. Long-Term Provisions:

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
Provision for Employee Benefits (Non Current)	14.07	14.08
Total	<b>14.07</b>	<b>14.08</b>

#### 7. Trade Payable:

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021
Payable for Goods and Services received		
<u>Trade Payable - MSME:</u>		
Trade Payable Less than year from the due date for payment	22.25	-
Trade Payable More than one year but Less than two year from the due date for payment	-	-
Trade Payable More than two year but Less than three year from the due date for payment	13.28	-
Trade Payable More than three year from the due date for payment	20.68	-
	<b>56.21</b>	<b>-</b>
<u>Trade Payable - Other than MSME:</u>		
Trade Payable Less than year from the due date for payment	224.66	76.33
Trade Payable More than one year but Less than two year from the due date for payment	26.46	307.29
Trade Payable More than two year but Less than three year from the due date for payment	91.57	169.18
Trade Payable More than three year from the due date for payment	181.73	12.84
	<b>524.42</b>	<b>565.64</b>
Disputed due to Micro, small and Medium Enterprises	-	-
Disputed due to other than Micro, Small and Medium Enterprises	-	-
Total	<b>580.63</b>	<b>565.64</b>

#### 8. Other Current Liabilities:

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
Current Maturities of Long-Term Debt	29.41	36.57
Advance from Customers	28.38	28.93
Duties & Taxes	57.31	72.52
Other Current Liabilities	300.30	367.43
<b>Total</b>	<b>415.41</b>	<b>505.45</b>

#### 9. Short Term Provisions:

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
Provision for Employee Benefits	1.25	3.75
Provision for Income Tax	45.69	190.38
Provision for Others	5.88	5.94
<b>Total</b>	<b>52.82</b>	<b>200.07</b>

#### 11. Long-Term Loans and Advances:

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
Security Deposits (Unsecured considered good)	19.34	20.28
Loans and advances to Related Parties	156.60	156.60
<b>Total</b>	<b>175.94</b>	<b>176.87</b>

#### 12. Other Non – Current Assets:

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
R&D Product Development Expenses	236.92	236.92
TDS/ MAT recoverable	0.83	173.17
<b>Total</b>	<b>237.75</b>	<b>410.08</b>

#### 13. Inventories:

Particulars	As at 31-03-2022 Rs.	As at 31-03-2021 Rs.
Raw Materials and Components	3,682.27	2,373.21
Work-in-Progress	413.82	1,667.03
Finished Goods	554.23	457.70
<b>Total</b>	<b>4,650.32</b>	<b>4,497.95</b>

Note: Inventory is taken as certified by Management.

**14. Trade Receivables:**

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
Unsecured, Considered Good		
- Receivables Outstanding for a period exceeding three years from the due date for payment.	122.77	193.57
- Receivables outstanding for a period exceeding two year but less than three years, from the due date for payment.	32.72	45.27
- Receivables outstanding for a period exceeding one year but less than two years, from the due date for payment.	13.91	16.25
- Receivables outstanding for a period exceeding six months, from the due date for payment.	841.14	852.12
- Receivables outstanding for a period not exceeding six months, from the due date for payment.	271.77	139.38
Disputed Trade Receivables considered Goods	-	-
Disputed Trade Receivables considered Doubtful	-	-
<b>Total</b>	<b>1,282.31</b>	<b>1,246.59</b>

**15. Cash & Cash Equivalent:**

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
Balances with banks (Inclusive of bank deposit)	5.27	12.06
Cash on hand/Imprest	261.48	309.09
<b>Total</b>	<b>266.75</b>	<b>321.15</b>

**16. Short Term Loans & Advances:**

Particulars	As at	As at
	31-03-2022	31-03-2021
	Rs.	Rs.
Advance To Creditors	595.04	576.11
Prepaid Exps	1.46	2.25
Other Current Assets	-	0.69
<b>Total</b>	<b>596.49</b>	<b>579.05</b>

**17. Revenue From Operations:**

Particulars	For The Year Ended on 31-	For The Year Ended on 31-
	03-2022	03-2021
	Rs.	Rs.
Sale of Products - Domestic	3,303.86	3,369.76
- Export	13.27	7.82
<b>Total</b>	<b>3,317.12</b>	<b>3,377.58</b>

**18. Other Income:**

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31- 03-2021 Rs.
Interest Income	0.39	0.76
Discount Received	1.08	0.25
Balances Written off	12.27	2.19
Other Non-Operating Income	8.33	2.34
<b>Total</b>	<b>22.07</b>	<b>5.54</b>

**19. Cost of Material Consumed:**

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Opening Stock	2,373.21	2,096.20
Purchases	1,927.15	2,550.91
Less Closing Stock	3,902.27	2,373.21
<b>Total</b>	<b>398.09</b>	<b>2,273.90</b>

**20. Changes in Inventories of Finished goods & Work in progress:**

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Opening Stock (Finished Goods & WIP )	2,124.74	1,693.86
Closing Stock (Finished Goods & WIP )	1,088.05	2,124.74
<b>Total</b>	<b>1,036.69</b>	<b>(430.88)</b>

**21. Employee Benefit Expenses:**

Particulars	For The Year Ended on 31-03- 2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Salaries and Wages	209.34	275.10
Contribution to Provident Fund and Other funds & Staff Welfare Exps	10.18	16.66
<b>Total</b>	<b>219.52</b>	<b>291.76</b>



**22. Finance Cost:**

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Interest On Long Term Borrowing	11.26	7.61
Other Borrowing Charges	3.92	3.18
<b>Total</b>	<b>15.18</b>	<b>10.79</b>

**23. Other Expenses:**

Particulars	For The Year Ended on 31-03-2022 Rs.	For The Year Ended on 31-03-2021 Rs.
Administration Charges	4.14	8.08
Auditors' Remuneration	3.15	2.50
Casual Labour Charges & Wages	145.46	82.36
Communication, Courier & Telephone Expenses	4.32	10.64
Consumable & Manufacturing Expenses	6.21	6.71
Directors Sitting Fees	-	0.15
Freight , Cartage & Packing	23.27	18.01
Insurance Expenses	4.41	-
Licenses & Fees	6.09	6.77
Loss on sale of Asset	28.35	-
Membership Expenses	0.45	1.12
Misc Expenses	5.19	-
Power & Fuel	44.38	41.56
Professional & Legal Expenses	22.32	7.71
R&D Expenses	1.27	4.73
Rent, Rates & Taxes	6.30	27.87
Repair & Maintenance Expenses	13.56	26.03
Security Expenses	4.17	6.37
Selling & Distribution Expenses	781.85	677.26
Software and Hardware Expenses	6.99	3.10
Stationery & Printing Expenses	2.15	1.83
Travelling & Conveyance Expenses	14.15	10.68
Balances Written off	-	95.57
<b>Total</b>	<b>1,128.19</b>	<b>1,039.04</b>

**24. In compliance to Accounting Standard 20 on “Earning per share”, the calculation of Earnings per Share (Basic and diluted) is as under:**

Particulars	Year Ended 31.03.2022	Year Ended 31.03.2021
A. Profit/Loss attributable to Equity Shareholders	32.26	38.99
B. Weighted average No. of Shares	15713430	15713430
C. Nominal value of equity share	10	10
D. Basic EPS (Rs.) (A)/(B)	0.21	0.25
E. Diluted EPS(Rs.)	0.21	0.25

**25. Contingent Liabilities:**  
**(Not provided for, as provided by the management)**

Particulars	Year Ended 31.03.2022	Year Ended 31.03.2021
<b>Corporate Social Responsibility</b>	74.59	67.13
<b>Income Tax Laws</b>	1502.24	1497.45

26. In the opinion of the Management, Current Assets, Loans and Advances shall have the value on realization, in the ordinary course of the business, equal to the amount at which they are stated in the Balance Sheet.

27. In compliance of Accounting Standard 17 (AS-17) on “Segment Reporting” as notified under Companies Accounting Standard Rules, 2006, the company is engaged in manufacturing of Fast Moving Consumer Health Products (FMCHP). Considering the nature of business and financial reporting of the company, the company is operating only one segment and hence the segment reporting is not applicable.

28. The Company has adopted Accounting Standard 15 on Employee Benefits as per Actuarial Valuation carried out by an independent actuary in the Book of Account of the Company and the Disclosure relating to same which is envisaged under the standard are disclosed as under :

1. Amount of Liability in respect of Gratuity

Particulars	Year Ended 31.03.2022	Year Ended 31.03.2021
<b>Opening Balance of Obligation</b>	<b>17.84</b>	<b>15.82</b>
Add:		
<b>Current Service Cost</b>	<b>3.02</b>	<b>3.26</b>
<b>Past Service Cost</b>	-	-
<b>Interest Cost</b>	<b>1.25</b>	<b>1.03</b>
<b>Benefits Paid</b>	-	-
<b>Actuarial Gain (Loss)</b>	<b>(6.78)</b>	<b>(2.27)</b>
<b>Closing Balance</b>	<b>15.33</b>	<b>17.84</b>

2. Amount of obligation recognized in statement of

Particulars	Year Ended 31.03.2022	Year Ended 31.03.2021
<b>Current Service Cost</b>	<b>3.02</b>	<b>3.26</b>
<b>Past Service Cost</b>	-	-
<b>Interest Cost</b>	<b>1.25</b>	<b>1.03</b>
<b>Expected Return on plan assets</b>	-	-
<b>Net Actuarial Losses (Gain) Recognised in the Year</b>	<b>(6.78)</b>	<b>(2.27)</b>
Expenses Recognised In Statement of Profit & Loss	<b>(2.51)</b>	<b>2.01</b>

29. Previous years’ figures are restated or regrouped or rearranged wherever necessary in order to confirm to the current years’ grouping and classifications.

30. In assessing the recoverability of Company’s assets such as Investments, Loans, intangible assets, Goodwill, Trade receivable, Inventories etc. the Company has considered internal and external information upto the date of approval of these Financial Statements. The company has performed sensitivity analysis on the assumptions used basis the internal and external information / indicators of future economic conditions and expects to recover the carrying amount of the assets and management has assessed, as a part of going concern assessment, impact of current event regarding COVID-19 and on entity’s operations and forecasted cash flow and management has a positive view regarding the operations of the company.

31. Additional Information

a) Reporting under Micro, small & Medium Enterprise Development Act, 2016

The Company has initiated the process of identification of Creditors which falls under category of MSME, the disclosure relating to amount due to MSME are made to the extent information received.

b) Payment to Auditors: (in Lakhs)

Particulars	Year Ended 31.03.2022	Year Ended 31.03.2021
<b>Payment to statutory Auditor as Audit Fees</b>	<b>3.00</b>	<b>2.50</b>

### 32. Details of Long Term Borrowings (Secured):

Sr. No.	Lender	Nature of facility	Loan Amount	Amount outstanding as at March 31, 2022	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	Axis Bank	Car Loan	Rs. 69.00 Lakhs	-	9.15%	Repayable in 60 Monthly Installment of Rs.1,43,735/- Each	Hypothecation of BMW car Purchased through Loan
2	HDFC Bank-I	Car Loan	Rs. 52.13 Lakhs	-	10.00 %	Repayable in 60 Monthly Installment of Rs.1,10,787/- Each	Hypothecation of Benz car Purchased through Loan
3	HDFC Bank-II	Car Loan	Rs. 21.25 Lakhs	Rs.12.00 Lakhs	13.50 %	Repayable in 60 Monthly Installment of Rs.48,900/- Each	Hypothecation of Mercedes car Purchased through Loan
4	HDFC Bank-III	Car Loan	Rs. 18.14 Lakhs	Rs. 6.05 Lakhs	9.50%	Repayable in 60 Monthly Installment of Rs.38,087/- Each	Hypothecation of Toyota car Purchased through Loan
5	HDFC Bank-IV	Car Loan	Rs. 4.13 Lakhs	Rs. 2.22 Lakhs	8.50%	Repayable in 60 Monthly Installment of Rs.8434/- Each	Hypothecation of Maruti Eco car Purchased through Loan
6	HDFC Bank-V	Car Loan	Rs. 88.60 Lakhs	Rs. 62.67 Lakhs	7.40%	Repayable in 60 Monthly Installment of Rs.1,77,113/- Each	Hypothecation of BMW car Purchased through Loan

### 33. Related Party Transactions:

Sr. No.	Nature of Relationship	Name of Related Parties
1	Key Management Personnel	Minto Purshotam Gupta Meenakshi M Gupta Hitesh Mohanalal Patel Yezdi Jal Batliwala

			Narinder Singh
			Savita Bhutani
			Mohak M Gupta
			Sheena Jain
2		Relatives of Key Person	Mohita M Gupta
3		Subsidiary	Beyoung Store Private Limited
4	Associates /Sister Concern/Enterprise		Nutricircle Limited
			Mintokashi Associates And Investments Private Limited
			Mintakashi FMCH Products India (OPC) Private Limited
			Calmour US Private Limited

Note: Related parties are identified by the Management and relied up on by the Auditor.

Sr. No.	Nature of Transaction	Associates /Sister Concern/Enterprise April'21 to March'22	Key Management Personnel & Relatives of Such Personnel April'21 to March'22
(A)	<b>Volume of Transactions</b>		
1	<b><u>Remuneration to KMP &amp; Relatives</u></b>		
	Minto Purshotam Gupta	--	30.00
	Meenakshi M Gupta	--	18.00
	Sheena Jain	--	5.17
	Mohak M Gupta	--	17.98
	Mohita M Gupta	--	12.61

Sr. No.	Nature of Transaction	Associates /Sister Concern/Enterprise April'21 to March'22	Key Management Personnel & Relatives of Such Personnel April'21 to March'22
2	<b><u>Unsecured Loan</u></b>		
	<u>Hitesh N. Patel</u>		
	Loan accepted	--	25.00
	Loan repaid	--	25.00
	<u>Mohita Gupta</u>		
	Loan accepted	--	20.00
	Loan repaid	--	20.00
3	<b><u>Sales</u></b>		
	<u>Uttam Kumar Singh</u>	-	0.07
4	<b><u>Purchase</u></b>		
	Mintakashi FMCH Products India (OPC) Limited	60.67	--

<b>5</b>	Commission & Brokerage		
	Uttam Kumar Singh	-	0.03
	Narendra Singh	-	0.02

For **Keyur Shah & Co.**  
Chartered Accountants  
(FRN: 141173W)

**For and on behalf of the Board of Director**

Sd/-

**Keyur Shah**  
Proprietor  
M.No.:153774

Sd/-

**Minto P Gupta**  
(Managing Director)  
DIN: 00843784

Sd/-

**Hitesh M Patel**  
(Director)  
DIN:02080625

Sd/-

**Mohak Gupta**  
(Chief Financial officer)  
PAN: ARTPG3989Q

Sd/-

**Apeksha Baisakhiya**  
(Company Secretary)  
PAN:CTXPB8692K

Date: 30<sup>th</sup> May, 2022

Place: Ahmedabad





## **Deccan Health Care Limited**

H.No. 6-3-348/4, Dwarakapuri, Colony Punjagutta, Hyderabad,  
T.G - 500 082, India

[www.deccanhealthcare.co.in](http://www.deccanhealthcare.co.in)